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1. Introduction 
1.1. Transendothelial migration of leukocytes 
Diapedesis of leukocytes, i.e. the transmigration through the vascular endothelium, is a highly 
regulated immunological process involved in leukocyte recruitment to sites of inflammation, and 
in lymphocyte homing1. 
chemotactic factors / chemokines 
EC
leuko-
cyte
tethering and rolling firm arrest diapedesis
blood 
vessel wall 
tissue site of
inflammation
subendothelial localization
selektins
integrins
figure 1: Leukocyte recruitment and extravasation to sites of inflammation. Sequential steps involved in this process are     
i) tethering, ii) rolling and iii) firm arrest of the circulating leukocyte on the activated endothelium, followed by                 
iv) diapedesis across the endothelial barrier and v) subendothelial migration. They are mainly mediated by selectin 
molecules, chemotactic factors and integrins and by their respective receptors or ligands, as indicated and described below. 
During normal immune surveillance, lymphocytes recirculate in search of foreign antigens from 
the microvasculature into tissues, percolate through draining lymph nodes of the lymphatic 
system and finally return to the blood stream via the thoracic duct. Thereby naive lymphocytes 
preferentially home to and recirculate among peripheral lymph nodes through high endothelial 
venules (HEVs) that consist of endothelial cells (ECs) specialized for lymphocyte emigration. 
Memory T cells, on the contrary, preferentially extravasate through normal tissue endothelium 
                                                 
1 The mechanisms of leukocyte diapedesis will be discussed hereinafter mainly for the process of transendothelial extravasation 
to sites of inflammation that corresponds in principle to mechanisms underlying transepithelial extravasation, e.g. through 
inflamed epithelia in case of mucosal infections, or lymphocyte homing. 
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of, for example, skin, lung and gut, and subsequently drain into their associated lymphoid 
tissues. This constitutive process of lymphocyte homing underlies similar principle mechanisms 
as inflammation-induced leukocyte diapedesis (Springer, 1994). 
 
Injury or infections cause inflammatory responses that lead to the recruitment of granulocytes, 
monocytes and T cells to sites of inflammation. Leukocyte transmigration occurs in different 
sequential and in part, overlapping steps, i.e. tethering, rolling, firm arrest and finally 
extravasation (Butcher, 1991; Springer, 1994). At the molecular level these leukocyte-EC 
interactions are mainly mediated by selectins and their carbohydrate ligands, activating 
chemoattractants and their leukocytic receptors, and IgSF proteins in combination with their 
integrin receptors, respectively (fig. 1). Patrolling leukocytes undergo initial attachment 
(tethering) to the vessel wall mediated by selectins that are mainly expressed on the endothelium 
in response to inflammation. Due to the shear forces of the rapidly flowing blood stream (see 
fig. 28), reversible repetitive selectin-binding leads to leukocyte rolling on the blood vessel wall. 
The attracted cells are thus slowed down and enabled to sense the environment for endothelial 
inflammation signals provided by chemoattractants. Interaction with respective receptors leads to 
activation of the leukocytes that effects mainly the binding properties of their integrin surface 
receptors and results in high-affinity and high-avidity binding to their endothelial 
immunoglobulin superfamily (IgSF) counter-receptors. The major integrins implicated are 
lymphocyte function-associated antigen (LFA)-1, Mac-1 (macrophage antigen-1; complement 
receptor type 3), very late antigen (VLA)-4 and their ligands intercellular adhesion molecule 
(ICAM)-1 and vascular cell adhesion molecule (VCAM)-1. The adhesive molecular interactions 
amplify in a cascade-like manner and finally result in strong, sustained arrest and spreading of 
the leukocytes onto the endothelium under the given blood flow conditions. 
 
Unlike the well-characterized molecular events involved in leukocyte rolling and their adhesion 
to activated endothelium, the mechanisms controlling the last step of their recruitment, i.e. the 
transendothelial extravasation, remains largely unknown (fig. 1) (Bianchi et al., 1997). The 
intercellular junctions of the endothelium, in particular the apical tight junctions, have to open 
and close in a highly coordinated and reversible manner to allow leukocytes to reach 
inflammatory sites in the tissue and to coincidentally disable bleeding or an impairment of the 
functional permeability barrier. 
 
Following transmigration into the tissue, leukocytes undergo directed migration through a 
concentration gradient of chemotactic cytokines (chemokines) to the site of inflammation 
(chemotaxis) (fig. 1). Depending on the type of leukocyte and its specialized function they 
release different inflammatory cytokines themselves. Thus they activate other white blood cells 
or enhance further leukocyte recruitment by stimulating the nearby endothelium to express 
additional adhesion molecules on its apical surface and to segregate chemokines. Moreover, 
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cytokine-activation influences the integrity of intercellular junctions and thus the paracellular 
permeability for additional recruited leukocytes across the endothelium (Shaw et al., 2001c). 
 
 
 
1.2. Intercellular junctions 
Cell-cell contacts in tissues are characterized by specialized junctions. They ensure adjustable 
impermeability of cell layers for cellular and molecular components of the lumen (tight 
junctions) and provide adhesive contact sites for actin filaments (adherens junctions) or 
intermediate filaments (desmosomes), respectively. Moreover, they may provide cellular 
communication and regulated molecular interchange between adjacent cells (gap junctions). 
 
Tight junctions (TJs) and adherens junctions (AJs) are formed by specific transmembrane 
proteins that promote homotypic cell adhesion (i.e. between cells of the same type) through their 
extracellular domains and anchor the cell-cell junctions to a complex network of cytoskeletal and 
signaling proteins by their cytoplasmic tails. In addition, transmembrane molecules such as 
junctional adhesion molecule (JAM)-1, platelet endothelial cell adhesion molecule (PECAM)-1 
(Newman, 1997) and CD99 (Schenkel et al., 2002) can concentrate at intercellular contacts 
(which for the latter two does not occur in direct association with TJs or AJs), and mediate cell 
adhesion by homophilic trans-interactions. 
 
 
1.2.1. Tight junctions (zonula occludens) 
TJs form a morphological and functional barrier between the apical and basolateral cell surface 
domains of endothelial or epithelial cell layers. They regulate selective diffusion of solutes and 
ions and the migration of immune cells along the paracellular space (barrier function). Moreover 
they constitute an intramembranous diffusion barrier restricting the intermix of apical and 
basolateral plasma membrane lipids and proteins (fence function), thus directly contributing to 
the maintenance of cell polarity (Schneeberger et al., 1992; Nusrat et al., 2000). TJs are 
particular well developed where permeability of endothelial or epithelial cell layers needs to be 
under strict control. A typical example is the impervious endothelial blood-brain barrier (BBB) 
where TJs are uniquely complex (Kniesel et al., 2000). On the contrary, in high endothelial 
venules (HEVs) implicated in lymphocyte homing with high extravasation rates (Girard et al., 
1995), tight junctional complexes are frequently absent or present in only a primitive 
organization. TJs are generally located at the very apical site of epithelial cell layers. Endothelial 
TJs, however, can be less strictly localized and spatially intermingled with AJs at more 
basolateral sites (Anderson et al., 1995). 
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The transmembrane constituents of TJs, all four membrane-spanning molecules, are the claudin 
proteins (Heiskala et al., 2001) and occludin (Furuse et al., 1993). They co-polymerize to 
heteropolymer TJ strands forming a continuous circumferential seal around the apical part of the 
cell and mediate adhesiveness to the TJ strands of the adjacent cells independently of 
extracellular Ca2+. The members of the claudin family thereby appear to be the primary seal-
forming proteins with the intrinsic ability to polymerize into continuous adhesive fibrils. They 
may mediate tissue-specific TJ properties by their respectively restricted expression and 
individual ability for homophilic (between identical molecules) and heterophilic (between 
different molecules) interactions in cis (both molecules anchored in the same cell membrane) and 
in trans (both molecules anchored in the membranes of separate, opposing cells) among 
themselves. Occludin exerts homophilic trans-interactions and can bind intracellularly actin 
filaments. Claudins and occludin bind each other and both can interact with the TJ proteins 
cingulin and, in a PDZ-dependent manner (see 1.7.5.), with the zonula occludens proteins ZO-1, 
ZO-2 and ZO-3. The latter are multi-domain proteins which interact with diverse cytoplasmic 
molecules mediating a direct link between the sealing proteins and the actin cytoskeleton 
(Lampugnani et al., 1997; Tsukita et al., 1999). Among them, ZO-1 may represent a cross-
talking element between AJs and TJs since its membrane targeting may be regulated by binding 
initially to AJ components such as α- and β-catenins with subsequent segregation to TJs. Further 
interaction partners of ZO-1 are both ZO-2, ZO-3 and the PDZ domain-containing AF-6 (ALL-1 
fusion partner from chromosome 6; S-afadin), a Ras substrate that is expressed at TJs as well as 
in AJs. Due to identical binding sites on AF-6, Ras can compete with ZO-1 for AF-6 binding 
which may provide a regulatory mechanism (Ebnet et al., 2000). A third TJ-specific 
transmembrane protein is JAM-1 that may not constitute TJ strands per se but laterally associates 
with them. The protein interactions of JAM-1 with TJ components are discussed below. 
 
The integrity of the TJs is dependent on the presence of extracellular Ca2+ that exerts its effects 
on AJs, in particular on cadherins, thus effecting TJs indirectly (Schneeberger et al., 1992; 
Cereijido et al., 2000). Therefore, the mechanisms of TJ assembly can be studied, besides in 
adenosine triphosphate (ATP) depletion-repletion experiments, in calcium-switch assays (Denker 
et al., 1998). The degree of TJ tightness is dependent on their functional state and can be rapidly 
adapted to physiological needs. Assembly and barrier function are both influenced by 
intracellular signaling mediated e.g. by tyrosine kinases, intracellular Ca2+, protein kinase C 
(PKC), (3',5')-cyclic adenosine monophosphate (cAMP) and phospholipase C (PLC) 
(Schneeberger et al., 1992; Anderson et al., 1995). 
 
Moreover, TJ have to open and close in a highly coordinated and reversible manner to ensure 
transmigration of immune cells under physiological or pathological conditions of inflammation 
as well as during normal immune surveillance. Cytokines such as tumor necrosis factor (TNF)-α 
and interferon (IFN)-γ, which are released by transmigrated leukocytes at sites of inflammation, 
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directly influence the constitution of TJs and thus the paracellular permeability across 
endothelial and epithelial cells (Nusrat et al., 2000). The molecular mechanisms of TJ regulation 
during leukocyte migration remain unclear. 
 
 
1.2.2. Adherens junctions (zonula adherens) 
AJs represent a ubiquitous and more basic type of organized intercellular contact structure. They 
are formed by clusters of transmembrane proteins belonging to the cadherin family, mainly 
VE-cadherin in vascular endothelial and E-cadherin in epithelial AJs (Yap et al., 1997; 
Nagafuchi, 2001). Homophilic interactions in trans of cadherins are dependent of extracellular 
Ca2+. In the cytosol they can directly link to the catenins β-catenin, plakoglobin and p120CAS, the 
former which in turn binds to α-catenin. α-catenin interacts with vinculin, α-actinin, ZO-1 and 
actin, thus stabilizing the junctions. The cadherin-association with p120CAS leads to more mobile 
and dynamic AJs and dissociates after junction maturation (Lampugnani et al., 1997). Like TJs, 
AJs are very dynamic and their composition can rapidly change according to the functional and 
maturational state of the cell. They are also involved in signal transduction, e.g. through 
β-catenin and plakoglobin-mediated signaling or through their recruitment of diverse signaling 
molecules to the sites of AJs. 
 
 
 
1.3. Selectins 
Selectins are adhesion molecules that mediate tethering and rolling of emigrating leukocytes on 
the endothelium (McEver et al., 1995; Ebnet et al., 1999). Their expression is strictly restricted 
to the leukocyte-vascular interaction system, and all three members, i.e. L-selectin, E-selectin 
and P-selectin, are critical involved in diapedesis during inflammation. The extracellular part of 
these type I transmembrane receptors consists of a N-terminal lectin-like carbohydrate 
recognition domain followed by an epidermal growth factor (EGF)-like domain and a varying 
number of short consensus repeats (SCRs). The main expression, regulation and molecular 
interaction features of the selectins are described below (table 1). For all three selectins the 
requirement for flow shear to mediate leukocyte rolling has been demonstrated (Lawrence et al., 
1997). 
 
The ligands of selectin receptors are glycoproteins (table 1), most of which are mucin-like with 
O-glycosylated carbohydrate side chains, such as CD34, glycan-bearing cell adhesion molecule 
(GlyCAM)-1, P-selectin glycoprotein ligand (PSGL)-1 and mucosal addressin cell adhesion 
molecule (MAdCAM)-1 also involved in integrin α4β7 binding (see 1.5.6.). The primary 
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recognition structure for selectins on the carbohydrate side chains of their ligands are terminally 
linked tetrasaccharides closely related to sialyl Lewis X (sLeX; CD15s), an α(2→3)-sialylated 
and α(1→3)-fucosylated lactosamine. L-selectin on neutrophils, but not on T cells, also express 
sLeX and thus serves as ligand for endothelial P- and L-selectin in neutrophil recruitment. 
 
 L-selectin E-selectin P-selectin 
CD nomenclature CD62L CD62E (ELAM-1) CD62P 
 
expression 
leukocytes; 
constitutive 
activated endothelium; 
transiently 
endothelium and platelets;
stored in granules 
 
induced by 
 
– 
 
TNF-α, LPS, IL-1 TNF-α, LPS; histamine, thrombin 
 
downregulation 
surface-located 
protease 
internalization and 
lysosomal degradation 
internalization and 
recycling 
 
 
main ligands 
GlyCAM, CD34, 
MAdCAM-1, 
CLA-1 
 
ESL-1, PSGL-1, 
L-selectin 
 
 
PSGL-1, L-selectin 
 
table 1: Expression, regulation and molecular interaction features of the selectin adhesion receptors. Abbreviations not 
further defined: ELAM-1 (endothelial leukocyte adhesion molecule-1), CLA-1 (cutaneous lymphocyte antigen-1), ESL-1 
(E-selectin ligand-1). Note: P-selectin is stored in α-granules of platelets or in Weibel-Palade bodies of endothelial cells 
that are fused to the plasma membrane by stimulation of proinflammatory mediators such as histamine and thrombin. 
The physiological importance of selectin-mediated interactions in leukocyte diapedesis is 
emphasized in type 2 leukocyte adhesion deficiency (LAD-II). This syndrome is characterized 
by an impaired fucose metabolism that causes the absence of fucose-containing sLeX moieties in 
selectin ligands of affected patients (Etzioni et al., 1992). The clinical picture includes recurrent 
bacterial infections mainly due to impaired neutrophil recruitment and thus is similar to that 
observed in LAD-I patients (see 1.5.5.5.). 
 
 
 
1.4. Chemokines 
The transition of transmigrating leukocytes from selectin-mediated activation-independent 
rolling to integrin-mediated activation-dependent firm arrest on the endothelium is induced by 
chemoattractants and their respective leukocytic receptors. Classical chemoattractants are the 
complement protein C5a, the lipid mediators leukotriene B4 (LTB4) and platelet-activating factor 
(PAF), and bacterial N-formyl peptides (Springer, 1994). The majority of chemoattractants are 
however the chemokines (Ebnet et al., 1999; Ward et al., 1998), a family of small (6-14 kDa) 
chemotactic cytokines expressed and secreted by leukocytes and several tissue cells such as ECs, 
epithelial cells, smooth muscle cells (SMC) and fibroblasts. Endothelial chemokines, for 
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example, are induced by inflammatory cytokines such as interleukin (IL)-1 and TNF-α. They 
exert their function as soluble molecules as well as immobilized on the endothelium or the 
extracellular matrix (ECM) through binding with high avidity to heparin and heparan sulfate 
proteoglycans. Within inflamed tissues chemokines mediate the directed migration of 
extravasated leukocytes along a positive chemical concentration gradient (chemotaxis) to the site 
of inflammation, cells which can sense a concentration difference of 1 % across their diameter 
(Springer, 1994). Prior to this, they can mediate the firm arrest of rolling leukocytes on the 
endothelium at sites of inflammation by activating integrins via their respective chemokine 
receptors (Butcher, 1991; Springer, 1994). They also appear to be involved in mediating earlier 
stages of leukocyte extravasation and post-arrest events, i.e. rolling and chemotactic 
transendothelial migration (Weber et al., 1996; Weber et al., 1999b; Cinamon et al., 2001a). 
 
Chemokines are classified according to the position of the first two out of four conserved 
cysteine residues. The two main subfamilies are CXC chemokines with one intervening amino 
acid between the first two cysteines that effect mainly neutrophils, and CC chemokines where 
this conserved residues are adjacent and that effect mainly monocytes, lymphocytes and 
eosinophiles (Ward et al., 1998). Notable representatives are the CC chemokines RANTES 
(regulated upon activation, normal T cell expressed and secreted; CCL5), monocyte 
chemoattractant protein-1 (MCP-1; CCL2), and macrophage inflammatory protein-1β (MIP-1β; 
CCL4) and the CXC chemokines IL-8 (CXCL8), growth-related oncogene-α (GRO-α; CXCL1) 
and stromal cell-derived factor (SDF)-1 (CXCL12)2. 
 
Chemokine receptors are seven transmembrane-spanning receptors expressed on leukocytes that 
are in general coupled to G proteins, in particular of the Gi class (Premack et al., 1996; Mellado 
et al., 2001). Thus the majority of chemokine receptor-mediated events are sensitive to 
Bordetella pertussis toxin (PTX). The signaling cascade of e.g. the IL-8–specific chemokine 
receptor CXCR1 leads to activation of PLC, PKC, small GTPases, Src-related tyrosine kinases 
and phosphatidylinositol-3-OH (PI3)-kinase, effecting processes involved in firm cell arrest and 
chemotaxis, such as activation of β1 and β2 integrin adhesion receptors and cytoskeletal 
rearrangements. 
 
 
 
 
 
 
 
                                                 
2 Note: A new systematic chemokine nomenclature has been recently proposed based on the chemokine receptor nomenclature 
currently in use (Zlotnik et al., 2000). Both classical and systematic names are stated. 
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1.5. Integrins 
Integrins are evolutionary conserved surface adhesion receptors expressed by nearly all cell 
types, playing key roles in many cellular processes. Spanning the plasma membrane they are 
connected to the cellular environment, i.e. the extracellular matrix or neighboring cells, as well 
as to the cytoskeleton and the intracellular signal machinery. Thus integrins can function as 
environment sensor molecules transducing extracellular signals to the inner cell (termed 
outside-in signaling) or adapt their extracellular function in response to internally generated 
signals (termed inside-out signaling). Besides environmental recognition they mediate cellular 
migration and adhesion and thus are key players in physiological processes such as embryonic 
development, angiogenesis, wound healing, hemostasis, immune response and inflammation 
(Hynes, 1992; Horwitz, 1998). They provide survival signals to prevent programmed cell death 
(apoptosis) (Meredith et al., 1993) but are also involved in pathological processes such as 
metastasis in cancer (Clezardin, 1998). 
 
 
1.5.1. Molecular structure of integrins 
EF hand-like motifs
cysteine-rich
region
COOHH2N β
I II III IV V VI VII
S S
COOHH2N α
I domain insert
with MIDAS motif
I-like domain with 
MIDAS-like motif
KxGFFKR
sevenfold repetitive element 
membraneextracellular region cytosol
figure 2: Schematic representation of the domain structure of integrin αβ heterodimers. The seven homologous 
repeats of the α chain are designated by numbers (I-VII). The subunits αL, αM, αX, αD, α1, α2, α10, and αE contain an 
I domain between the repeat domains II and III. The MIDAS motif within the I domain is highlighted. I domain-
containing integrins have three EF hand-like motifs (“●”; V-VII) whereas other integrins have four (“○●”; IV-VII) 
(Leitinger et al., 2000). The sevenfold repetitive element is predicted to fold to form a β-propeller structure (Springer, 
1997; Xiong et al., 2001). In some cases, α subunits are cleaved at their membrane-proximal extracellular part via 
posttranslational proteolysis of the precursor molecule and linked there by a disulfide bond (Hynes, 1992). The 
integrin β chain contains a I-like domain with a MIDAS-like motif and a cysteine-rich region at the membrane-
proximal part. Adapted from Leitinger et al., 2000. 
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Cells can regulate their adhesive properties by cell type-dependent selective expression of 
different integrin molecules. To date, the integrin family consists of approximately 25 
heterodimeric glycoprotein members. 19 α (120-180 kDa) and 9 β (90-110 kDa) subunits, all 
type I transmembrane proteins that have been identified, associate in a non-covalent manner to 
specific αβ complexes (fig. 2). Both types of integrin subunits consist of large extracellular 
domains of 700-1100 aa that form a globular head structure at their N-terminal section 
containing the ligand binding regions (Humphries, 2000). By contrast their cytoplasmic tails of 
30-50 aa are short, with exception of the β4 intracellular tail formed by over 1000 residues 
(Hemler, 1990). Integrin α and β chains are assembled in the endoplasmic reticulum (ER), a 
requirement for their transport to the cell surface or, in some cases, to intracellular granules 
(Kishimoto et al., 1989; Green et al., 1998) 
 
 
1.5.1.1. The integrin α chain 
The N-terminus of integrin α chains contains a sevenfold repetitive element (I-VII) of about 
60 aa (fig. 2). The last four repeats (IV-VII) resemble EF hand-like motifs with the consensus 
sequence DxDxDGxxD3, characterized as divalent cation binding sites presumably for Ca2+ ions 
(Leitinger et al., 2000). In I domain-containing α subunits, however, only the last three 
N-terminal repeats (V-VII) resemble EF hand-like motifs. The α chains of leukocyte β2 integrins 
(i.e. αL, αM, αX, and αD) as well as the α1, α2, α10 and αE chains contain this additional domain 
between the repeats II and III. The I domain is homologous to the von Willebrand factor (vWF) 
A domain and consists of approximately 200 aa residues. Within its sequence there is a highly 
conserved Mg2+/Mn2+ binding motif termed metal ion-dependent adhesion site (MIDAS) that is 
implicated in the ligand binding of the respective integrins (Gahmberg et al., 1997; Leitinger et 
al., 2000). Previously the I domain allosteric site (IDAS), localized at a site spatially distinct 
from the MIDAS, was identified as a second domain involved in the ligand binding regulation of 
the β2 integrin LFA-1 (Huth et al., 2000; Lupher et al., 2001). 
 
The cytoplasmic tails of integrin α subunits exhibit only minor similarity between different 
family members, apart from the highly conserved membrane-flanking KxGFFKR motif that 
exerts an inhibitory effect on ligand binding in non-activated integrins. The deletion of the 
KxGFFKR sequence has been shown to result in the expression of constitutively active integrins, 
suggesting that this conserved motif functions in the maintenance of default low-affinity states in 
integrins (Williams et al., 1994; Dedhar et al., 1996). 
                                                 
3 Single-letter amino acid code. Lowercase x represents any unspecified amino acid. Other lowercase letters correspond to 
residues conserved in at least three integrin subunits. Uppercase letters corresponds to near-invariant residues. Dashes represent 
non-conserved residues and/or gaps. Letters in brackets, separated by slashes, constitute mutual alternative amino acids at this 
sequence position. 
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1.5.1.2. The integrin β chain 
The extracellular part of integrin β subunits exhibits two regions of homology. N-terminally 
there is a I domain-like motif with similarity to the α chain I domain, including the presence of a 
MIDAS-like metal binding motif. The membrane-proximal part is formed by a four-fold repeat 
of cysteine-rich, EGF-like domains of 40 aa residues (Green et al., 1998; Humphries, 2000). 
 
Conserved intracellular sequences of integrin β chains are the membrane-flanking sequence 
KLLv-ihDRRE and, with the exception of β4, the NPx(Y/F) motif (Williams et al., 1994; Liu et 
al., 2000a). 
 
 
1.5.2. Inside-out signaling 
Many integrin receptors are normally in a low-affinity state and require activation to exert their 
adhesive function, especially integrins expressed in hematopoietic cells. Otherwise, circulation 
of patrolling blood cells in the vasculature or cell migration, accomplished by regulated cycles of 
attachment and de-attachment, would not be feasible due to firm cellular arrest mediated by 
integrin adhesion receptors locked in a sustained, constitutively active state. A rapid and highly 
regulated activation is ensured by signal transduction pathways affecting integrins inside-out 
signaling and thus their affinity and avidity state. 
 
 
1.5.2.1. Affinity 
The affinity of integrins for their extracellular ligands, in particular of those with an I domain 
(Liddington et al., 2002), is regulated by conformational changes induced at the cytoplasmic tails 
of the heterodimer and transfered to its extracellular segment. For non-activated integrins the 
conserved membrane-flanking cytoplasmic motifs in both the α and the β chains are crucial for 
the maintenance of their low-affinity state. Mutations in or deletion of either the KxGFFKR or 
the KLLv-ihDRRE sequences, has been shown to result in a constitutive active state of integrins 
accompanied by high affinity binding to their ligands (Hughes et al., 1998; van Kooyk et al., 
1999). Structural changes in activated integrins can be detected by specific monoclonal reporter 
antibodies (Shattil et al., 1985; Dransfield et al., 1989; Diamond et al., 1994). 
 
 
1.5.2.2. Avidity 
The avidity of integrins can be regulated by their clustering on the membrane surface, e.g. at 
focal adhesion contacts. This alteration in surface distribution depends on the lateral mobility of 
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the integrins within the plasma membrane. This is thought to be enabled by a temporary 
disconnection from their cytoskeletal association (Lub et al., 1997a; van Kooyk et al., 2000; 
Leitinger et al., 2000). Avidity-activated LFA-1 can be specifically detected by the reporter mAb 
NKI-L16 that recognizes a cluster-dependent epitope on the LFA-1 αL chain (Keizer et al., 1988; 
van Kooyk et al., 1991). 
 
 
1.5.2.3. Integrin activation 
Different signaling pathways have been implicated in integrin inside-out signaling, although the 
precise nature of the direct molecular link to integrins remains largely unknown. For example, 
the small GTP binding protein R-Ras can activate integrins (Zhang et al., 1996). On the contrary, 
the effect of H-Ras is more controversially discussed. H-Ras signaling to the Raf-1/ extracellular 
signal-related kinase (ERK) pathway suppresses integrin activation as shown for β1 and β3 
integrins, whereas signal transduction via other pathways may lead to an integrin activation as 
demonstrated for β1 and β2 integrins (Hughes et al., 1997; Shibayama et al., 1999). For 
chemokine-triggered regulation of LFA-1 avidity in T cells, it appears that H-Ras is involved in 
both transient LFA-1 activation by signaling to PI3-kinase and in the subsequent down-
regulation by activation of the Raf-1/ERK pathway, thus establishing a complex and bimodal 
involvement of H-Ras (Weber et al., 2001a). Rho, another member of the Ras superfamily, 
exerts an influence on integrin activation by its regulatory function in cytoskeletal organization 
(Laudanna et al., 1996). 
 
Intracellular Ca2+ is also involved in inside-out signaling, e.g. by effecting clustering and 
adhesion properties of leukocyte integrins through activation of the Ca2+-dependent protease 
calpain (Leitinger et al., 2000). Furthermore, PI3-kinase (Hughes et al., 1998) and PKC signal to 
integrins, the latter affecting integrin avidity but not affinity (Kolanus et al., 1997; Gahmberg et 
al., 1998). There are indications that cytoplasmic domains of integrins, which exhibit conserved 
serine, threonine and tyrosine residues, are phosphorylated in response to activators such as 
PKC. However, a significant role for phosphorylation in integrin activation has not yet been 
established (Hibbs et al., 1991a; Hynes, 1992; Williams et al., 1994; Gahmberg et al., 1998). 
 
Phorbol esters such as phorbol-12-myristate-13-acetate (PMA) efficiently activate leukocyte 
integrins in less than one hour via PKC (Gahmberg et al., 1997). A more physiological 
stimulation compared to PMA is achieved e.g. by inflammatory cytokines like SDF-1α 
(CXCL12) (Campbell et al., 1998; Weber et al., 1999a). The G protein–coupled chemokine 
receptors are an example for the influence of outside-in signals from other surface receptors to 
integrin-activating signaling, as is the engagement of the T-cell receptor (TCR)/CD3 complex in 
LFA-1 activation (Dustin et al., 1989). 
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Integrin inside-out signaling is also induced by direct interactions of intracellular regulatory and 
cytoskeletal proteins with integrin subunits. Additionally, lateral protein interactions in cis with 
adjacent membrane proteins can influence the activation state of integrins. Both aspects are 
described below. In addition to the effects of intracellular signaling, activation of integrins is also 
directed by extracellular signals. Since they represent metalloproteins, integrin function is 
dependent on extracellular divalent metal cations, i.e. Mg2+, Mn2+ and Ca2+, which influence 
their conformation and thus are important determinants of their affinity state. However, the role 
of Ca2+ appears to be more complex, since in some systems it revealed an inhibitory effect on 
integrin adhesiveness (Leitinger et al., 2000; Humphries, 2000; Plow et al., 2000). 
 
 
1.5.3. Outside-in signaling 
Beside their functional role as adhesion receptors, integrins are capable of delivering 
extracellular information to the interior of the cell. Integrin-triggered signal transduction 
cascades (outside-in signaling) lead to diverse cellular responses regulating gene expression, cell 
growth, migration, differentiation and survival (Hynes, 1992; Miranti et al., 2002). 
 
Outside-in signaling of integrins occurs frequently at focal contacts, where clusters of ligand-
bound integrins complex with cytoskeletal, signaling and adaptor molecules. Importantly, 
integrin-initiated signals mediate the tyrosine phosphorylation of a number of cellular proteins, 
including Src and Fyn tyrosine kinases as well as the autophosphorylation of focal adhesion 
kinase (FAK). Activated FAK in turn phosphorylates paxillin and CAS that serve as scaffolds for 
the recruitment of various adapters and signaling molecules. Further signal transduction can lead 
to the activation of elements of the ERK/mitogen-activated protein kinase (MAPK) pathway 
(Howe et al., 1998; Giancotti, 2000). However, integrins transduce their outside-in signals to 
many other downstream pathways, affecting regulatory proteins such as PI3-kinase, PLC and the 
small GTPases Rho, Rac and Cdc42 (Howe et al., 1998; Longhurst et al., 1998; Boudreau et al., 
1999; Schoenwaelder et al., 1999; Dib et al., 2000). Subsequent events include the modulation of 
cytoplasmic Ca2+ concentrations (Schwartz, 1993), PKC activity (Vuori et al., 1993) and the 
Na+/H+ antiporter activity accompanied by changes in intracellular pH values (Schwartz et al., 
1991). 
 
Integrins, which posses no intrinsic catalytic activity, signal not only in a direct but also in a 
collaborative manner. In the latter case they take advantage of the downstream signaling 
pathways of other surface receptors described below by trans-activation (receptor cross-talk) to 
transduce specific signals to the cell interior. Moreover, outside-in signaling of integrins can 
regulate the function of other integrins. For example, ligand-bound exogenous αIIbβ3 has been 
shown to suppress the adhesive function of the endogenous integrin α5β1 in the same cells 
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(trans-dominant inhibition) due to a blockade of αIIbβ3 signaling to the suppressed target integrin 
(Díaz-González et al., 1996). 
 
 
1.5.4. Integrin-interacting proteins 
1.5.4.1. Integrin ligands: ECM proteins and counter-receptors 
The majority of integrins bind extracellularly to ECM proteins. At least eight bind to fibronectin 
(α4β1, α5β1, αVβ1, αVβ3, αIIbβ3, αVβ6, α4β7) and five to laminin (α1β1, α2β1, α3β1, α6β1, α6β4). 
Other ECM ligands include collagen IV and vitronectin. A key recognition sequence for 
integrins on some ECM proteins is the tripeptide motif RGD that is for example involved in the 
binding of fibronectin to its integrin receptor α5β1. Other integrins recognize different motifs 
(Hynes, 1992; Plow et al., 2000). Due to their binding specificities, ECM proteins exert 
fundamental influence on many cellular processes with regard to their outside-in signal 
transduction and cytoskeletal connection mediated by their respective integrin receptor(s). 
 
However, certain integrins interact with counter-receptors on other cells or in soluble plasma. 
One important example is the binding of αIIbβ3 on activated platelets to soluble fibrinogen or 
vWF in the process of wound healing (Hynes, 1992; Clemetson et al., 1998). The leukocyte-
specific integrin αEβ7 has been shown to bind epithelial expressed E-cadherin (Cepek et al., 
1994) that is involved in the formation of interepithelial AJs. Some integrin ligands belong to the 
family of IgSF proteins and contribute to endothelial adhesion or diapedesis of leukocytes. 
Beside the interaction of ICAMs with β2 integrins (see below) this includes the interaction of 
α4β1 (VLA-4) with VCAM-1 (CD106), α4β7 with MAdCAM-1 and αVβ3 with PECAM-1 
(CD31) (Elices et al., 1990; Berlin et al., 1993; Piali et al., 1995; Elices et al., 1990; Berlin et al., 
1993; Piali et al., 1995). 
 
 
1.5.4.2. Cytoskeletal integrin connections 
The connection of integrins to the actin cytoskeleton is mainly formed via their β tails through 
the association with the actin binding proteins talin and filamin as well as the actin bundling 
protein α-actinin (Calderwood et al., 2000; Critchley, 2000). Talin interacts with both vinculin 
and paxillin, the latter binding FAK that further phosphorylates signaling and adaptor molecules 
as described. Concerning the α subunit, paxillin has been shown to bind directly α4 but not other 
integrin α tails, reducing focal adhesion and stress fibre formation and thus enhancing cell 
migration (Liu et al., 1999; Giancotti, 2000). 
 
14  Introduction 
Interactions of integrins with the cytoskeleton are thought to occur mainly as a consequence of 
integrin-ligand engagement (outside-in signaling). This contributes to cytoskeleton-
reorganization, formation of focal adhesion complexes and to integrin activation (Hughes et al., 
1998; Schoenwaelder et al., 1999). On the other hand, cytoskeletal association is required for 
integrin inside-out signaling. Thereby active receptor conformations may be stabilized (affinity), 
and transient disconnection during cytoskeletal reorganization allows lateral motility required for 
integrin clustering (avidity). Thus, extracellular integrin interactions can directly influence the 
state of cytoskeleton organization and vice versa. 
 
 
1.5.4.3. Direct cytoplasmic interaction partners 
The majority of protein interactions between integrins and cytoplasmic proteins described so far 
are specific for the β tail (Liu et al., 2000a). Integrin-linked kinase (ILK), a serine/threonine 
kinase involved in cell adhesion, anchorage-dependent cell growth and fibronectin matrix 
assembly, binds to β1, β2 and β3 cytoplasmic tails and may regulate integrin affinity (Hannigan et 
al., 1996). A link between integrins and PKC is provided by the Trp-Asp (WD) repeat protein 
Rack-1. This receptor for activated PKC binds in vivo with its C-terminal three WD motifs to the 
membrane-proximal region of β1, β2 and β5 tails following stimulation with phorbol ester 
(Liliental et al., 1998). More specifically, the WD repeat protein WAIT-1 interacts with the 
leukocyte integrins α4β7 and αEβ7 (Rietzler et al., 1998). The integrin cytoplasmic domain-
associated protein (ICAP)-1 interacts specifically with the highly conserved NPxY sequence of 
β1 tails and is phosphorylated upon β1 integrin-mediated cell-matrix adhesion (Chang et al., 
1997). Differently, β3-endonexin recognizes a unique membrane-distal NITY motif found on 
integrin β3 tails (Shattil et al., 1995; Eigenthaler et al., 1997) and thereby can increase αIIbβ3 
affinity and fibrinogen-dependent platelet aggregation (Kashiwagi et al., 1997). 
 
The β2 integrin LFA-1, described in detail below, interacts via its β subunit with the Jun 
activation domain-binding protein 1 (JAB1), a coactivator of the transcription factor c-Jun. This 
interaction results in an enhanced activity of the transcription factor activator protein (AP)-1 
(Bianchi et al., 2000), indicating a role of LFA-1 in the regulation of gene expression. A 
functional regulator of LFA-1 avidity is given by cytohesin-1, a cytosolic guanine nucleotide 
exchange factor (GEF) for ADP ribosylation factor (ARF)-GTPases that is predominantly 
expressed in hematopoietic cells (Kolanus et al., 1996). Cytohesin-1 binds specifically with its 
N-terminal SEC7 domain to the membrane-proximal residues in the β2 tail (Geiger et al., 2000). 
By this interaction cytohesin-1 has a functional role in the activation of LFA-1–mediated T cell 
adhesion and spreading on the LFA-1 ligand ICAM-1 (Kolanus et al., 1996) as well as in 
chemokine-induced T cell arrest on cytokine-activated endothelium with subsequent 
transendothelial migration under flow conditions (Weber et al., 2001b). Plasma membrane 
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recruitment of cytohesin-1 is mediated by the PI3-kinase product phosphatidylinositol-(3,4,5)-
triphosphate (PIP3). PIP3 specifically binds the pleckstrin homology (PH) domain of cytohesin-1 
(Nagel et al., 1998a; Nagel et al., 1998b). In this way cytohesin-1 takes part in the linkage of 
phospholipid signaling via PI3-kinase to LFA-1 activation. Similarly the general receptor of 
phosphoinositides 1 (GRP1; cytohesin-3) but not the ARF nucleotide binding site opener 
(ARNO; cytohesin-2) interacts with CD18 and induces LFA-1–mediated lymphocyte adhesion to 
ICAM-1 (Korthäuer et al., 2000). 
 
Surprisingly in contrast to the integrin β subunit, only few direct interaction partners have been 
identified for the cytosolic part of integrin α subunits. The interaction with WAIT-1 described 
above is one example. Calcium and integrin-binding protein (CIP) binds to αIIb and may be a 
candidate regulatory protein for αIIbβ3 (GPIIb/IIIa) in platelets (Naik et al., 1997). Most 
importantly, the ubiquitously expressed Ca2+-binding protein calreticulin binds to the highly 
conserved and functionally important KxGFFKR motif in integrin α tails (Rojiani et al., 1991). 
It has been hypothesized that by this interaction, calreticulin disrupts the native default inactive 
state of integrins that is normally mediated by the KxGFFKR motif and thus activates integrin 
function (Dedhar, 1994). Its physiological role is demonstrated by calreticulin-null embryonic 
stem cells that have a severe defect in integrin-mediated cell adhesion (Coppolino et al., 1997). 
 
 
1.5.4.4. Lateral receptor interactions of integrins 
Besides extracellular and cytosolic protein interactions, integrin receptors also cooperate in 
direct lateral association with other plasma membrane receptors (trans-activation). They are thus 
able to signal to different pathways (Boudreau et al., 1999; Schwartz et al., 2002). For example, 
β1 integrins were shown to activate platelet-derived growth factor (PDGF) β-receptor 
independently of the presence of the PDGF ligand (Sundberg et al., 1996). Transmembrane-4 
superfamily (TM4SF) proteins (tetraspans) such as CD9, CD63, CD81 and CD151 can associate 
directly with certain integrins. Some of them recruit signaling enzymes such as PI4-kinase and 
PKC into complexes with integrins, linking them to phospholipid signaling and enabling PKC-
dependent phosphorylation, e.g. of the α3 or the α6 cytoplasmic domain (Hemler, 1998; 
Longhurst et al., 1998; Giancotti, 2000). Another integrin cross-talk partner is the five 
membrane-spanning integrin-associated protein (IAP; CD47) associated with the ubiquitous 
expressed αVβ3 and the platelet-restricted αIIbβ3. Several αvβ3-dependent neutrophil functions 
are strongly influenced by anti-CD47 treatment and IAP knock-out mice suggest a central role in 
leukocyte migration (Porter et al., 1998). Contrary to these receptors, uPAR (urokinase-type 
plasminogen activator receptor; CD87) is an example of a cell surface receptor that lacks 
intracellular domains and thus has to signal through membrane-spanning lateral interaction 
partners such as the β1, β2 and β3 integrins (Ossowski et al., 2000). 
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1.5.5. Leukocyte-specific β2 integrins 
Approximately half of the known integrins are expressed by lymphocytes, monocytes and 
granulocytes. Cell-cell contacts mediated by β2 integrins contribute to processes such as antigen 
presentation, cytotoxicity, phagocytosis and extravasation. Besides the β7 group (α4β7, αEβ7), 
β2 integrins are presented exclusively on leukocytes. Presently four different α chains, i.e. the 
I domain-containing αL, αM, αx and αD, are known to associate with the β2 (CD18) chain. The 
genes that encode them are located on chromosome 16, whereas the gene for CD18 is located on 
chromosome 21 (Gahmberg et al., 1998). 
 
 
1.5.5.1. LFA-1 
One of the most abundant leukocyte integrins is the lymphocyte-function associated antigen-1 
(LFA-1; αLβ2; CD11a/CD18). LFA-1 is predominantly expressed in lymphocytes and 
neutrophils and consists of the 180-kDa αL chain associated with the 95-kDa β2 chain common 
to all CD11/CD18-integrins. As a cell-adhesion receptor, LFA-1 is involved in a broad range of 
immunologic processes including B lymphocyte responses, antigen-induced T cell proliferation, 
T cell-mediated cytotoxicity, and natural killer (NK) cell activity (Dustin et al., 1989; Arnaout, 
1990; Springer, 1990). Furthermore, LFA-1 is a key player in the highly regulated process of 
lymphocyte homing and leukocyte extravasation to sites of inflammation, mediating firm arrest 
on the endothelium and subsequent transmigration (Butcher, 1991; Springer, 1994). Additionally 
LFA-1 appears to participate in the initial step of slowing-down the velocity of rolling 
leukocytes (Sigal et al., 2000; Henderson et al., 2001; Dunne et al., 2002). 
 
Without stimulation LFA-1 surface expression is generally not sufficient for adhesion thus 
allowing unresisted leukocyte circulation and highly specific regulation of its adhesive 
properties. Activation of LFA-1 is mainly achieved by inside-out signaling triggered, for 
example, by TCR signals (Dustin et al., 1989), cytokines such as IL-12 (Mukai et al., 2001), 
chemokines such as SDF-1 (Peled et al., 1999) and other inflammation mediators. LFA-1 avidity 
can be rapidly induced with PKC-activating phorbol esters such as PMA (Dustin et al., 1989) 
leading to the phosphorylation of S756 in the β2 tail. However, mutational analysis has not 
revealed a significant role for phosphorylated S756 in LFA-1–mediated adhesion (Hibbs et al., 
1991a). The adjacent T758-T759-T760 motif does appear to be critical for this process, since 
mutation of one of these residues leads to decreased adhesion (Hibbs et al., 1991a; Gahmberg et 
al., 1998). The crucial role of intracellular partners or extracellular divalent cations in LFA-1 
function has already been discussed. 
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Extracellularly, LFA-1 binds to ICAMs, a subfamily of type I membrane glycoproteins within 
the IgSF (Simmons, 1995; Gahmberg et al., 1997). The main ligand is ICAM-1 (CD54) that is 
present on leukocytes, ECs and many other tissues although at low expression levels (Marlin et 
al., 1987). On resting ECs it is rapidly inducible by inflammatory cytokines such as TNF-α, 
IFN-γ and IL-1. Truncation of the β2 but not that of the αL cytoplasmic domain eliminates 
LFA-1–binding to ICAM-1 (Hibbs et al., 1991b), revealing the importance of integrin inside-out 
signaling in ligand binding. However, complete deletion of the β2 cytoplasmic domain results in 
a constitutively active and LFA-1–clustering mutant that binds strongly to ICAM-1 (Lub et al., 
1997b). An important aspect of ICAM-1 binding to LFA-1 is its dimerization at the cell surface 
(Jun et al., 2001). In addition to ICAM-1, LFA-1 binds to ICAM-2 (CD102) on ECs, leukocytes 
and platelets, to ICAM-3 (CD50) on lymphocytes, to the Landsteiner-Wiener blood group 
antigen ICAM-4 (LW) exclusively expressed on red cells and finally to the brain-specific 
telencephalin (TLN; ICAM-5) (Gahmberg et al., 1997; Gahmberg et al., 1998). 
 
 
1.5.5.2. Mac-1 
Mac-1 (αMβ2; CD11b/CD18; complement receptor type 3, CR3; macrophage antigen-1) 
recognizes a wide spectrum of ligands, which include ICAM-1 (Diamond et al., 1991), the 
platelet glycoprotein (GP) Ibα (Simon et al., 2000), the blood coagulation factors fibrinogen and 
factor X, and the complement fragment iC3b. It is exclusively expressed on monocytes, 
macrophages, neutrophils and NK cells. The levels of Mac-1 at the cell surface but not that of 
LFA-1 can be rapidly increased in response to chemotactic factors due to its storage in 
intracellular pools. Mac-1 plays an important role in phagocytosis of microorganisms and is 
involved in ICAM-1–mediated leukocyte attachment (Kishimoto et al., 1989; Arnaout, 1990). 
Knock-out mice experiments have revealed a dominant role for LFA-1 compared to Mac-1 in the 
relative contribution to neutrophil adhesion and extravasation (Lu et al., 1997; Ding et al., 1999). 
Moreover, both β2 integrins display different kinetics of activation in lymphocytes upon 
chemokine stimulation, i.e. transient avidity for LFA-1 and sustained avidity for Mac-1, a 
function of their respective cytoplasmic α tails (Weber et al., 1999a). 
 
 
1.5.5.3. p150,95 
The expression of p150,95 (αxβ2; CD11c/CD18; CR4) is mainly restricted to myeloid cells. Like 
Mac-1 it is stored in intracellular granules and can also function as receptor for iC3b and 
fibrinogen (Dickeson et al., 1998). Additionally, p150,95 represents beside CD14 the second 
monocyte receptor for endotoxin (Ingalls et al., 1995). 
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1.5.5.4. αDβ2 
αDβ2 (CD11d/CD18) is the most recently identified β2 integrin (Danilenko et al., 1995; van der 
Vieren et al., 1995) and is mainly found in macrophages and granulocytes of the splenic red 
pulp. αDβ2 preferentially binds to ICAM-3. 
 
 
1.5.5.5. Leukocyte adhesion deficiency type 1 (LAD-I) 
The physiological importance of β2 integrin adhesion molecules is revealed by the inherited 
autosomal recessive disorder LAD-I in which defects in the β2 (CD18) gene cause a deficiency 
or loss in expression of all β2 (CD11/CD18) integrins (Anderson et al., 1987; Kishimoto et al., 
1989). This disease is characterized by recurrent severe and life-threatening bacterial infections 
and impaired wound healing with clinical similarities to LAD-II (see 1.3.). Concerned patients 
show abnormalities in many adhesion-dependent leukocyte functions including endothelial 
arrest, aggregation, chemotaxis, phagocytosis and cytotoxicity. The severity is directly related to 
the degree of β2 integrin deficiency and may lead in severe cases to death during infancy. The 
molecular basis of this disease is a defective biosynthesis of CD18 due to mutations mainly 
localized around the MIDAS-like motif in the I-like domain (Leitinger et al., 2000). These 
mutations impair heterodimer formation of the β2 precursor with the respective α chain 
precursor, a process essential for subsequent carbohydrate processing and surface expression of 
the mature integrin (Anderson et al., 1987; Arnaout, 1990). Thus, the surface expression of 
CD18 but as well that of the unaffected CD11 subunits is deficient in the leukocytes of LAD-I 
patients. Differently mutated β2 subunits vary in their ability to complex with the α subunit, 
which leads to the heterogeneity of the clinical phenotype of LAD-I and offers insights into the 
structural basis of the integrin αβ heterodimer formation (Shaw et al., 2001a). LAD-I patients 
can be cured by bone marrow transplantation that restores leukocyte function. 
 
 
1.5.6. α4 integrins 
The VLA-4/VCAM-1 interaction (Elices et al., 1990) provides a second lymphocyte-EC 
adhesion mechanism distinct from the LFA-1/ICAM-1 interaction (Ronald et al., 2001). Very 
late antigen (VLA)-4 (α4β1; CD49d/CD29) is an atypical member of the ECM (fibronectin, 
laminin, collagen) receptor family of β1 integrins (Hemler, 1990) with expression restricted to 
lymphocytes, monocytes and eosinophils. VLA-4 and the lymphocytic α4β7 functions both as a 
matrix (fibrinogen) and cell receptor. In the case of the latter, they bind to VCAM-1 (CD106) 
(Elices et al., 1990; Berlin et al., 1993). Similar to ICAM-1, this IgSF member is expressed on 
the endothelium in response to inflammatory induction e.g. by TNF-α, IL-1 or LPS (Springer, 
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1995). In addition to VCAM-1, α4β7 also interacts specifically with the IgSF protein 
MAdCAM-1 expressed by mucosal venules (Berlin et al., 1993). In contrast to the β2 integrins, 
VLA-4 and α4β7 are able to support not only firm arrest and transmigration but also rolling of 
non-neutrophilic leukocytes on activated endothelium (Stewart et al., 1995). LFA-1 and VLA-4 
appear to exert distinct functions in the process of extravasation. In the case of monocytes, 
VLA-4 preferentially mediates cell arrest and subsequent lateral migration along the endothelium 
to the site of interendothelial junctions, where in turn LFA-1 is more crucial for diapedesis itself 
(Weber et al., 1998). 
 
 
 
1.6. Immunoglobulin superfamily 
The immunoglobulin superfamily (IgSF) (Williams et al., 1988) consists of proteins that contain 
modular domains with homology in sequence and tertiary structure to the variable (type V) and 
the constant (type C1 and C2) domain of antibodies (Bork et al., 1994; Holness et al., 1994; 
Vaughn et al., 1996). Immunoglobulin (Ig)-like domains are constituted by 70 – 110 aa that form 
two β-sheets in a sandwich-like structure with seven to nine antiparallel β-strands. Two cysteine 
residues at a distance of 55 to 75 aa form an intramolecular disulfide bond within the Ig-like 
loop. Most IgSF members are integral transmembrane proteins with extracellular Ig-like 
domain(s) and divergent cytoplasmic tails. Despite the conserved folding of the Ig-like domains 
there is great diversity in the function of IgSF proteins as recognition and binding molecules, 
undergoing homophilic or heterophilic interactions both in cis and in trans. Noted members of 
the IgSF are TCR, class I and class II major histocompatibility complexes (MHC), CD4, CD8, 
FcγRII, the PDGF receptor, and integrin ligands such as ICAM-1, VCAM-1 and PECAM-1. On 
leukocytes, approximately 50 % of the surface proteins are IgSF molecules. Considering the 
dynamic process of cell-cell adhesion, the binding of a single IgSF molecule to its interaction 
partner may be very weak but can lead to significant adhesive strength by multivalent 
presentation as occurs in particular on activated cell surfaces. 
 
 
 
1.7. Junctional adhesion molecule (JAM)-1 
The type I transmembrane protein JAM-1 is a novel member of the IgSF family that was first 
characterized in the mouse (Martìn-Padura et al., 1998) and found to be identical to murine 
antigen 106 (Malergue et al., 1998). Due to its predominant expression at intercellular junctions 
between endothelial and epithelial cells and data from Chinese hamster ovary (CHO) cell 
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transfectants suggesting a role in cell-cell interaction, this surface protein was termed junctional 
adhesion molecule (Martìn-Padura et al., 1998). Identification of the human homologue (Ozaki 
et al., 1999; Williams et al., 1999) revealed similarity with the partially sequenced platelet 
surface glycoprotein F11 antigen (F11R) (Kornecki et al., 1990; Naik et al., 1995). The 
subsequent determination of the complete sequence of F11R revealed its identity with human 
JAM-1 (Sobocka et al., 2000; Gupta et al., 2000). 
 
 
1.7.1. Expression, localization and function of JAM-1 
JAM-1 is expressed in the tissue of most major organ systems, such as heart, liver, lung, 
pancreas and kidney (Gupta et al., 2000; Liang et al., 2000; Naik et al., 2001). Northern blot 
analysis revealed the expression of JAM-1 at the mRNA level as a single 2-kb transcript in mice 
(Martìn-Padura et al., 1998; Malergue et al., 1998), whereas human JAM-1 is transcribed into 
multiple mRNA molecules of 4.0, 2.4 and 1.9 kb resulting from differences in the size of the 
3'-UTR (Williams et al., 1999; Naik et al., 2001). 
 
JAM-1 is predominantly expressed in endothelial and epithelial cells. Immunofluorescence and 
immunoelectron microscopy as well as immunohistochemistry has localized JAM-1 expression 
specifically at apical tight junctional structures. Here it colocalizes with typical TJ markers such 
as ZO-1, occludin and cingulin, but not with AJ-associated molecules like β-catenin or 
E-cadherin (Martìn-Padura et al., 1998). In epithelial cells JAM-1 was also found to localize 
subapically to TJs at more basolateral areas of intercellular contacts (Liang et al., 2000; Liu et 
al., 2000b). The junctional localization can be influenced by proinflammatory cytokines. A 
combined treatment of human umbilical vein endothelial cell (HUVEC) monolayers with TNF-α 
and IFN-γ causes JAM-1 to redistribute from the intercellular junctions over the cell surface, 
implicating a functional role in inflammatory processes (Ozaki et al., 1999; Shaw et al., 2001c). 
Its specific localization and data from resealing experiments of disrupted TJs (Liu et al., 2000b; 
Liang et al., 2000) suggest a functional role in generation and/or maintenance of TJs and the 
formation of cell polarity. The expression of JAM-1 in hematopoietic cells is discussed 
elsewhere within this report. 
 
 
1.7.2. Molecular structure 
Located on chromosome 1q21.1-21.3 (Naik et al., 2001), the human JAM-1 gene encodes a 
protein of 299 aa (see fig. 17) with an N-terminal signal sequence (27 aa), a large extracellular 
domain (211 aa), a single transmembrane domain (17 aa) and a short (44 aa) cytoplasmic tail 
(Liu et al., 2000b). The extracellular part contains two Ig-like loops each flanked by two cysteine 
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residues (C50 and C109, C153 and C212) forming a disulfide bond. Thus JAM-1 belongs to the 
IgSF family and resembles structurally other cell adhesion molecules (CAMs). Whether the 
Ig-like domains are of type V or type C2 is still controversial (Naik et al., 2001; Aurrand-Lions 
et al., 2001b). JAM-1 exhibits two N-glycosylation sites, N185 and N191, that are both located 
in the membrane-proximal Ig-like domain 2. They lead in some cells to heterogeneous 
expression of JAM-1 due to differential glycosylation. Here, JAM-1 appears as ~40 kDa and 
~37 kDa proteins in western blot analysis, and enzymatic deglycosylation reveals a core protein 
with a molecular mass of ~35 kDa (Naik et al., 1995; Liang et al., 2000). The cytoplasmic tail of 
JAM-1 is highly charged, contains several putative phosphorylation sites for PKC and other 
protein kinases and is distinguished by the PDZ domain-binding motif FLV at the C-terminal 
end. 
 
JAM-1 is highly conserved among mammals, with murine, bovine and human JAM-1 displaying 
approximately 70 % overall identity at the amino acid level (Ozaki et al., 1999). The high degree 
of conservation within the cytoplasmic tail with more than 80 % identity suggests similar 
intracellular function and/or regulation. 
 
 
1.7.3. Extracellular homophilic interactions in cis and in trans 
Analytical ultracentrifugation of rsJAM, the recombinant soluble expressed extracellular domain 
of murine JAM-1, reveals 89 % associates as dimers while 11 % forms tetramers but none appear 
as monomers. This demonstrates, in addition to the results of other in vitro studies, the capacity 
for dimerization and oligomerization (Bazzoni et al., 2000a; Liang et al., 2000). The presence of 
JAM-1 dimers on the cell surface, i.e. homophilic JAM-1 interactions in cis, was demonstrated 
in transfected CHO cells using a membrane-impermeable protein cross-linker (Bazzoni et al., 
2000a). Such homophilic interactions in cis are meditated by the N-terminal Ig-like domain 1 of 
JAM-1, forming an U-shaped dimer formation (see fig. 29) as revealed from the crystal structure 
of rsJAM (Kostrewa et al., 2001). 
 
Endothelial and epithelial JAM-1 exerts adhesive properties at intercellular junctions by 
homophilic binding in trans (between JAM-1 molecules of opposing cells) and thus participates 
in the arrangement of TJs and more basolateral junctional structures. Exogenously expressed in 
confluent CHO cells, JAM-1 is specifically concentrated at cell-cell contacts and decreases the 
paracellular permeability of the cell monolayer. If the CHO cells, which do not exert organized 
TJs, are only partially transfected, JAM-1 is solely concentrated at cell-cell contacts if the 
adjacent neighboring cell is also transfected (Martìn-Padura et al., 1998; Naik et al., 2001). 
Trans-homophilic interactions seems thus to mediate the recruitment of JAM-1 to intercellular 
junctions. Notably, soluble JAM-1–Fc chimera or monoclonal antibodies (mAbs) raised against 
JAM-1 inhibit or significantly slow down the resealing of disrupted intercellular junctions 
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between epithelial cells (Liang et al., 2000; Liu et al., 2000b), displaying the importance of 
trans-homophilic adhesive JAM-1 binding for the integrity of the cell monolayer. The X-ray 
structure of crystallized rsJAM revealed that pairs of cis-dimers contact each other in trans at 
their respective N-terminal Ig-like domain 1 (Kostrewa et al., 2001), suggesting that this domain 
mediates most likely both cis- and trans-homophilic JAM-1 interactions. 
 
 
1.7.4. Extracellular heterophilic interactions 
JAM-1 was shown to function as a reovirus receptor (Barton et al., 2001). The cell surface 
protein is recognized with high affinity by the globular head of the viral attachment protein σ1. 
JAM-1 is sufficient for virus attachment and endocytosis but it may not necessarily mediated 
these processes. However, the activation of nuclear factor (NF)-κB and apoptosis accompanying 
reovirus infection fully depends on the binding of reovirus to cellular JAM-1 via σ1. 
Furthermore, the extracellular binding of the JAM-1 mAb F11 to human platelet JAM-1 (F11R) 
has been shown to induce platelet activation and aggregation by cross-linking JAM-1 with 
FcγRII in cis (Kornecki et al., 1990; Naik et al., 1995; Sobocka et al., 2000). 
 
 
1.7.5. Intracellular interactions 
The most striking element in the cytoplasmic domain of JAM-1 is its C-terminal PDZ domain-
binding motif FLV. Nearly all intracellular proteins described so far that interact with JAM-1 
contain PDZ domains, protein-binding domains of 80 – 90 aa in size recognized initially as 
sequence repeats in the mammalian postsynaptic density protein PSD-95, the Drosophila disc 
large tumor suppressor Dlg, and the mammalian tight junction protein ZO-1 (PDZ). PDZ 
proteins are predominantly localized at or involved in the formation of intercellular junctions, in 
particular of TJs, beneath the plasma membrane. They often express multiple copies of PDZ 
domains within their sequence, each of which can exert specificity to different PDZ-binding 
motif-containing interacting proteins. Thus they are able to function as scaffolding proteins at 
appropriate plasma membranes. Thereby they can form transmembrane-associated 
heterogeneous protein complexes with linkage to signal transduction pathways or to the actin 
cytoskeleton (Pawson et al., 1997; Fanning et al., 1999). Association of JAM-1 with these 
binding partners at junction compartments has been shown to generally depend on the C-terminal 
PDZ domain-binding motif of JAM-1. Whereas the extracellular JAM-1/JAM-1 interactions in 
trans appear to be sufficient to localize JAM-1 at the site of cell-cell boarders, intracellular 
JAM-1 interactions with PDZ domain-containing proteins might be necessary for the correct 
junctional localization and, in turn, enable JAM-1 to recruit and integrate such interacting 
partners into specific junctional structures. 
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The junctional zonula occludens protein (ZO)-1 binds directly JAM-1 with its PDZ domain(s) 2 
and/or 3 and thus may link JAM-1 to PDZ domain 1-bound occludin and the actin filament 
system (Bazzoni et al., 2000b; Ebnet et al., 2000; Itoh et al., 2001). The PDZ domain-mediated 
interaction of JAM-1 with AF-6 links JAM-1 to the cytoskeleton (Ebnet et al., 2000), and may 
also mediate intracellular signaling since AF-6 can alternatively bind ZO-1 or the small GTPase 
Ras which has been reported to perturb cell-cell contacts and to decrease AF-6 and ZO-1 surface 
expression (Yamamoto et al., 1997). AF-6 can recruit JAM-1 to TJs independent of its 
homophilic extracellular trans-interactions (Ebnet et al., 2000). The AF-6/JAM-1 binding occurs 
only in recently confluent monolayers, suggesting a dynamic regulatory function of this 
interaction in the formation rather than in the maintenance of cell junctions. A third cytoskeleton 
linker may exist with the calmodulin-dependent serine protein kinase (CASK) that colocalizes in 
a PDZ domain-dependent manner with epithelial JAM-1 at both tight and basolateral junctions 
(Martínez-Estrada et al., 2001). The multi-PDZ domain protein 1 (MUPP1) is localized at 
epithelial TJs and may act as multivalent scaffold protein organizing various proteins beneath the 
plasma membrane of TJs. It interacts with claudin by its PDZ domain 10 and with JAM-1 by its 
PDZ domain 9 (Hamazaki et al., 2002). ASIP (atypical PKC isotype-specific interacting 
protein), the vertebrate homologue of the Caenorhabditis elegans polarity protein PAR-3, is also 
localized at epithelial TJs (Izumi et al., 1998). ASIP forms a complex with the mammalian 
homologue of PAR-6, atypical PKC (aPKC) and the small GTPases Cdc42 and Rac-1. JAM-1 
directly associates with the first PDZ domain of ASIP and might be able to recruit this signaling 
complex to TJs (Ebnet et al., 2001; Itoh et al., 2001). A cytoplasmic association of JAM-1 in a 
PDZ domain-independent manner has been demonstrated with the TJ protein cingulin (Bazzoni 
et al., 2000b). 
 
The exemplified large number of interactions with TJ proteins suggests an important role for 
JAM-1 in the organization of this intercellular contact structure. The dependence of JAM-1 on a 
single PDZ domain binding motif implicates a complex regulation of its interactions that may, 
among other factors, be dependent on the junctional maturation state (Martínez-Estrada et al., 
2001). The sequence and organization of TJ assembly and sealing, the functional role of the 
documented JAM-1–protein interactions and their influence and reliance on intracellular 
signaling, however, remains unclear. 
 
With respect to intracellular signaling, JAM-1 has been reported to be phosphorylated by PKC 
upon platelet activation at Ser284 (Naik et al., 1995; Ozaki et al., 2000). Interestingly, the 
cytoplasmic tail of JAM-1 has sequence homology with that of occludin, suggesting a similar 
down-stream signaling pathway (Liu et al., 2000b). 
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1.7.6. JAM-2 and JAM-3: co-founders of the JAM subfamily 
During the last 2 years, the junctional adhesion molecule (F11R, JAM-1, antigen 106) emerged 
as prototype of a distinct JAM subfamily within the IgSF family. Additional members that have 
since been identified are human JAM-2 (Cunningham et al., 2000) identical to human vascular 
endothelial junction-associated molecule (VE-JAM) (Palmeri et al., 2000), murine JAM-2 
(Aurrand-Lions et al., 2000; Aurrand-Lions et al., 2001a), human JAM-3 (Arrate et al., 2001) 
and murine JAM-3 (Aurrand-Lions et al., 2000) identical to murine VE-JAM (Palmeri et al., 
2000). Since human JAM-2 is homologous to murine JAM-3 but not to murine JAM-2, and since 
human JAM-3 is homologous to murine JAM-2 but not to murine JAM-3, this nomenclature 
requires some adjustment. To avoid ambiguity, hereinafter the JAM family member identified by 
Palmeri (designated human VE-JAM) and Cunningham and co-workers (Palmeri et al., 2000; 
Cunningham et al., 2000) is referred to as human JAM-2, and thus murine VE-JAM and the 
identical protein identified by Aurrand-Lions and co-workers (designated murine JAM-3) 
(Palmeri et al., 2000; Aurrand-Lions et al., 2000) is referred to as murine JAM-2. The 
designation of human JAM-3 by Arrate and co-workers (Arrate et al., 2001) is retained and thus 
the murine homologue reported by Aurrand-Lions and co-workers (designated murine JAM-2) 
(Aurrand-Lions et al., 2000; Aurrand-Lions et al., 2001a) is referred to as murine JAM-3. 
 
The close relationship between the three JAM family members JAM-1, -2, and -3 (with there 
human chromosomal localization 1q21.1-21.3 (Naik et al., 2001), 21q21.2 (Palmeri et al., 2000) 
and 11q25 (Arrate et al., 2001), respectively), is revealed by the high degree of sequence identity 
amounting to 31-36 % and a similarity of approximately 50 % at the amino acid level. The two 
extracellular Ig-like domains of JAM-2 and JAM-3 exhibit a V-C2 structure, with an extra pair 
of cysteines in their membrane-proximal C2 loops not present in JAM-1. These structural 
properties are characteristic for the cortical thymocyte Xenopus (CTX) family (Chrétien et al., 
1998), thus the JAM members form a subgroup within the group of CTX family proteins 
(Aurrand-Lions et al., 2001b). Different to JAM-1, the two N-glycosylation sites in JAM-2 and 
JAM-3 are distributed over both Ig-like loops in humans. The homology of the JAM family 
members concerns the overall sequence as well as the cytoplasmic tails. Here they exhibit two 
almost identical regions, A(Y/Q)(S/R)(R/K)GYF in the membrane-proximal part and 
C-terminally the PDZ-binding motif-containing sequence E(G/N)(D/E)F(K/R)(H/Q)(T/K)(S/K)-
SF(L/V/I)(V/I). This suggests similar cytoplasmic functions and/or regulation of JAM-1, -2, 
and -3. 
 
In contrast to JAM-1, the human JAM-2 and murine JAM-3 (not investigated so far for murine 
JAM-2 and human JAM-3) are restricted to endothelial expression and were not detected in 
epithelia. Interestingly, murine JAM proteins show heterogeneity in their subcellular localization 
at cell-cell contacts in transfected Madin-Darby canine kidney (MDCK) cells. JAM-3 is 
specifically expressed at the apical TJs, similar to JAM-1 that is however also localized at more 
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basolateral junctional areas in epithelial cells. On the contrary, JAM-2 is expressed only 
diffusely over the lateral site of intercellular junctions (Aurrand-Lions et al., 2001b). Additional 
functional features of the JAM subfamily members are discussed elsewhere within this report. 
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2. Aim 
In a search for specific interaction partners of the integrin αL (CD11a) subunit using the yeast-
two hybrid (YTH) system, a powerful genetic-based assay for the investigation of protein-protein 
interactions in vivo, the IgSF protein human JAM-1 was identified as a candidate binding partner 
of the β2 integrin LFA-1 (αLβ2). 
 
Subsequently, this protein-protein interaction and its specificity were to be verified in 
independent experiments and its functional implications at the molecular and cellular levels to be 
analyzed. Furthermore, the localization of the LFA-1–binding region within the JAM-1 sequence 
and redundancy with other β2 integrin receptors was to be investigated. Establishment of a 
polyclonal antibody against human JAM-1 and a CHO cell line expressing heterotopic JAM-1 
enabled the testing of the relevance of this novel interaction between these members of the 
integrin and JAM family in the cell-cell attachment of leukocytes. Cellular adhesion and 
transmigration assays performed both under static and laminar flow conditions using cells 
isolated from the human vasculature were employed to investigate the functional role of the 
LFA-1/JAM-1 interaction in the recruitment of leukocytes to sites of inflammation under more 
physiological conditions. 
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3. Materials and methods 
Protocols were adapted from standard methods (Sambrook et al., 1989; Ausubel et al., 1995), 
unless referred to otherwise. 
 
All solutions and media were prepared with ultra-pure water (Milli-Q Plus ultrapure purification 
pak, Milli-RO Plus purification pak; Millipore, Molsheim, France). 
 
Reagents were from Sigma (St. Louis, MO) and Merck (Darmstadt, Germany), unless stated 
otherwise. Biochemicals, biomaterials, solutions, assays and small equipment for life science 
research were mainly from Amersham (Uppsala, Sweden), Bio-Rad (Hercules, CA), Boehringer 
Mannheim (Mannheim, Germany), Clontech (Palo Alto, CA), Difco Laboratories (Detroit, MI), 
GibcoBRL (Life Technologies; Paisley, Scotland), New England Biolabs (Frankfurt, Germany), 
Qiagen (Hilden, Germany), Roche Diagnostics (Mannheim, Germany), Santa Cruz 
Biotechnology (Santa Cruz, CA) and, if not stated otherwise, from Sigma. 
 
 
3.1. General equipment 
autoclave   autoclave type 23; MELAG Medizintechnik (Berlin, Germany) 
centrifuges   Biofuge pico; Heraeus (Osterode, Germany)   
    Omnifuge 2.OR; Heraeus (Osterode, Germany)   
centrifuges, refrigerated Biofuge pico; Heraeus (Osterode, Germany)   
    Centrikon H-401, with rotors A8.24 and A6.9; Kontron-Hermle  
    (Gosheim, Germany) 
freezer, -70°C   ULT1706; Revco Scientific (Asheville, NC) 
incubator   WTB binder (Tuttlingen, Germany) 
liquid nitrogen tank  BT40; L’air liquide (Champigny, France) 
magnetic stirrer  MR3001; Heidolph (Kelheim, Germany) 
micor-pipettes   P20, P200, P1000; Gilson (Middleton, WI) 
microscope    IX50; Olympus Optical GmbH (Hamburg, Germany) 
pH meter   model 765 Calimatic; Knick (Berlin, Germany) 
scales    model BP 2100S; Sartorius (Göttingen, Germany)   
    model RI60P; Sartorius (Göttingen, Germany) 
spectrophotometer   UVICON 930; Kontron instruments (Echingen, Germany) 
thermomixer   Thermomixer compact; Eppendorf (Hamburg, Germany) 
vortexer   REAX top; Heidolph (Kelheim, Germany) 
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3.2. General solutions 
HBSS, 10x   Hanks’ balanced salt solution 
HEPES   N-(2-hydroxyethyl)-piperazine-N'-(2-ethanesulfonic acid) 
HHMC   HBSS  1x       
    HEPES 10 mM       
    MgCl2  1 mM        
    CaCl2  1 mM       
    BSA  0.5% (w/v)   (bovine serum albumin) 
PBS    Dulbecco’s phosphate buffered saline, w/o calium and   
    magnesium; PAA Laboratories (Linz, Austria) 
 
 
3.3. Mammalian cell culture procedures 
3.3.1. General  
Cell culture work was performed under sterile conditions under a laminar flow hood using sterile 
disposable plastic ware. 
 
 
3.3.2. Media and cell culture solutions 
Media and cell culture solutions were from PAA (PAA Laboratories, Linz, Austria), GibcoBRL 
and, if not stated otherwise, from Sigma. 
 
Unless purchased sterile, all media, solutions and supplements used in cell culture work were 
sterilized with a vacuum-driven 0.2-µm filter membrane filtration system or a 0.2-µm syringe 
filter. They were stored at 4°C and prewarmed to 37°C prior to use. 
 
 
3.3.3. Culturing 
Cell lines were placed in polystyrene culture flasks provided with 0.2-µm hydrophobic vent caps 
and maintained in a humidified 5 % CO2 atmosphere in an incubator at 37°C. All culture media 
were supplemented to complete media with 10 % (v/v) fetal calf serum (FCS) and 50 mg/l of the 
antibiotic gentamicin to avoid bacterial contamination. Before use, FCS was treated for 30 min at 
70°C to inactivate complement and stored at –20°C. Unless specified otherwise, cells were 
propagated in RPMI 1640 medium. 
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3.3.4. Cell harvest and subcultering  
In general, adherent cells were grown to confluence and then detached by trypsinization (see 
below), whereas suspension cells were cultured to a density of approx. 106 cells/ml. They were 
harvested by centrifugation at 1,200 rpm for 5 min at room temperature. The supernatant was 
removed and cells were washed by resuspension in phosphate buffered saline (PBS) with 
subsequent recentrifugation. For subculturing, cells were resuspended in fresh medium and 
replaced in culture flasks at a density of approx. 2·105 cells/ml. 
 
 
3.3.5. Trypsinization of adherent cell monolayers 
Monolayers of adherent cell lines (CHO, HeLa, HUVEC) were dispersed by trypsin/EDTA-
treatment (4 ml per 75-cm2 culture flask) for 1-2 min. After incubation, the cell suspension was 
diluted with 1 volume of complete medium, washed, and then split (subcultivation ratio 
1:6 - 1:10) or harvested by centrifugation. 
 
 
3.3.6. Cell number determination 
If cell density was to be determined, 50 µl of the cell suspension was mixed with 50 µl 0.4 % 
trypan blue solution to visualize non-viable cells. The cell numbers in four 0.1-mm3 volumes 
were counted in a Neubauer hemacytometer under a binocular microscope and used to determine 
the mean cell density. 
 
 
3.3.7. Freezing and thawing of mammalian cells 
Cell lines were stored in 2-ml cryovials in a liquid nitrogen storage freezer. Cells were harvested 
at a concentration of 106 - 107 cells/ml, washed with PBS and resuspended in 2 ml freezing 
medium. The freezing medium consisted of complete culture medium supplemented to 10 % 
with the cryo-protective agent dimethylsulfoxide (DMSO). The cryovials were placed in a –70°C 
freezer O/N and transferred to liquid nitrogen for long-time storage. 
 
Cryopreserved cells were thawed rapidly in a 37°C water bath, transferred in 5 volumes of 
prewarmed medium and centrifuged. The DMSO-containing supernatant was discarded and cells 
were seeded at high density in culture flasks. 
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3.3.8. Materials 
cell culture incubator  Steri-Cult Incubator; Forma Scientific (Mariette; OH) 
CO2    carbon dioxide 3.0; Linde Gas (Höllriegelskreuth, Germany) 
culture flask    Corning Inc. (Corning, NY) 
filtration system, 0.2 µm Stericup; Millipore (Bedford, MA) 
gentamicin    GibcoBRL 
laminar flow hood  BDK Luft- und Reinraumtechnik, Sonnenbühl-Genkingen,  
    Germany) 
RPMI 1640 medium   PAA 
syring filter, 0.2 µm   Acrodisc; Pall (Ann Arbor, MI) 
trypsin/EDTA solution (1x) porcine trypsin (0.5 g/l) and EDTA⋅Na4 (0.2 g/l) in HBSS 
 
 
 
3.4. Immortalized cell lines 
3.4.1. Chinese hamster ovary (CHO) cells 
The epithelial CHO cell line (obtained from L.B. Klickstein, Harvard Medical School, Boston, 
MA) is derived from the ovary of a Chinese hamster (Cricetulus griseus). The adherent cells 
were cultured in DMEM/F12 medium. 
 
 
3.4.2. HeLa cells 
HeLa cells are adherent epithelial-like cells established from a patient with adenocarinoma and 
were obtained from ATCC (American Type Culture Collection, Manassas, VA). They were 
cultured in RPMI 1640 medium. 
 
 
3.4.3. Jurkat T lymphocytes and related J-β2.7, J-β2.7/αL and J-β2.7/αM cells 
Jurkat cells are human T lymphocyte cells established from the peripheral blood of a patient with 
acute lymphoblastic leukemia. They were obtained from ATCC and cultured in RPMI 1640 
medium. 
 
J-β2.7 cells are Jurkat cells that completely lack cell surface LFA-1 due to the lack of αL 
expression effectuated by chemical mutagenesis (Weber et al., 1997b). J-β2.7 cell lines with 
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reconstituted LFA-1 surface expression (J-β2.7/αL) and heterotopic Mac-1 expression 
(J-β2.7/αM), respectively, were generated by transfection with αL (CD11a) or αM (CD11b) 
encoding cDNA (Weber et al., 1997b; Weber et al., 1999a). The Jurkat-related cell lines were 
provided by Dr. Kim Weber and maintained in normal RPMI 1640 culture medium with G418 
supplementation (see 3.5.) in case of the transfectants J-β2.7/αL and J-β2.7/αM. 
 
 
3.4.4. HL-60 cells 
HL-60 is a promyelocytic cell line. These leukocytes were established from the peripheral blood 
of a patient with acute promyelocytic leukemia. They were obtained from ATCC and cultured in 
RPMI 1640 medium. 
 
 
3.4.5. Mono Mac 6 cells 
Mono Mac 6 is a monocytic cell line that was established from the peripheral blood of a patient 
with acute monocytic leukemia and was obtained from H.W. Ziegler-Heitbrock (Institut für 
Inhalationsbiologie, GSF, Gauting, Germany). The cells were maintained in 24-well plates with 
2 ml MM6 medium per well. They were seeded at a density of 2⋅105 cells/ml and cultured 
3-4 days before being subcultured or used in experiments. To subculture Mono Mac 6 cells they 
were pooled without discarding the medium and diluted to the initial concentration by adding 
fresh MM6 medium. For harvesting, cells were centrifuged at 800 rpm for 5 min at 25°C. 
 
Materials 
MM6 medium           
 RPMI 1640        1x  
 FCS (added after ultrafiltration; see below)    10 %  
 penicillin        0.1 U/l  
 streptomycin        100 µg/ml 
 MEM non-essential amino acid solution (100x)   1x  
 insulin, in phosphate-free buffer (0.9 mg/ml)   9 µg/ml 
 oxalacetat         1 mM  
 pyruvate        1 mM 
The MM6 medium was ultrafiltered with a 20-kD cut off column (Ultrafilter U2000; 
Gambro Dialysatoren GmbH, Hechingen, Germany) to avoid LPS contamination which 
results in cell clumping, maturation and retarded growth. Subsequently the solution was 
supplemented with heat-inactivated FCS of low LPS content and sterilized by 0.2-µm 
filtration. 
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phosphate-free buffer          
 The phosphate-free buffer consisted of Puck’s saline A solution (137 mM NaCl,
 5.4 mM KCl, 4.2 mM NaHCO3, 5.0 mM glucose, pH 6) and 7.5 % sodium
 bicarbonate solution at a ratio of 5:6. 
 
 
3.4.6. THP-1 cells 
THP-1 is a monocytic cell line established from the peripheral blood of a patient with acute 
monocytic leukemia. The cells were obtained from ATCC and maintained in RPMI 1640 
medium. 
 
 
 
3.5. Establishing of stable transfected CHO cell lines 
CHO cell lines expressing recombinant proteins were generated by stable transfection of wild-
type CHO cells (CHO-WT). Therefore the protein-encoding cDNA sequence was subcloned into 
the multiple cloning site (MCS) of the mammalian expression vector pcDNA3. CHO-WT cells 
were electroporated with the plasmid to express the recombinant protein under the control of the 
cytomegalovirus (CMV) promotor. Selection of successfully transfected cells was performed 
with the antibiotic G418 sulfate (geneticin) against which pcDNA3 provides resistance. To 
ensure homogeneity in the genetic subset, selected cells were singularized and screened for 
expression of the recombinant protein. 
 
107 CHO-WT cells were resuspended in 1 ml ice-cold PBS, placed into an electroporation 
cuvette with a 0.4-cm electrode gap and mixed with 25-30 µg plasmid DNA. After 5 min of 
incubation on ice the cells were subjected to a high-voltage electric pulse of 270 V, 960 µF with 
a pulse control of 200 Ω. They were allowed to recover on ice for 5 min and then cultured for 
2 days in non-selection medium. The medium was then replaced by selective medium containing 
0.1 % (w/v) G418 sulfate. Non-transfected cells lost adhesive properties by death within 
1-2 weeks and were removed by medium exchange. Outlived transfected cells were cultured to 
confluence under selection conditions. 
 
After the selection phase cells were seeded into 96-well plates at a calculated density of 
0.5 cell/well. Propagation of colonies derived from single cells was ensured for each well by 
microscopy. Upon reaching an appropriate cell density the clones were screened for recombinant 
protein expression by flow cytometry, western blotting and RT-PCR. A stable transfected cell 
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line was established by culturing of one of the generated clones showing the required expression 
profile. 
 
Materials 
electroporation cuvette 0.4 cm; Gene Pulser cuvette; Bio-Rad 
electroporator   Gene Pulser II; Bio-Rad 
G418 sulfate (geneticin) Calbiochem (Schwalbach, Germany) 
pcDNA3 vector  Invitrogen (Groningen, Netherlands) 
 
 
 
3.6. Isolation of cells from the human vascular system 
3.6.1. CD4+CD45RO+ T cell isolation 
Peripheral blood mononuclear cells (PBMCs) were prepared by dextran-sedimentation and 
subsequent Ficoll-hypaque density gradient centrifugation from citrate anti-coagulated human 
blood. CD4+CD45RO+ memory T cells were isolated from the PBMC preparation by negative 
selection using magnetic cell separation. 
 
A sample of 50 ml venous blood from a healthy volunteer was taken in a syringe filled with 6 ml 
0.1 M sodium citrate and 5 ml 6 % (w/v) dextran in PBS. After 30-45 min of erythrocyte 
sedimentation the plasma supernatant was stratified over 12.5 ml Ficoll solution and centrifuged 
at 2,000 rpm for 20 min at 25°C (w/o brake). The pellet of granulocytes and residual 
erythrocytes was discarded (or subjected to neutrophil isolation; see below) and the supernatant 
was diluted 1:1 with RPMI 1640 medium/2 mM EDTA. Mononuclear cells were harvested as 
pellet from a second centrifugation at 1,000 rpm for 5 min at 25°C and resuspended in 50 ml 
buffer. Cells were washed by an additional resuspension-centrifugation step. Viability of the 
cells was determined by trypan blue exclusion. 
 
For magnetic cell sorting, the freshly isolated PBMCs were resuspended in buffer (80 µl per 107 
cells), mixed with a cocktail of hapten-conjugated antibodies4 (20 µl per 107 cells) and incubated 
for 10 min at 8°C. The cells were washed with 10 ml buffer, centrifuged at 1,000 rpm for 5 min 
at 25°C and mixed with paramagnetic anti-hapten and anti-CD45RA microbeads (each 20 µl per 
107 cells). Cells were incubated at 8°C for 15 min, washed, centrifuged, resuspended in buffer 
                                                 
4 B cells, monocytes, NK cells, cytotoxic T cells, dendritic cells, early erythroid cells and platelets from PBMCs were labeled by 
a cocktail of hapten-conjugated CD8, CD11b, CD16, CD19, CD36 and CD56 antibodies for subsequent positive selection in a 
magnetic field. 
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(500 µl per 108 cells) and passed through an equilibrated separation column placed in a magnetic 
field. Magnetically labeled non-T helper cells and CD4+CD45RA+ cells were retard on the 
column, whereas non-labeled CD4+CD45RO+ T cells were recovered in the eluate for immediate 
experimental application. 
 
Materials 
antibodies, beads, columns MACS CD4+ T cell isolation kit,  MACS CD45RA MicroBeads; 
    Miltenyi Biotec (Bergisch Gladbach, Germany) 
buffer    ice-cold PBS, 0.5 % (w/v) BSA, 2 mM EDTA 
Ficoll solution   Biocoll Seperating Solution; Biochrom KG (Berlin, Germany) 
sodium citrate, sterile  tri-sodium citrate dihydrate for erythrocyte sedimentation;  
    Apotheke Klinikum Innenstadt (University Munich) 
 
 
3.6.2. Isolation of polymorphonuclear neutrophils (PMNs) 
Citrate anti-coagulated venous blood from a normal donor was subjected to erythrocyte 
sedimentation and subsequent plasma centrifugation over Ficoll-hypaque as described above. 
The pellet was resuspended in distilled water for hypotonic lysis of residual erythrocytes. After 
30 s of incubation 0.1 volume 10x HHMC lacking calcium and magnesium were added and cells 
were centrifuged at 1,000 rpm for 5 min at 20°C. The neutrophil pellet was finally resuspended 
in 1x HHMC. Trypan blue exclusion showed greater then 95 % viability of the cells. 
 
 
3.6.3. Human umbilical vein endothelial cells (HUVECs) – umbilical cord preparation 
3.6.3.1. Isolation 
Human ECs were isolated from the veins of umbilical cords according to Jaffe et al., 1973. From 
each end of the freshly obtained umbilical cord 1 cm was cut off and the cord was hung up 
vertical. The upper end of the umbilical vein was cannulated and than sealed with artery clips. 
The vein was perfused with sterile PBS to wash out blood and sealed at the remaining end. 
Approx. 5 ml 0.1 % (w/v) α-chymotrypsin in PBS was infused to slight flatulence in order to 
detach the HUVECs from the interior vein wall. After 20 min of incubation at 37°C and a short 
cord massage the solution was flushed from the vein by perfusion with 10 ml PBS into 2 ml FCS 
that neutralizes α-chymotrypsin activity.  
 
HUVECs were harvested by centrifugation at 800 rpm for 8 min at 25°C, resuspended in 24 ml 
EGM medium, divided into 2 collagen-coated 75-cm2 flasks and cultured at 37°C as described 
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below. After 3 h the medium was renewed and blood residuents were removed from adherent 
cells by washing with PBS. The medium was changed after 24 h and cells were grown to 
confluence (passage 0) and then subcultured. 
 
 
3.6.3.2. Culturing 
HUVECs were cultured to confluence at 37°C under 5 % CO2 in EGM medium with medium 
being changed twice a week. Adherent cells were detached by trypsinization. The cell suspension 
was diluted 1:2 with EGM medium, centrifuged with 800 rpm at 25°C for 8 min and reseeded at 
a concentration of approx. 5·104 cells/ml. HUVECs of passage 2-5 were used for experiments. 
 
 
3.6.3.3. Collagenization 
For adhesive growth, all cell culture flasks, petri dishes, 96-well plates and transwell-filter 
membranes subjected to HUVEC monolayer seeding were collagen-coated by incubation with a 
sterile collagen G solution of final 75 µg/ml in PBS for 15 min at room temperature. 
 
 
3.6.3.4. Materials 
collagen G solution  3 mg/ml collagen from calf skin in 12 mM HCl;    
    Biochrom KG (Berlin, Germany) 
EGM medium   Endothelial cell Growth Medium (low serum); PromoCell  
    (Heidelberg, Germany) 
umbilical cords  Frauenklinik vom Roten Kreuz (Munich) 
 
 
 
3.7. Cell adhesion and transmigration applications 
3.7.1. Static cell adhesion assay 
Static adhesion assays for cells in suspension onto adherent cell monolayers or immobilized 
proteins as adhesion targets were carried out in 96-well plates. Cells in suspension were labeled 
with the fluorescent dye BCECF/AM and incubated with the respective adhesion target covering 
the base of the well. Cells lacking adhesive properties during the experimental procedure were 
removed by repeated steps of flick washes. Remaining cells with established adhesive cell 
interactions were evaluated by fluorescence spectrometry. 
36  Materials and methods 
CHO cells or HUVECs were resuspended in complete culture medium, seeded into flat-bottom 
wells of 96-well tissue culture plates and cultured to confluence within 2-3 days. HUVEC 
monolayers were seeded in collagenized wells and stimulated with TNF-α (100 U/ml) plus 
IFN-γ (200 U/ml) O/N at 37°C where appropriate. Non-specific adhesion was blocked by 
incubation of the cell monolayers for 2 h at 37°C with 200 µl medium containing 0.5 % BSA. 
The monolayers were then preincubated for 30 min at room temperature with anti–JAM-1, 
ICAM-1 mAb or ICAM-1 Fab and, for control purpose, with preimmunization serum or IgG1 
isotype control, as indicated. 
 
Cells in suspension tested for adhesion (i.e. Jurkat, J-β2.7, J-β2.7/αL, J-β2.7/αM, HL-60, 
CD4+CD45RO+ and CHO cells) were fluorescence labeled by resuspension at a density of 
106 cells/ml in HHMC that was supplemented with BCECF/AM at a final concentration of 
1.6 µM. They were incubated for 30 min at 37°C, washed with PBS and resuspended in HHMC 
at a density of 2·106 cells/ml. Some cells were pretreated for 30 min at room temperature with 
TS1/22 mAb, TS1/18 mAb or IgG1 isotype control, as indicated. CD4+CD45RO+ T cells 
subjected to cytokine-stimulated HUVEC monolayers were additionally preincubated with anti–
VLA-4. The cell suspension was added at 105 cells/50 µl/well into the microtiter plate after 
supplementing with either PMA (100 ng/ml) or SDF-1α (1 µg/ml), as indicated. The cells were 
left to adhere to the confluent cell monolayers at 37°C during 30 min in the case of PMA 
stimulation or 5 min in the case of SDF-1α stimulation. 
 
The fluorescence of the initial input cells was determined using a fluorescence plate reader with 
excitation and emission wavelengths of 485 nm and 535 nm, respectively. Non-adherent cells 
were then progressively removed by flick washes of the microtiter plate. The wells were 
replenished with 200 µl HHMC and the fluorescence of the remaining adherent cells was 
measured. The flick washes were continued until the fluorescence values attained approx. 10 % 
of the input value. All experiments were done in triplicate. Adhesion was expressed as the 
percentage of input cells. Where appropriate, background binding of unstimulated cells was 
subtracted from the overall adhesion values. 
 
For static adhesion assays of CHO cell suspension cultures to LFA-1 as an adhesion target, the 
protein was immobilized in a flat-bottom 96-well microtiter plate at a concentration of 3 µg/ml 
in 10 mM Tris pH 9.0 using 40 µl/well O/N at 4°C. Likewise soluble ICAM-1–Fc was adsorbed 
at 10 µg/ml for adhesion assays with PMA-stimulated (100 ng/ml) J-β2.7/αM cells. The purified 
LFA-1 was derived from lysates of human tonsil and spleen and isolated by immunoaffinity 
chromatography (Klickstein et al., 1996; Dustin et al., 1989), soluble ICAM-1–Fc was purified 
from CHO Lec 3.2.8.1 cells (Weber et al., 1999a). Non-specific adhesion was blocked for 2 h 
with 200 µl HHMC/0.5 % BSA. Where indicated, immobilized LFA-1 was preincubated with 
TS1/18 mAb or an IgG1 isotype control. Cells in suspension were labeled with BCECF/AM. 
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CHO cells were pretreated with anti–JAM-1 or preimmunization serum, J-β2.7/αM cells with the 
αL mAb TS1/22 or the αM mAb CBRM1/29, as indicated. They were aliquoted into the 
microtiter plate with 105 cells/50 µl/well and left to adhere to immobilized LFA-1 respective 
ICAM-1 for 30 min at 37°C. The assay was continued as described above. All experiments were 
done in triplicate. Adhesion was expressed as the percentage of input cells. 
 
 
3.7.2. Transmigration assay (chemotaxis) 
In vitro transmigration under static conditions was investigated using transwell-filter inserts 
(fig. 3). Cells in suspension were allowed to transmigrate towards a chemokine gradient 
(chemotaxis) through HUVEC monolayers grown on the 5.0-µm filters. 
upper compartiment
lower compartiment
HUVEC monolayer
transwell-filter insert
microtiter plate well
5-µm filter membrane
fig. 3: Schematic representation of a chemotactic transmigration assay with a transwell-filter insert (6.5 mm in 
diameter) placed in the slot of a 24-well microtiter plate. The polycarbonate membrane of the transwell-filter 
consists of pores with 5.0 µm in size. It provides a substrate for seeding HUVEC monolayers that in 
combination with the filter membrane divides the transwell assay into an upper compartment (filter insert) and a 
lower compartment (well). This allows chemotaxis of cells in suspension from the upper to the chemokine-
containing lower compartment by their interaction with the confluent endothelial monolayer. 
HUVECs were grown to confluence on the collagenized membrane of the transwell-filter insert 
within 1-2 days at 37°C. Some HUVEC monolayers were preincubated for 30 min with anti–
JAM-1 or preimmunization serum, ICAM-1 mAb, ICAM-1 Fab or IgG1 isotype control, as 
indicated. CD4+CD45RO+ T cells and neutrophils, respectively, were resuspended in RPMI 1640 
medium supplemented with 0.5 % BSA and were incubated for 30 min with TS1/22 or IgG1 
isotype control as indicated. Neutrophils were additionally pretreated for 30 min with 5 % human 
serum to block Fc receptors. The chemokine gradient was established by filling the lower 
compartment with chemokine-supplemented RPMI 1640 medium. The HUVEC-coated 
transwell-filter insert was placed in the well and the cell suspension was added over the 
unstimulated endothelial monolayer. Cells were allowed to transmigrate at 37°C for 90 min 
towards a SDF-1α (1 µg/ml) gradient (for CD4+CD45RO+ T cells) or for 60 min towards an IL-8 
(100 ng/ml) gradient (for neutrophils), respectively. Cell input and transmigrated cells were 
counted by flow cytometry. 
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3.7.3. Cell-cell interaction under conditions of laminar flow 
A flow chamber with parallel plate geometry (fig. 4) was used to investigate cell-cell interactions 
(i.e. intercellular adhesion and cell spreading/transmigration) under laminar flow conditions (see 
fig. 28), simulating in vitro the physiological fluid shear stress present in the human 
microvasculature (Lawrence et al., 1991). 
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fig. 4: Parallel plate flow chamber with transparent polycarbonate base, rubber gasket and interchangeable 
35-mm tissue culture dish. The chamber was mounted on the stage of a phase-contrast microscope equipped 
with a video camera system. Polycarbonate base and rubber gasket were held in place by vacuum application. 
The cell suspension was passed through the inlet manifold by an automatic syringe pump connected to the 
outlet manifold. The shear stresses acting at the chamber walls were regulated by the applied flow rate. 
HUVECs were seeded on a 35-mm tissue culture dish and grown to confluence within 1-2 days. 
The monolayer was stimulated with TNF-α (100 U/ml) or costimulated with TNF-α (100 U/ml) 
+ IFN-γ (200 U/ml) O/N at 37°C. SDF-1α was immobilized on the HUVECs at a concentration 
of 1 µg/ml 30 min prior to the flow experiment, except for assays with neutrophils. HUVECs 
were preincubated with anti–JAM-1 or preimmunization serum, ICAM-1 mAb, ICAM-1 Fab or 
IgG1 isotype control, as indicated, for 30 min at 37°C. Subsequently the culture dish was inserted 
into the flow chamber. 
 
Cells in suspension subjected to adhesion under flow conditions were preincubated with TS1/22, 
TS1/18 or IgG1 isotype control, as indicated, for 30 min at 37°C. In the case of cytokine-
stimulation of the HUVEC monolayer, T lymphocytes were likewise pretreated with VLA-4 
mAb. Neutrophils were pretreated with 5 % human serum to block Fc receptors. The cell 
suspension was adjusted to 5·105 cells/ml in RPMI 1640 medium and tempered to 37°C. 
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The HUVEC monolayer and the polycarbonate base were assembled together with a rubber 
gasket that held their flat surfaces approx. 250 µm apart in the area of the gasket gap. Here, a 
well-defined laminar flow of suspension cells was induced over the cell monolayer, generated by 
an automatic syringe pump. The cells were perfused through the flow chamber at a controlled 
flow rate of 0.1 ml/s effecting a wall shear stress5 of 1.5 dyn/cm2. Cell-cell interactions were 
directly visualized and documented by video microscopy. 
 
Experiments were video-analyzed by quantification of interaction events in between multiple 
0.25-mm2 fields of view, starting after a flow equilibration period of 5 min. Adhesion was 
defined as occurring when cells formed a firm contact with the HUVEC monolayer for at least 
10 s under flow conditions. Transmigrating cells were defined as firmly adhesive cells that 
underwent shape change indicative of spreading and migration beneath the cells of the 
endothelial monolayer. Results were expressed as cells/mm2. 
 
 
3.7.4. Materials 
Biomaterials 
ICAM-1, soluble  ICAM-1–Fc purified from CHO Lec 3.2.8.1 cells   
    from L.B. Klickstein, Harvard Medical School, Boston, MA 
IFN-γ    human recombinant; PeproTech (Rocky Hill, NJ) 
IL-8    human recombinant; PeproTech (Rocky Hill, NJ) 
LFA-1, purified  from L.B. Klickstein, Harvard Medical School, Boston, MA 
SDF-1α   human recombinant; PeproTech (Rocky Hill, NJ) 
TNF-α    human recombinant; PeproTech (Rocky Hill, NJ) 
 
Reagents 
BCECF/AM   2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxy-fluorescein/  
    acetoxymethylester; Molecular Probes (Leiden, Netherlands) 
    stock: 1 µg/µl (~1.6 mM) in dry DMSO (Merk) at –20°C 
PMA    Promega (Mannheim, Germany) 
 
 
 
 
 
                                                 
5 The existing wall shear stresses were calculated from the chamber geometry and the volumetric flow rate as described 
(Lawrence et al., 1987). 
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Equipment and materials 
96-well tissue culture plates  ICN (Costa Mesa, CA) 
flow chamber           
 polycarbonate base from L.V. McIntire (Rice University, Houston, TX) 
flow chamber           
 rubber gasket  PharmElast SF1332; SF Medical Ltd. (Watford, UK) 
fluorescence plate reader  SpectraFluor Plus; software: easyWin fitting; TECAN  
    (Crailsheim, Germany) 
syringe pump    model 210; Fabrique Auxetatis-Unis (USA) 
transwell-filter inserts  Costar, Corning Inc. (Acton, MA) 
video system   videotimer VTG-10; FoR.A       
    time-lapse videocasette recorder SR-L900E; JVC (Japan)   
    Trinitron color video monitor SSM-1; Sony (Park Ridge, NJ)  
    video camera 3-CCD; JVC (Japan) 
 
 
3.7.5. Statistical analysis 
Statistical analysis was performed with InStat software (GraphPad Software, San Diego, CA), 
using analysis of variance (ANOVA) and signed-rank tests according to Kruskal-Wallis as 
multiple comparison procedures, and Tukey tests, Student’s t-tests and Bonferroni tests to 
determine the statistical significance between two interventions, where appropriate. A 
statistically significant difference for a particular comparison was only claimed when the 
criterion P < 0.05 or better was fulfilled. Similarly, the effect of a JAM-1 and ICAM-1 antibody 
combination was only considered as additive when the level of significance, as indicate by the 
P-value, was lower for the combination than for either antibody alone, and the combination was 
statistically different with P < 0.05, as compared to either intervention alone. 
 
 
 
3.8. Yeast two-hybrid system screening procedures 
3.8.1. Introduction: the yeast two-hybrid system 
The yeast two-hybrid (YTH) system, initially developed by Fields et al., 1989, is a yeast-based 
genetic assay to detect protein-protein interactions in vivo. The consequent transcriptional 
induction of one or more reporter genes is used to detect such positive interactions (Fields et al., 
1994). 
 
Materials and methods  41 
3.8.1.1. Modular nature of transcriptional activators:                  
DNA-binding and activation domains 
Detection of protein-protein interactions using the YTH system relies on the modular nature of 
many site-specific eukaryotic transcriptional activators. These factors include a DNA-binding 
domain (DBD) and a transcriptional activation domain (AD). The DBD mediates binding of the 
transcriptional activator to a specific DNA sequence located upstream of a reporter gene. The 
AD of the transcription factor interacts with proteins of the basal transcriptional machinery, 
recruiting them to the promoter and thus inducing transcription initiation. The DBD and AD do 
not necessarily need to be covalently linked to mediate transcriptional activation (Brent et al., 
1985; Keegan et al., 1986). Hence, if these domains are fused separately to any two interacting 
proteins X and Y, the principle of the YTH system, they can subsequently be brought into 
proximity as a result of this protein-protein interaction, and thereby reconstitute a functional 
transcription factor. In this way, the interaction between two such hybrid proteins (i.e. DBD-X 
and AD-Y), directed to the yeast nucleus, enables transcription activation of the appropriate 
reporter gene, and thus constitutes a positive signal in the YTH assay. 
 
 
3.8.1.2. Bait and prey: the library screening application of the YTH system 
A protein of interest fused to a DBD can be used as a so-called ”bait” to screen a library for a 
unknown interacting protein partner, termed ”prey”. The cDNA library consists of a collection of 
plasmids that encode AD-fusion proteins. The generation of the two protein hybrids, bait and 
prey, is performed at the DNA level by subcloning the appropriate coding sequences into YTH 
vectors, i.e. the DBD-fusion vector pAS2-1 for the bait and the AD-fusion vector pGAD10 for 
library cDNAs. Both plasmids are sequentially transformed into the host strain S. cerevisiae 
CG-1945, yielding a yeast population where the cDNA library is expressed at the protein level. 
Consequently, each yeast cell expresses both the bait and one library protein, ensured by 
nutritional selection for co-transformed cells. The yeast strain phenotype maintains auxotrophy 
for these nutritional markers (i.e. tryptophan and leucine). In addition, CG-1945 contains two 
chromosomally integrated reporter gene constructs, the yeast HIS3 gene and the bacterial lacZ 
gene, upstream of which are positioned binding sites for the transcriptional DBD. A positive 
bait-prey interaction causes the physical reconstitution of a functional DBD-AD transcription 
factor due to steric proximity of these domains on the coat-tails of the bait and prey hybrids and 
leads to activation of the reporter genes. Transcriptional activation of HIS3 confers histidine 
prototrophy and allows in a first screening step the nutritional selection for yeast cells bearing an 
interacting hybrid pair. These pre-selected cells are additionally tested by an enzymatic colour 
assay for the action of lacZ-encoded β-galactosidase. From a candidate yeast colony positive for 
expression of both reporter genes, the unique bait-encoding plasmid is segregated. The prey 
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plasmid encoding the potential interaction partner of the bait is isolated, amplified and 
subsequently characterized by sequencing its library cDNA insert. 
 
 
3.8.2. Yeast strain S. cerevisiae CG-1945 
genotype:   MATa, ura3-52, his3-200, ade2-101, lys2-801, trp1-901, leu2-3, 
   112, gal4-542, gal80-538, cyhr2, LYS2::GAL1UAS-GAL1TATA-HIS3,
   URA3::GAL417-mers(x3)-CyC1TATA-lacZ 
transformation markers: trp1, leu2, cyhr2 
reporter genes:  HIS3, lacZ 
 
 
3.8.3. Culturing S. cerevisiae 
Yeast strains were grown by shaking at 30°C in liquid culture medium or were spread on dry 
agar plates as described for bacteria and grown for 2-3 days at 30°C in the inverted position. 
Liquid cultures were obtained by inoculation with a single yeast colony picked from an agar 
plate. The growth phase was determined by measurement of the optical density (OD600) as 
described for bacteria. Transformed cells were selectively grown on synthetic dropout (SD) 
medium depleted from the corresponding nutritional marker(s) in turn provided by the 
transformed plasmid(s) (see below). For long-term storage of yeast strains, single colonies were 
resuspended in 1 ml of the appropriate medium supplemented with sterile glycerol to a final 
concentration of 25 % and frozen at –70°C. 
 
 
3.8.4. Media for culturing S. cerevisiae 
Media were autoclaved for 20 min at 121°C and cooled to approximately 55°C before adding 
glucose or dropout solutions. Glucose stock solutions were autoclaved separately and dropout 
solutions were filter-sterilized. 
 
YPD: (yeast extract/peptone/dextrose) 
 complete medium for non-selective routine growth of yeast 
 yeast extract   10 g/l 
 peptone   20 g/l 
 glucose, 40% (w/v)  50 ml/l (= 20 g/l) 
 agar    20 g/l   (where appropriate) 
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SD medium: (synthetic dropout medium; ”THLA medium”) 
SD is a synthetic minimal medium used in yeast transformations to select for specific 
 phenotypes. It consists of yeast nitrogen base (YNB) without amino acids and glucose
 as carbon sources. The medium is supplemented with various dropout solutions that
 contains essential amino acids or nucleotides for which the strain to be selected is
 auxotrophic. 
 
 YNB without amino acids   6.7 g/l 
 -Leu/-Trp/-His DO supplement  0.6 g/l 
 dropout solutions T, H, L, A   added as appropriate,    
       concentrations see below 
 glucose, 40% (w/v)    50 ml/l (= 20 g/l) 
 agar      20 g/l   (where appropriate) 
 
SD/Trp¯ (HLA) medium: 
 selecting for strains containing pAS2-1(TRP1) 
 
SD/Trp¯/Leu¯ (HA) medium: 
 selecting for strains containing pAS2-1(TRP1) and pGAD10(LEU2) 
 
SD/Trp¯/Leu¯/His¯ (A) medium: 
selecting for yeast colonies bearing a positive YTH protein-protein interaction (HIS3
 expression) under continuous selection for the bait expression vector pAS2-1(TRP1)
 and the library protein expression vector pGAD10(LEU2) 
 
SD/Trp¯/His¯ (LA) medium: 
 medium to test for bait-mediated non-specific self-activation of the HIS3 reporter gene 
 in yeast strains transformed with the bait-encoding expression vector pAS2-1(TRP1) 
 
SD/Leu¯ (THA) medium: 
selecting for yeast strains containing the library vector pGAD10 (LEU2);  
 supplemented with 1 µg/ml cycloheximide where appropriate; THA/cycloheximide 
 medium selects for the segregation of bait-expressing pAS2-1(TRP1) vectors in 
 co-transformed yeast cells (see 3.8.9.) 
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Dropout solutions for SD media: 
 
 abbr. dropout sol.   final conc.  stock sol. 
 T L-tryptophan     20 µg/ml  500x 
H L-histidine⋅HCl⋅H2O    20 µg/ml   500x 
 L L-leucine   100 µg/ml  100x 
 A adenine hemisulfate    20 µg/ml  100x 
 
 
3.8.5. YTH cloning and control vectors 
3.8.5.1. Bait-fusion vector pAS2-1 
pAS2-1 enables the fusion of a bait-encoding cDNA to the Gal4 DBD-encoding sequence by 
subcloning into the MCS. The bait hybrid is expressed under the control of the S. cerevisiae 
alcohol dehydrogenase 1 (ADH1) promoter and targeted to the yeast nucleus by a nuclear 
localization signal in the N-terminus of Gal4. pAS2-1(TRP1) contains the TRP1 nutritional gene 
that allows yeast auxotrophs to grow on tryptophan-deficient synthetic medium (SD/Trp¯) and 
confers cycloheximide sensitivity to CG-1945 by encoding the CYH2 protein (see 3.8.9.). 
 
cDNA encoding the cytoplasmic domain of CD11a was subcloned into the DBD-fusion vector 
pAS2-1 as described (see 3.11.2.). The subsequently transformed yeast strain CG-1945 
expressing the bait hybrid failed to grow on selective histidine-depleted LA medium, indicating 
that the DBD-fused bait itself did not activate the reporter gene HIS3 in a non-specific way6. 
 
 
3.8.5.2. Prey-fusion library vector pGAD10 
The cDNA library screened against the bait hybrid consisted of prey-encoding cDNAs subcloned 
into the EcoRI site of pGAD10(LEU2), a Gal4 AD-fusion vector. The prey hybrids are expressed 
under the control of the ADH1 promotor and targeted to the yeast nucleus by a heterologous 
nuclear localization signal included in the AD. The nutritional gene LEU2 allows yeast 
auxotrophs to grow on leucine-deficient synthetic medium (SD/Leu¯). 
 
 
                                                 
6 In the case of non-specific activation, the false-positive background can be suppressed to a level that is only overcome by a 
specific HIS3 activation when using medium supplemented with 3-amino-1,2,3-triazole (3-AT), a competitive inhibitor of the 
HIS3 gene product (Kishore et al., 1988). 
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3.8.5.3. Control vectors 
The control plasmids pVA3-1(TRP1) and pTD1-1(LEU2) were sequentially introduced into 
wild-type CG-1945 strain by small-scale transformations. This co-transformed yeast strain 
provides a positive control for the YTH assay as it expresses two interacting hybrids, the murine 
p53 fused to a DBD (encoded by pVA3-1) and the Simian virus 40 (SV40) large T-antigen fused 
to an AD (encoded by pTD1-1), thereby leading to histidine prototrophy and a positive signal in 
the β-Gal assay (Bartel et al., 1993). 
 
 
3.8.6. Amplification of the human leukocyte cDNA library 
The AD-fused cDNA library was prepared from a commercially purchased library culture of 
E. coli DH5α. The library based on mRNA of peripheral blood leukocytes pooled from 350 
humans 18-40 in age. cDNA inserts (0.8-5.0 kb, 1.7 kb in average) were generated by oligo(dT) 
and random priming and subcloned into the EcoRI site of the YTH library vector pGAD10 
(Clontech). The number of independent clones was 1.6·106. The library had to be amplified to 
yield enough plasmid DNA for a representative screening and for long-term storage. 
 
The E. coli library culture was spread on large LB/amp agar plates with a number of colony 
forming units (cfu) that was six times the number of independent clones (40,000 cfu/plate) and 
incubated overnight at 37°C. The colonies were scraped off the agar using 5-8 ml LB/amp 
medium per plate, pooled on ice and cultured for 4 h at 37°C. The plasmids were isolated in 
large-scale plasmid preparations (gigapreps; see 3.10.7.) and the obtained plasmid cDNA library 
was aliquoted at a concentration of 1 µg/µl. The titre was determined to be 5.8·109 cfu/ml of 
library suspension, ensuring that the amplified plasmid cDNA library was representative. 
 
 
3.8.7. Lithium acetate-mediated yeast transformation 
For both small-scale and large-scale transformations of yeast with plasmid cDNA the lithium 
acetate (LiOAc) method (Ito et al., 1983; Schiestl et al., 1989) was used in a modified protocol. 
Competence in yeast cells is induced by the monovalent alkali cation Li+ in combination with 
polyethylene glycol (PEG), and DMSO-enhanced DNA-uptake is effected by a heat pulse. 
 
 
3.8.7.1. Simple plasmid transformation – small-scale 
The small-scale preparation produces 2 ml of competent cells sufficient for 20 simple plasmid 
transformations. After transformation the yeast cells were grown under nutritional selection for 
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the corresponding plasmid. For YTH screening, the small-scale transformation is the first of two 
sequential transformations, shuttling the bait plasmid into wild-type CG-1945 cells. The resulting 
bait-expressing strain is tryptophan prototrophic and can be selectively grown on SD/Trp¯ (HLA) 
medium. 
 
A stationary phase culture of wild-type CG-19457, grown overnight in 10 ml YPD at 30°C, was 
used to inoculate 50 ml of fresh medium to an OD600 of 0.5. The culture was shaken for 3 h at 
30°C to mid-log phase and centrifuged at 2,500 rpm for 5 min. The pellet was resuspended in 
40 ml TE, centrifuged, resuspended in 2 ml of LiOAc/TE and left at room temperature for 
10 min. 100 µl of these competent yeast cells (sufficient for a single transformation) were 
transferred to a DNA mix composed of 100 µg denatured carrier DNA and 1-2 µg (1 µg/µl) of 
the bait-encoding fusion vector pAS2-1(TRP1). After addition of 700 µl LiOAc/PEG/TE the 
transformation mix was vortexed vigorously and incubated for 30 min at 30°C. 88 µl DMSO was 
added and the suspension was mixed by pipetting. The cells were then treated for 7 min with a 
heat shock of 42°C and centrifuged twice at 10,000 rpm for 10 s with subsequent resuspension in 
1 ml TE. The transformed cells were spread on SD/Trp¯ plates (100 µl of non-diluted, 1:10 or 
1:50 diluted cell suspension to ensure growth of well-separated single colonies) and incubated 
for approx. 3 days at 30°C. 
 
 
3.8.7.2. cDNA library transformation – large-scale 
A large-scale protocol was used to transform in a second step the pGAD10(LEU2) cDNA library 
plasmids into the bait-transformed yeast strain. This procedure yields 1 ml of competent cells 
sufficient for a single library transformation. The resulting yeast population expressing bait and 
individual prey hybrids is tryptophan and leucine prototrophic and can be selectively grown on 
SD/Trp¯/Leu¯ (HA) medium. 
 
Five, 4-ml aliquots of SD/Trp¯ (HLA) medium were inoculated with the bait-expressing yeast 
strain and incubated for 20 h at 30°C. The cultures were transferred into 100 ml YPD medium to 
a final OD600 of 0.3. The cells were shaken for 3-4 h at 30°C to reach mid-log phase (OD600 of 
0.6-0.8) and centrifuged at 2,500 rpm for 5 min. The pellet was resuspended in 50 ml TE, 
recentrifuged, resuspended in 2 ml of LiOAc/TE and left at room temperature for 10 min. A 
DNA mix composed of 2 mg denatured carrier DNA and 200 µg of cDNA library plasmids was 
then added. After addition of 14 ml LiOAc/PEG/TE, the transformation mix was vortexed 
vigorously and incubated for 30 min at 30°C. 1.8 ml DMSO was added and the suspension was 
                                                 
7 Note: The yeast strain and culture media described here correspond to a bait transformation of wild-type cells within a YTH 
screening procedure. For transformation of an ulterior plasmid type, the SD medium after transformation has to be adapted to the 
nutritional marker of this plasmid. In the case of shuttling a plasmid into a pretransformed yeast strain, these cells have to be 
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mixed by pipetting. The yeast cells were treated for 7 min by a heat shock of 42°C with 
occasional swirling and cooled down to room temperature in a water bath. They were 
centrifuged, washed with 50 ml TE, recentrifuged and resuspended in 100 ml YPD. The culture 
was shaken for 1 h at 30°C and then centrifuged twice. The pellet was resuspended first in 50 ml 
TE and then in 100 ml selective SD/Trp¯/Leu¯ (HA) medium. In between, in order to measure 
the efficiency of the library transformation, a 10-µl and 100-µl aliquot of the HA culture was 
spread on small HA agar plates and incubated for 2-3 days at 30°C. The library transformation 
efficiency was then determined as the number of transformants/µg plasmid DNA grown on these 
agar plates. The 100-ml HA culture itself was further grown for 16 h at 30°C. The suspension 
was centrifuged three times and the pellet resuspended twice in 50 ml TE and once in 6 ml TE. 
Subsequently the cells were subjected to nutritional selection for HIS3 reporter gene activation 
without delay. 
 
 
3.8.8. Detection of reporter gene activation 
3.8.8.1. Nutritional selection for HIS3 reporter gene-activated yeast cells 
Histidine prototrophy is the first selectable marker for a bait-prey protein interaction in the YTH 
system. Hence, in a first step, yeast cells were screened by nutritional selection on 
histidine-depleted SD/Trp¯/Leu¯/His¯ (A) medium. 
 
The complete culture of previously library-transformed yeast cells (see 3.8.7.2.) was directly 
spread on large selective A agar plates using 100 µl cell suspension/plate to allow growth of 
isolated cell colonies. The plates were incubated for several days at 30°C. Candidate clones that 
have grown by day 8 were transferred to and collected on fresh A agar plates (master plates) and 
subsequently subjected to a β-Gal filter assay. 
 
 
3.8.8.2. β-Gal filter assay 
Activation of the lacZ reporter gene and subsequent expression of β-galactosidase (β-Gal) is the 
second marker in the YTH system and provides a screenable color phenotype for yeast cells that 
contain an interaction between the bait and prey hybrid proteins. 
 
Candidate His+ yeast colonies from master plates and a positive control yeast strain 
(pVA3-1/pTD1-1–transformed) were spread on a selective A plate and grown for 3 days at 30°C. 
An aluminium boat with a flat bottom was constructed and floated on liquid nitrogen. A 
                                                                                                                                                             
grown in SD medium lacking the nutritional marker of the pretransformed plasmid and afterwards in SD medium additionally 
depleted for the nutritional marker of the second plasmid. 
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Whatman filter paper of appropriate size was laid over the yeast colonies on the A plate and both 
filter paper and agar medium were marked with asymmetric stitches. The filter paper was 
removed and placed colony-side-up on the pre-cooled aluminium boat. After 30 s, boat and filter 
paper were immersed in the liquid nitrogen for 5 s. The filter paper was removed and placed 
colony-side-up in a petri dish until thawed. 3.2 ml of Z buffer and 63 µl of 2 % X-Gal were 
placed in the lid of a petri dish (volumes calculated for small petri dishes, 90 mm diameter). A 
fresh piece of Whatman filter paper and then the yeast-bearing filter paper (colony-side-up) were 
placed in the liquid. The dish was covered with its bottom, sealed with parafilm and incubated at 
37°C in the darkness. The colour of the yeast colonies was checked from time to time. 
Development of the blue color took from 30 min to 1 h. 
 
 
3.8.9. Cycloheximide counterselection of yeast segregants 
Further analysis of a His+/β-Gal+ candidate yeast strain found positive in a YTH screen requires 
the generation of a segregant strain that has lost the known bait-expressing vector pAS2-1(TRP1) 
and retains only the library vector pGAD10(LEU2) encoding the as yet unknown bait-interacting 
prey protein. Candidate clones are grown on SD/Trp+/Leu¯ (THA) medium supplemented with 
cycloheximide (naramycin A). The THA medium allows spontaneous segregation of 
pAS2-1(TRP1) while maintaining the selective pressure for pGAD10(LEU2). Only yeast cells 
that undergo this spontaneous pAS2-1–segregation can survive on THA/cycloheximide medium 
due to cycloheximide sensitivity conferred by the pAS2-1 plasmid8. 
 
A single colony of a candidate His3+/lacZ+-clone was resuspended in 100 µl TE and spread on a 
THA/cycloheximide agar plate. The plate was incubated for 3-5 days at 30°C until 
cycloheximide-resistant colonies appeared. Individual colonies were checked for the loss of 
pAS2-1(TRP1) by negative selection on tryptophan-depleted HA medium. A verified colony, 
bearing only the library plasmid, was subjected to a yeast miniprep to isolate this vector for 
further analysis of the candidate prey cDNA. 
 
 
3.8.10. Yeast miniprep and isolation of the prey-encoding library vector 
The prey-encoding library vector is isolated from the candidate colony by a yeast miniprep and 
used to transform E. coli DH5α for further amplification and purification purposes. Vector 
                                                 
8 pAS2-1 confers cycloheximide sensitivity by the CYH2 gene. Cycloheximide acts on the CYH2 protein and thereby inhibits 
protein translation in yeast. The strain CG-1945 is normally cycloheximide resistant due to its cyh2 mutant allele that encodes a 
mutated CYH2 protein and is so not affected by this drug. Nevertheless pAS2-1–transformed CG-1945 fails to grow on 
cycloheximide since the wild-type CYH2 gene of the vector is dominant to the cyh2 mutant allele in the strain genome (Guthrie et 
al., 1991). 
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shuttling form yeast to bacteria is necessary due to genomic DNA contamination in yeast 
plasmid preparations. 
 
5 ml of THA medium were inoculated with a bait-plasmid–segregated candidate yeast colony. 
The culture was incubated for 1-2 days at 30°C until saturation and centrifuged at 2,500 rpm for 
5 min. The pellet was resuspended in 300 µl yeast cell breaking buffer and transfered to an 
Eppendorf tube filled to a volume of 150 µl with acid-washed glass beads that were used as a 
physical agent for yeast cell wall disruption. 400 µl phenol/chloroform/isoamyl alcohol was 
added. The tube was vortexed vigorously for 2 min and centrifuged at 14,000 rpm for 5 min. The 
aqueous phase was extracted with chloroform and centrifuged at 14,000 rpm for 1 min. The yeast 
plasmid DNA was ethanol precipitated, resuspended in 25 µl TE and used for E. coli 
transformation by electroporation. The prey-encoding library vector was subsequently amplified 
in DH5α, isolated in a plasmid maxiprep and identified by sequence analysis. 
 
 
3.8.11. Materials, solutions and reagents  
Biomaterials and materials 
carrier DNA   sheared, denatured Herring testis DNA, 10 µg/µl in TE;  
    Clontech (Palo Alto, CA); denatured at 95°C for 20 min and 
    cooled immediately on ice just prior to use 
cDNA library   human leukocyte cDNA MATCHMAKER library, subcloned  
    into pGAD10 (GenBank accession number U13188), provided  
    in E. coli DH5α; Clontech 
glass beads   acid-washed glass-beads, 0.4-0.6 mm; Sigma 
parafilm   American National Can (Menasha, WI) 
pAS2-1   YTH cloning vector, GenBank accession number U30497;  
    Clontech 
pTD1-1   YTH control vector; Clontech 
pVA3-1   YTH control vector; Clontech 
S. cerevisiae CG-1945 Clontech 
Whatman filter paper  Qualitative #1; Whatman (Maidstone, UK) 
 
Solutions and buffers 
LiOAc/PEG/TE  100 mM LiOAc/40 % (w/v) PEG-4000/1x TE, prepared  
    immediately prior to use from sterile stock solutions,  
    i.e. 1 M LiOAc, 10x TE and 50 % (w/v) PEG-4000 
LiOAc/TE   100 mM LiOAc/0.5x TE, prepared immediately prior to use  
    from sterile stock solutions, i.e. 1 M LiOAc and 1x TE 
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PEG-4000   polyethylene glycol, 4000 g/mol average molecular weight,  
    prepared as 50 % (w/v) stock solution and autoclaved 
TE (10x)   Tris-base  200 mM     
    EDTA     10 mM 
X-Gal, 2 %   5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside,  
    20 mg/ml in N,N-dimethylformamide (DMF), stored at –20°C 
yeast cell breaking buffer  LiCl    2.5 mM     
    Tris, pH  850 mM     
    Triton X-100  4 %      
    EDTA   62.5 mM 
Z buffer    Na2HPO4  60 mM     
    NaH2PO4  40 mM     
    KCl   10 mM     
    MgSO4    1 mM     
    pH 7 
 
Reagents 
Reagents used in the YTH assay were mainly from Difco Laboratories (Detroit, MI) and are 
listed if not from Sigma (St. Louis, MO) or mentioned elsewhere. 
 
agar (Bacto-agar)   Difco Laboratories 
chloroform    Merck (Darmstadt, Germany) 
D-(+)-glucose (dextrose)  Fluka (Buchs, Switzerland) 
-Leu/-Trp/-His DO supplement Clontech 
PEG-4000    Fluka (Buchs, Switzerland) 
peptone (Bacto-peptone)  Difco Laboratories  
phenol/chloroform/isoamyl alcohol  25:24:1; Roth (Karlsruhe, Germany) 
X-Gal     Amersham  
yeast extract (Bacto-Yeast extract) Difco Laboratories 
yeast nitrogen base (YNB)  (without amino acids); Difco Laboratories 
 
 
 
3.9. Work with E. coli 
3.9.1. General  
E. coli were cultured at 37°C with LB medium autoclaved for 20 min at 121°C. Bacteria 
transformed with an ampicillin resistance-conferring plasmid were selectively propagated by 
supplementing the LB medium with 100 µg/ml ampicillin (LB/amp medium). All solutions and 
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supplements used for work with E. coli were autoclaved or filter-sterilized. Bacterial strains were 
long-term stored at –70°C in LB medium supplemented with glycerol to a final concentration of 
15 %. 
 
 
3.9.2. Culturing bacteria 
3.9.2.1. Growth on solid media 
Dry LB agar plates were inoculated with a single bacterial colony or with a bacterial suspension 
by spreading with a sterile inoculation loop or a glass spreader, respectively, to achieve single 
colony growth. The plates were incubated inverted overnight at 37°C. 
 
 
3.9.2.2. Growth of liquid cultures 
For small liquid cultures 5-10 ml LB or LB/amp medium were inoculated with a single bacterial 
colony and incubated overnight. Bacteria were harvested by centrifugation. Starter cultures were 
incubated for 8 h and used to inoculate fresh liquid medium. 
 
For large liquid cultures 100-250 ml LB or LB/amp medium were inoculated with a starter 
culture to a dilution of 1:500 - 1:1000 and incubated overnight at 37°C with shaking. Bacteria 
were harvested by centrifugation. 
 
 
3.9.3. Optical density of bacterial cultures 
The optical density of liquid bacterial cultures at a wavelength of 600 nm (OD600) was measured 
in plastic cuvettes against pure medium as a blank in a spectrophotometer. Each 0.1 OD600 unit 
corresponds to approx. 108 cells/ml (~3·106 cells/ml in the case of yeast cells) for OD600 < 1. 
 
 
3.9.4. Transformation of E. coli with plasmids 
3.9.4.1. Preparation of competent cells by CaCl2 treatment 
100 ml LB medium were inoculated with an overnight culture of E. coli DH5α and grown at 
37°C with shaking to an OD600 of 0.4. The culture was centrifuged at 4,000 rpm for 15 min at 
4°C. The pellet was resuspended in 50 ml ice-cold 100 mM MgCl2, incubated for 30 min on ice, 
centrifuged at 4°C and resuspended in 50 ml ice-cold 100 mM CaCl2. The suspension was 
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incubated for 30 min on ice and centrifuged at 4°C. The cells were resuspended in 2 ml ice-cold 
100 mM CaCl2, incubated for 24 h at 4°C, supplemented with ice-cold 0.5 ml glycerin and 
2.5 ml 100 mM CaCl2 and stored in 100-µl aliquots at –70°C. 
 
 
3.9.4.2. Heat-shock transformation of E. coli 
Treatment of competent bacteria with a brief heat shock enables transformation by DNA. 
Plasmid DNA or a plasmid ligation reaction, were mixed at an appropriate concentration with 
50 µl thawed competent bacteria and incubated for 30 min on ice. The bacteria were treated for 
90 s by a heat shock of 42°C, placed on ice, diluted with 300 µl LB medium and incubated for 
1 h at 37°C with shaking. An aliquot of 50-200 µl was spread on a LB/amp agar plate and 
incubated overnight at 37°C to select for transformed bacteria. 
 
 
3.9.4.3. Preparation of electrocompetent cells 
100 ml of LB medium were inoculated with an overnight culture of E. coli DH5α. Cells were 
grown at 37°C with shaking to an OD600 of 0.4, chilled for 20 min on ice and centrifuged at 
4,000 rpm for 20 min at 4°C. The pellet was resuspended in 100 ml ice-cold water. Bacteria were 
then successively recentrifuged and resuspended in each of the following ice-cold solutions: 
100 ml water, 16 ml 10 % glycerol and finally 2 ml 10 % glycerol. The cells were then aliquoted 
and stored at –70°C. 
 
 
3.9.4.4. Electroporation of E. coli 
Electroporation with high voltage is the most efficient method for transforming E. coli. An 
efficiency of about 109 transformants/µg input plasmid DNA can be achieved. This method was 
used to transform yeast plasmid DNA into E. coli DH5α. 
 
50 µl of thawed electrocompetent cells were mixed with up to 1 µg yeast plasmid DNA and 
transferred into an ice-cold electroporation cuvette with a 0.2 cm electrode gap. The cuvette was 
placed into an electroporator and pulsed with 2.5 kV, 25 µF and a pulse control of 200 Ω. 
Immediately 1 ml LB medium was added and the culture was grown for 1 h at 37°C with 
shaking. An aliquot of 50-200 µl was spread on a selective LB/amp agar plate and grown 
overnight at 37°C. 
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3.9.5. Materials 
ampicillin   stock: 100 µg/µl, stored at –20°C 
E. coli DH5α    MaxEfficiency DH5α competent cells; GibcoBRL   
    genotype: F Φ80dlacZ∆M15 ∆(lacZYA-argF)U169 deoR 
    recA1 endA1 hsdR17(rk, mk+) phoA supE44 λ thi-1   
    gyrA96 relA1 
electroporation cuvette  0.2 cm; Eurogentec (Seraing, Belgium) 
electroporator   Gene Pulser II; Bio-Rad 
 
 
 
3.10. DNA processing and manipulation 
3.10.1. Restriction endonuclease digestion of DNA 
Type II restriction endonucleases were used to digest double-stranded DNA for analytical or 
preparative purposes. These restriction enzymes bind to short, specific nucleotide sequences and 
cleave the DNA within this region by hydrolyzing a phosphodiester bond in each strand. The 
recognition sequences (palindromes) possess twofold rotational symmetry. Staggered cleavage 
generates complementary, cohesive 5' and 3' ends (sticky ends). Cleavage in the axis of 
symmetry yields blunt ends. 
 
For preparative purposes, 1-10 µg DNA were digested with 1-20 U of restriction enzyme in a 
volume of 50-100 µl. Complete digestion was confirmed by agarose gel electrophoresis. For 
analytical purposes, 0.2-2 µg DNA were digested with 1-5 U enzyme in a volume of 20-50 µl. In 
both cases digests were incubated for 2 h at 37°C. Reaction buffers were supplied by the 
manufacturer. Enzymes were heat-inactivated as recommended by the supplier or removed by 
phenol:chloroform extraction. 
 
 
3.10.2. Phenol:chloroform extraction 
To inactivate and remove proteins, e.g. restriction enzymes, nucleic acid solutions were extracted 
with phenol:chloroform. Thereby denatured proteins form a layer at the interface between 
aqueous and organic phases during centrifugation. The aqueous phase contains the purified DNA 
that can subsequently be concentrated by ethanol precipitation or directly used for further 
manipulations. 
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An equal volume of phenol:chloroform:isoamyl alcohol (25:24:1) was added to the DNA 
sample. After vortexing vigorously the emulsion was centrifuged at 13,000 rpm for 1 min and 
the upper aqueous phase was carefully separated from the interface and organic phase. An 
additional chloroform extraction was performed in order to remove residual phenol. 
 
 
3.10.3. Ethanol precipitation of DNA 
In the presence of relatively high concentrations of monovalent cations, ethanol induces a 
structural transition in nucleic acid molecules which causes them to aggregate and precipitate 
from solution. Ethanol precipitation was used to concentrate and/or desalt DNA solutions and to 
remove any residual organic phase following a phenol:chloroform extraction. 
 
5 M NaCl solution was added to the DNA sample to a final concentration of 250 mM. Three 
volumes of ethanol (-20°C) were added, the solution was stored on ice for 10 min and then 
centrifuged at 13,000 rpm for 15 min at 4°C. The pellet was washed with one volume of ice-cold 
70 % ethanol, recentrifuged for 5 min and dried in a speedvac evaporator. The DNA was 
dissolved in water or TE (pH 8) for 20 min at 37°C at an appropriate concentration. 
 
 
3.10.4. Dephosphorylation of linearized plasmid DNA by CIP 
In order to prevent self-ligation of vector ends in cloning strategies, linearized plasmid DNA was 
treated with calf intestine alkaline phosphatase (CIP). CIP catalyzes the hydrolysis of 
5'-phosphate residues to 5'-hydroxyl ends. Since T4 DNA ligase requires 5'-phosphate residues 
to catalyze new phosphodiester bonds, ligation is only possible between vector ends and inserts, 
but not between vector ends themselves. 
 
Dephosphorylation was carried out directly following plasmid linearization. CIP was added to 
the digestion mixture at a concentration of 1 U per pmol linearized vector DNA. After 45 min 
incubation at 37°C, CIP and the restriction enzymes were removed by phenol:chloroform 
extraction. The plasmid was recovered by ethanol precipitation. 
 
 
3.10.5. Ligation of DNA fragments 
DNA fragments bearing either sticky or blunt ends can be ligated in vitro with bacteriophage 
T4 DNA ligase. This enzyme catalyzes the formation of new phosphodiester bonds between a 
5'-phosphate residue of one and a 3'-hydroxyl residue of another double-stranded DNA fragment 
generated by restriction endonucleases. 
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Ligation occured overnight at 16°C in a volume of 10-20 µl containing 1x ligation buffer 
supplied by the manufacturer and 1-2 U ligase. The insert DNA was employed at a 2-5 molar 
excess relative to the linearized and dephosphorylated vector DNA. 
 
 
3.10.6. Miniprep: small-scale preparation of plasmid DNA 
Plasmid DNA was purified from bacteria cultures by alkaline lysis of the bacterial cells and 
subsequent silica-based anion exchange column chromatography. A small culture of bacteria is 
grown in order to amplify in vivo the plasmid of interest. The bacteria are harvested and 
resuspended in buffer P1 (50 mM Tis·Cl pH 8.0, 10 mM EDTA, 100 µg/ml RNase A). 
Treatment with lysis buffer P2 (0.2 N NaOH, 1 % SDS) causes denaturation of the DNA by 
NaOH and of the bacterial proteins by SDS. The mixture is neutralized by buffer P3 (3 M 
potassium acetate, pH 5.5) causing reannealing of plasmid DNA and precipitation of SDS. 
Proteins, chromosomal DNA, SDS and cell debris are removed by centrifugation while the 
plasmid DNA stays in solution. 
 
3 ml of a small overnight culture was centrifuged at 13,000 rpm for 1 min at room temperature. 
The bacterial pellet was resuspended in 250 µl P1. 250 µl P2 and 350 µl P3 were added, 
followed by gently mixing. The suspension was centrifuged at 13,000 rpm for 10 min and an 
equilibrated spin column was loaded with the supernatant. After washing of the column, the 
DNA was eluted by adding 50 µl water or TE and centrifugation of the column at 13,000 rpm for 
1 min. 
 
 
3.10.7. Midiprep, maxiprep and gigaprep: large-scale preparations of plasmid DNA 
The alkaline lysis method, as described for minipreps, was used to produce high yields of 
plasmid DNA from large-scale bacterial cultures. 
 
For midipreps, a bacteria culture of 100 ml was centrifuged at 4,000 rpm for 15 min at 4°C. The 
pellet was resuspended in 4 ml P1, supplemented with 4 ml P2 and incubated at room 
temperature for 5 min. After addition of 4 ml ice-cold P3 the mixture was incubated on ice for 
15 min and centrifuged at 4,000 rpm for 30 min at 4°C. The supernatant was filtered over a pre-
wetted folded filter and placed on an equilibrated anion exchange column that was subsequently 
washed twice. The absorbed DNA was eluted with elution buffer by gravity according to the 
manufacture’s instruction. The eluate was precipitated by adding 0.7 volumes room-temperature 
isopropanol and subsequent centrifugation at 9,000 rpm for 30 min at 4°C. The pellet was 
washed with 2 ml 70 % ethanol, recentrifuged for 10 min, dried under vacuum and redissolved in 
100 µl water or TE to an appropriate concentration. Maxipreps (for 250-ml cultures) and 
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gigapreps (for library cDNA isolation, see 3.8.6.) were performed likewise using appropriate 
columns and scaled-up protocols. 
 
 
3.10.8. Quantification of DNA and RNA solutions 
The concentration of nucleic acid solutions was determined by spectrophotometry. The 
ultraviolet (UV) absorption was measured at a wavelength of 260 nm (OD260) using a quartz 
cuvette of 1 cm width. For double-stranded DNA an OD260 = 1.0 corresponds to approximately 
50 µg DNA/ml. For RNA an OD260 = 1.0 corresponds to approximately 40 µg RNA/ml. In 
addition the OD280 was measured to estimate the purity of the nucleic acid sample. A ratio 
OD260/OD280 of significantly less than 1.8-2.0 indicates phenol or protein contamination. 
 
DNA samples were diluted 1:200, RNA samples 1:250, and measured in a spectrophotometer 
against a blank of pure water. An OD260 of 1.0 corresponds to a concentration of 10 µg DNA/µl 
respectively 10 µg RNA/µl of the original, non-diluted solution. 
 
 
3.10.9. Agarose gel electrophoresis 
Agarose gel electrophoresis was used for analytical and preparative purposes. The method is 
based on the migration of the negatively charged DNA towards the anode in an electric field. 
The fragments migrate through the gel matrix at rates inversely proportional to the logarithm 
(log10) of the number of base pairs. Visualizing of DNA bands within an agarose gel is 
performed by DNA staining with the intercalating fluorescent dye ethidium bromide and 
subsequent illumination under UV light. The length of a DNA fragment is determined by 
comparison of its mobility to that of DNA standards. 
 
The agarose gel, 1-2 % (w/v) agarose melted in 1x TBE electrophoresis buffer and supplemented 
with 0.5 µg/ml ethidium bromide, was placed in a electrophoresis tank and submerged in 1x 
TBE buffer. The DNA samples were mixed with DNA loading buffer and loaded into the gel 
wells. In addition 10 µl of a DNA standard was loaded in parallel with the samples. Horizontal 
electrophoresis was carried out at approximately 110 V. The stained gel was photographed under 
UV light. 
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3.10.10. Recovery of DNA from agarose gels 
For preparative purposes DNA fragments of interest were cut out from stained agarose gels with 
a razor blade under UV illumination. The gel slides were solubilized and DNA was recovered by 
column chromatography. 
 
Agarose gel slide were weighed (= 1 volume) and dissolved in 3 volumes of solubilization buffer 
by incubation for 10 min at 50°C. 1 volume isopropanol was added and the solution was applied 
to a silica-gel spin column. The column was centrifuged at 13,000 rpm for 1 min, washed with 
buffer and centrifuged again. DNA was eluted by adding 50 µl water or TE and centrifugation of 
the column at 13,000 rpm for 1 min. All buffers were provided by the manufacturer. 
 
 
3.10.11. Sequencing of DNA 
The sequence of specific target regions in between plasmid DNA was determined by a 
commercial sequencing service (MWG Biotech, Ebersberg, Germany). The sequence data were 
verified on the basis of the corresponding fluorescence electropherogram and subjected to 
computer analysis. 
 
 
3.10.12. Computer-assisted sequence analysis 
The GCG program (Wisconsin Sequence Analysis Package, Version 8.1-UNIX, 1995; Genetics 
Computer Group, Madison, WI, USA) was used together with public scientific internet 
applications for computer-assisted DNA and protein sequence analysis and database alignments. 
 
 
3.10.13. Materials 
Biomaterials and enzymes 
agarose   agarose NA; Amersham Pharmacia Biotech (Uppsala, Sweden) 
calf intestine alkaline         
 phosphatase (CIP) Boehringer Mannheim (Mannheim, Germany) 
restriction enzymes  New England Biolabs (Fankfurt, Germany) and    
    Boehringer Mannheim (Mannheim, Germany) 
T4 DNA ligase  Boehringer Mannheim (Mannheim, Germany) 
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Reagents and solutions 
chloroform   Merck 
DNA loading buffer (6x) 0,25% (w/v) bromophenol blue     
    0,25% (w/v) xylene cyanol      
    30% (v/v) glycerol       
    50 mM EDTA 
DNA standard   Gene Ruler DNA ladder mix; MBI Fermentas    
    (Souffelweyersheim, France) 
ethidium bromide  1 % (w/v); Serva, Boehringer Ingelheim (Heidelberg, Germany) 
phenol/chloroform/isoamyl           
     alcohol (25:24:1) Roth (Karlsruhe, Germany) 
TBE buffer (5x)  Tris-base 108 g       
    boric acid   55 g       
    EDTA  40 ml of 0.5 M, pH 8.0    
    ad  2 l 
TE    10 mM Tris (pH 7.6), 1 mM EDTA (pH 8.0) 
 
Equipment and materials 
electrophoresis system Sub-Cell GT agarose gel electrophoresis system; Bio-Rad 
gel extraction kit   QIAquick Gel Extraction Kit; Qiagen (Hilden, Germany) 
midiprep, maxiprep and          
       gigaprep kits QIAGEN Plasmid Midi, Maxi and Giga Kits; Qiagen (Hilden, 
    Germany) 
miniprep kit   QIAprep Spin Miniprep Kit; Qiagen (Hilden, Germany) 
photographic film  Polapan; Polaroid (Offenbach, Germany) 
photo camera   MP-4 Land Camera, model 44-31; Polaroid (Cambridge, MA) 
speedvac   Vacuum cncentrator centrifuge Univapo 150 H; UniEquip  
    (Martinsried, Germany) 
UV illuminator  model N90M; UniEquip (Martinsried, Germany) 
 
 
 
3.11. PCR applications 
3.11.1. DNA amplification by PCR 
The polymerase chain reaction (PCR) constitutes an enzymatic in vitro amplification of specific 
DNA segments. Amplification occurs in automated, temperature-controlled cycles of 
denaturation, annealing and elongation in a thermal cycler. Initially, double-stranded template 
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DNA is separated into its complementary single strands by heating (denaturation). At a lower 
temperature two oligonucleotide primers, flanking the DNA region to be amplified, hybridize to 
their respective complementary sequences on opposite strands (annealing) and serve as primers 
for DNA synthesis in a 5'→3' direction (elongation). Primer extension is catalyzed at a slightly 
increased temperature by a thermostable DNA polymerase that adds deoxyribonucleotide 
triphosphates (dNTPs) to the recessed 3'-hydroxyl end of extending strands, thereby generating 
new double-stranded DNA across the primer-flanked region. The products of each reaction cycle 
are then denatured to permit a new amplification cycle. Theoretically, for n cycles a 2n-fold 
amplification of a specific DNA sequence is obtained. 
 
Primers were commercially synthesized (MWG Biotech, Ebersberg, Germany). They were 
designed corresponding to the DNA segment to be amplified, provided with restriction sites for 
endonuclease digestion or epitope-encoding sequences for immunological purposes where 
appropriate. Pairs of primers were designed to have equivalent melting temperatures (Tm), 
calculated according to the formula9 Tm [°C] = (A+T)·2 + (G+C)·4. The annealing temperature 
for each PCR was typically estimated by Tm minus 5°C and optimized experimentally. For 
preparative DNA amplification as part of cloning strategies, Deep VentR DNA polymerase was 
used in preference to Taq DNA polymerase, due to its 3'→5' proofreading exonuclease activity 
which minimizes the risk of nucleotide misincorporation during elongation. 
 
Reaction parameters for DNA amplification were as follows: 
 template DNA  ~200 ng (except in negative control PCR) 
 sense-primer (forward) 1 µM 
 antisense-primer (reverse) 1 µM 
 DNA polymerase  1-2 U 
 PCR reaction buffer  1x 
 dNTPs    each 200 µM 
 final reaction volume  100 µl (preparative PCR), 30-50 µl (analytical PCR) 
 
Thermal cycle parameters for PCRs were as follows: 
 initial denaturation  94°C, 5 min 
denaturation   94°C, 30-60 s 
 annealing   60-65°C (primer pair and template specific), 30-60 s 
 elongation   72°C for Taq DNA polymerase, approx. 60 s/kb  
     74°C for Deep VentR DNA polymerase, approx. 60 s/kb 
 cycles    30 
 final elongation  72°C/74°C, 10 min 
                                                 
9 A, T, G, C: number of the 2'-deoxynucleosides adenosine (A), thymidine (T), guanosine (G) and cytidine (C) within a primer 
sequence. 
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A negative control was included in each PCR experiment using H2O instead of template DNA to 
allow the detection of amplified DNA molecules due to contamination. PCR products were 
analyzed by agarose gel electrophoresis. In preparative experiments, the DNA fragments were 
subcloned into appropriate vectors and sequenced to exclude errors. 
 
 
3.11.2. Synthesis of a cDNA insert encoding the cytoplasmic region of CD11a  
The DNA sequence encoding the cytoplasmic tail of CD11a (nt 3425-3649)10 was subcloned 
within the NdeI (5971)/EcoRI (5988) restriction site of the YTH vector pAS2-1 (Dr. G. Heiss). 
 
Primers11 used for the amplification of this cDNA insert were 
5'-CGTCATATGAAGGTTGGTTTCTTCAAACGGAAC-3' (forward) and  
5'-CCGGAATTCGGCATCCTGAGTCCAGTTCTG-3' (reverse). 
 
The plasmid paαL, full-length CD11a cDNA subcloned into the HindIII/XbaI restriction site of 
pAPRM8 (Klickstein et al., 1996), served as template DNA for the PCR. 
 
 
3.11.3. Synthesis of JM1121 and JAM(HA) cDNA inserts 
cDNA sequences encoding full-length human JAM-1 without (JM1121) and with (JAM(HA)) the 
hemagglutinin (HA) epitope YPYDVPDYA were subcloned into the KpnI (895)/ BamHI (907) 
site of the mammalian expression vector pcDNA3. 
 
Primers used for the amplification of JM1121 cDNA were 
JM101           5'-GCGGGGTACCATGGGGACAAAGGCGCAAGTCGA-3' (forward) and
 JM102           5'-GCGGGGATCCTCACACCAGGAATGACGAGGTCT-3' (reverse). 
 
Primers used for the amplification of JAM(HA) cDNA were JM101 (forward) and 
JM302           5'-GCGGGGATCCTCAAGCGTAATCTGGAACATCGTATGGGTA- 
  TCCAGCCACCAGGAATGACGAGGTCT-3' (reverse). 
 
The prey-encoding library vector isolated from the bona fide yeast colony αLMC3 during the 
YTH screening (see 4.1.) served as JAM-1 DNA template for the synthesis of both fragments. 
 
                                                 
10 Nucleotide numbers of CD11a refer to GenBank accession number Y00796 (Larson et al., 1989). 
11 normal: gene-specific DNA sequence, bold: restriction site; underlined: start/stop codon; underlined dotted: tag-encoding 
sequence; italic: clamp or bridge. 
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3.11.4. Synthesis of Ig-like domain–deleted JAM-1 cDNA constructs by PCR overlap 
extension (deletion mutagenesis) 
The overlap extension method (Horton et al., 1989) enables the fusion of two independent but 
overlapping DNA fragments without the use of restriction enzymes or ligase. After initial 
denaturation of both molecules, the single strands of each fragment that include the overlapping 
sequence at their 3' ends can anneal to each other and serve as primers for one another (strand 
self-priming). By the action of DNA polymerase the single strands are extended in 5'-3' direction 
starting at the particular 3' end of the overlapping region (overlap extension). Thereby the 
different strands serve as template DNA for one another to ultimately generate a single, fused 
double-stranded DNA molecule that itself is further amplified during subsequent PCR steps in 
the presence of two primers flanking the DNA region on the ”ligated” fragment to be amplified. 
 
Two PCR fragments, NJAM and CJAM, were synthesized using JAM-1–encoding pJM1121 as 
template DNA (table 2). NJAM contained the 5' part of JAM-1 ending just before the Ig-like 
domain to be deleted. Its 3' end consisted of the last 25 nt before and the first 25 nt after this 
domain, accomplished by the appropriate design of the antisense primer (Ig1D-N02 respective 
Ig2D-N02). Conversely, CJAM based on the 3' part of JAM-1, beginning just after the Ig-like 
domain to be deleted. The 5' end of CJAM constituted the same DNA sequence as the 3' end of 
NJAM, accomplished by the sense primer used (Ig1D-C01 respective Ig2D-C01). Thus, both 
fragments provided a mutual overlapping sequence of approximately 50 bp, containing sequence 
areas before and after the Ig-like domain to be deleted but specifically excluding the domain 
sequence itself. This sequence overlap was used to fuse both molecules by PCR overlap 
extension (table 3). NJAM and CJAM were purified by preparative agarose gel electrophoresis, 
mixed together, supplemented with primers flanking the terminal ends of JAM-1 and subjected to 
PCR. Strand self-priming, overlap extension and PCR amplification yielded the synthesis of 
hybrid JAM-1 molecules deleted for the corresponding Ig-like domain. The fragment was 
electrophoretically purified and subcloned into the expression vector pcDNA3. The identity and 
integrity of the hybrid molecule was confirmed by complete DNA sequencing. 
 
fragment nt numbers sense primer antisense primer 
NJAM∆D1      1-123, 394-418 JM101 Ig1D-N02 
CJAM∆D1   99-123, 394-900 Ig1D-C01 JM102 
CJAM∆D1(HA)   99-123, 394-897, HA Ig1D-C01 JM302 
NJAM∆D2      1-393, 652-676 JM101 Ig2D-N02 
CJAM∆D2 369-393, 652-900 Ig2D-C01 JM102 
CJAM∆D2(HA) 369-393, 652-897, HA Ig2D-C01 JM302 
 
table 2: Sense and antisense primers used for generation of NJAM and CJAM fragments for use in PCR 
overlap extension synthesis. Nucleotide numbers refer to the coding sequence of human JAM-1 (nt 
1-900); ”HA” indicates implementation of a HA-encoding tag sequence at the 3’ end of the fragment. 
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fused DNA nt numbers self-priming molecules flanking primers 
JAM∆D1 1-123, 394-900 NJAM∆D1, CJAM∆D1 JM101, JM102 
JAM∆D1(HA) 1-123, 394-897, HA NJAM∆D1, CJAM∆D1(HA) JM101, JM302 
JAM∆D2 1-393, 652-900 NJAM∆D2, CJAM∆D2 JM101, JM102 
JAM∆D2(HA) 1-393, 652-897, HA NJAM∆D2, CJAM∆D2(HA) JM101, JM302 
 
table *3: Flanking sense and antisense primers used for the fusion of self-priming NJAM and CJAM fragments 
by PCR overlap extension to synthesize mutagenized JAM-1 DNA molecules deficient for the sequence 
region encoding the N-terminal Ig-like domain 1 (JAM∆D1) or the membrane-proximal Ig-like domain 2 
(JAM∆D2) of human JAM-1. Nucleotide numbers refer to the coding sequence of human JAM-1 (nt 1-900); 
”HA” indicates implementation of a HA-encoding tag sequence at the 3' end of the fragment. 
 
Primers12 used to generate self-priming molecules were 
 
Ig1D-C01 (forward) 
5'-T099TCTGAACCTGAAGTCAGAATTCCT123║C394CATCCAAGCCTACAGTTAACAT416-3' 
Ig1D-N02 (reverse) 
5'-G418GATGTTAACTGTAGGCTTGGATGG394║A123GGAATTCTGACTTCAGGTTCAG101-3' 
Ig2D-C01 (forward) 
5'-G369GTCAAGCTCATCGTGCTTGTGCCT393║T652ATGGGACACCCATGACTTCAAA674-3' 
Ig2D-N02 (reverse) 
5'-C676ATTTGAAGTCATGGGTGTCCCATA652║A393GGCACAAGCACGATGAGCTTG372-3'. 
 
 
3.11.5. Analytical PCR 
Gene expression analysis of JAM-1 and β-actin at the RNA level using RT-PCR included 
analytical PCR and is described below (see 3.12.). 
 
Prior to sequencing of prey-encoding cDNA inserts from pGAD10-based library vectors of 
candidate HIS3+/lacZ+ yeast colonies the insert sizes were determined by analytical PCR. 
 
Primers13 used for the amplification of these inserts flanked the EcoRI restriction site within the 
MCS of pGAD10 and were 
GAD101 5'-G797ATGAAGATACCCCACCAAACCCA821-3' (forward) and  
GAD102 5'-C888TTGCGGGGTTTTTCAGTATCTAC864-3' (reverse). 
 
                                                 
12 normal: sequence region before the Ig-like domain to be deleted; bold: sequence region after the Ig-like domain to be deleted; 
”||” indicates the position of the omitted Ig-like domain sequence (fusion locus). The nucleotide numbers indicated with 
superscripts correspond to the coding sequence of human JAM-1. 
13 Nucleotide numbers indicated with superscripts correspond to the sequence of pGAD10. 
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3.11.6. Materials 
Deep VentR DNA polymerase New England Biolabs 
dNTPs     PCR nucleotide mix, contains the deoxynucleotides 
     dATP, dGTP, dCTP, dTTP each at 10 mM;   
     Roche Diagnostics (Mannheim, Germany) 
oligonucleotide primers  synthesized to order by MWG Biotech (Ebersberg,  
      Germany); dissolved in water to final 100 pmol/µl 
PCR reaction buffer   10x buffer as provided by the supplier of the appropriate 
     DNA polymerase 
Taq DNA polymerase  Qiagen (Hilden, Germany) 
thermal cycler    Mastercycler gradient; Eppendorf (Hamburg, Germany) 
 
 
 
3.12. Gene expression analysis at the RNA level using RT-PCR 
Gene expression analysis at the RNA level, i.e. determination of target-specific mRNA 
transcripts in the cell, includes isolation of total RNA, reverse transcription of mRNA to cDNA 
and amplification of the target cDNA by PCR. Cells were dissolved by a mono-phasic solution 
of phenol and guanidine isothiocyanate (Trizol Reagent). Addition of chloroform and subsequent 
centrifugation lead to phase separation under conditions at which RNA remained water-soluble 
and proteins or DNA were found in the organic phase or the interphase. The total RNA was 
subsequently isolation from the aqueous phase and served as template for the synthesis of cDNA 
via reverse transcriptase polymerase chain reaction (RT-PCR) using viral reverse transcriptase 
and random hexamer primers. The cDNA pool was subsequently subjected to analytical PCR 
using gene-specific oligonucleotide primers. 
 
5·106 CHO cells were harvested, washed in PBS, homogenized in 1 ml Trizol reagent and 
incubated for 5 min at room temperature. Phase separation was generated by addition of 200 µl 
chloroform and centrifugation at 13,000 rpm for 15 min at 4°C. The RNA was precipitated from 
the aqueous phase by addition of 500 µl isopropanol, incubation for 10 min at room temperature 
and centrifugation at 13,000 rpm for 10 min at 4°C. The pellet was washed with 1 ml 75 % 
ethanol, recentrifuged at 7,500 rpm for 5 min at 4°C, and dried for 5-10 min at 55°C. The RNA 
was redissolved in 100 µl water with incubation for 10 min at 55°C and its concentration was 
determined by spectrophotometry (see 3.10.8.). Samples were stored at –70°C. To prevent 
degradation of RNA due to RNase contamination, only diethylpyrocarbonate (DEPC)-treated 
water was used. For this the water was supplemented with DEPC to final 0.1 % (v/v), incubated 
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overnight at room temperature and autoclaved. The utilized glassware was baked overnight at 
140°C prior to use. Work with RNA was performed wearing gloves. 
 
Reaction parameters for the first strand cDNA synthesis by RT-PCR were as follows: 
 template RNA   5 µg (volume respective to the RNA concentration) 
 random hexamer primers 5 µM       
 first strand buffer  1x       
 DTT (dithiothreitol)  10 mM      
 dNTPs    each 0.5 mM      
 reverse transcriptase  200 U       
 final reaction volume  20 µl 
 
Template RNA and random hexamer primers were mixed with water to a final volume of 12 µl 
and incubated for 10 min at 70°C. The remaining components excluding the enzyme were added 
and the solution was incubated for 10 min at 25°C and additionally for 2 min at 42°C. The 
reverse transcriptase was supplemented and the RT-PCR was performed for 50 min at 42°C. The 
enzyme was heat-inactivated for 15 min at 70°C and the first strand cDNA samples were stored 
at –20°C. 
 
Subsequently, for gene expression analysis, 10 % of a cDNA-containing first strand reaction mix 
was subjected to analytical PCR (see 3.11.) in order to amplify cDNA fragments derived from 
expressed target gene-specific mRNA transcripts, i.e. JAM-1–related cDNA and as a control 
β-actin cDNA.  
 
Primers used for amplification of JAM-1–related cDNA were JM101 (forward) and JM102 
(reverse). JM101 (forward) and JM302 (reverse) were used to amplify HA-tagged sequences (see 
3.11.3.). 
 
Primers used for the amplification of β-actin cDNA were     
 5-bAct  5'-AGAGATGGCCACGGCTGCTT-3' (forward) and  
 3-bAct  5'-ATTTGCGGTGGACGATGGAG-3' (reverse)            
and allowed amplified β-actin fragments derived from genomic DNA contamination or spliced 
mRNA transcripts to be distinguished (see 4.7.). A human foreskin fibroblast preparation served 
as positive control for β-actin cDNA amplification. 
 
Materials 
dNTPs    (see 3.11.6.) 
DTT (0.1 M)   GibcoBRL 
ethanol (75 %)  prepared with DEPC-treated water 
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first strand buffer  GibcoBRL 
human foreskin fibroblast          
  preparation kind gift of K. Bauer (IPEK, University Hospital, Munich) 
random hexamer primers Primer ”random”; Boehringer Mannheim 
reverse transcriptase  Superscript II, Rnase H reverse transcriptase, derived from 
    moloney murine leukemia virus (MMLV); GibcoBRL 
Trizol reagent   total RNA isolation reagent; GibcoBRL 
 
 
 
3.13. Protein analysis 
3.13.1. Measurement of protein concentrations (BCA method) 
Bicinchoninic acid (BCA) is a selective detection reagent for the cuprous cation Cu1+ that is 
generated by protein-mediated reduction of Cu2+ in an alkaline environment. The complex of two 
BCA molecules with a Cu1+ ion exhibits an absorption maximum at a wavelength of 562 nm, 
allowing spectrophotometric quantification of proteins in aqueous solution. 
 
Proteins were quantitative precipitated by addition of 1 ml ice-cold 12 % trichloroacetic acid 
(TCA), incubation for 30 min on ice and centrifugation at 13,000 rpm for 30 min at 4°C. The 
supernatant was removed and the pellet was resuspended in 100 µl water. Using a BSA stock 
solution, a set of protein standards with 0-25 µg BSA/100 µl was prepared. To each set of 
protein standards and protein samples, 2 ml of freshly prepared BCA working solution was 
added. The protein solutions were incubated for 30 min at 60°C, cooled to room temperature and 
their absorption was measured at the wavelength of 562 nm in a spectrophotometer. Based on the 
absorption values of the protein standards a calibration curve was calculated and used for 
determination of the protein concentrations in the samples. All protein standards and samples 
were prepared in duplicate. 
 
Materials 
BSA stock solution  2.0 µg/µl BSA standard; Pierce Chemicals (Rockford, IL) 
BCA Protein Assay Kit  Pierce Chemicals (Rockford, IL) 
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3.13.2. Whole cell lysates 
Mammalian cells were harvested, washed with PBS and counted in a Neubauer hemacytometer. 
Approximately 2·106 cells were centrifuged at 1,200 rpm for 5 min at 25°C. The pellet was 
resuspended on ice in 200 µl ice-cold 1x SDS sample buffer supplemented with protease 
inhibitors and where appropriate with DTT by drawing through a 20G needle with a 1-ml insulin 
syringe. The cell lysates were heated for 5 min at 96°C and subjected to SDS-PAGE or long-
term storage at –70°C. 
 
Materials 
DTT supplementation 25 mM (where appropriate); GibcoBRL 
protease inhibitor           
 supplementation  aprotein  2 µg/ml (stock solution at –20°C: 10 µg/µl)  
    leupeptin 5 µg/ml (stock solution –20°C: 5 µg/µl) 
SDS sample buffer (2x) (see 3.13.4.) 
 
 
3.13.3. Fractionated cell lysates 
Intact cells were lysed and separated into membrane and cytosolic cell fractions for protein 
analysis. Approximately 3·107 CHO cells were washed twice in PBS and then resuspended in 
500 µl ice-cold hypotonic lysis buffer and disrupted by 60-80 strokes in a glass Dounce 
homogenizer on ice. The homogenate was incubated on ice for 10 min and centrifuged at 110 g 
for 5 min at 4°C to remove nuclei, unbroken cells and large debris. The postnuclear supernatant 
was ultracentrifuged at 100,000 g for 30 min at 4°C, resulting in a supernatant containing the 
cytosolic cell fraction. The pellet was washed with 1 ml lysis buffer by passage 5 times through a 
26G syringe canula and then ultracentrifuged again. The supernatant was discarded and the 
pellet, containing membranes and cytoskeletons, was resuspended in 400 µl hypotonic lysis 
buffer supplemented with 1 % (v/v) Igepal CA-630 detergent. This membrane fraction was 
incubated on ice for 10 min. The fractionated protein samples were stored at -70°C. 
 
Materials 
hypotonic lysis buffer HEPES  10 mM     
    KCl   10 mM     
    MgCl2   10 mM     
    EDTA   0.5 mM     
    Complete, mini 1 tablet/8.4 ml buffer    
    pH   7.9 
Igepal CA-630  (Octylphenoxy)polyethoxyethanol; formerly Nonidet P-40 
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Complete, mini  EDTA-free protease inhibitor cocktail tablets; Roche  
    Diagnostics (Mannheim, Germany) 
ultracentrifugation tubes Microfuge tube polyallomer; Beckman Instruments (Palo Alto,  
    CA) 
ultracentrifuge  Optima TLX Ultracentrifuge; Beckman Instruments (Palo Alto, 
    CA) 
 
3.13.4. SDS-PAGE 
Whole cell lysates and protein samples were resolved for analytical purposes by polyacrylamide 
gel electrophoresis (PAGE). The use of the anionic detergent sodium dodecyl sulfate (SDS) 
enables separation according to the molecular weight of the proteins. It binds to the polypeptides 
and confers a negative charge which is in direct proportion to their size. The gel matrix is 
prepared by polymerization of acrylamide and N,N'-methylenebisacrylamide via free radicals. 
Initial radicals arise from chemical decay of ammonium persulfate (APS) catalyzed by 
N,N,N',N'-tetramethylethylenediamine (TEMED). The electrophoresis towards the anode is 
carried out in a discontinuous buffer system that first concentrates SDS-protein complexes 
within a stacking gel before they migrate into the resolving gel. The size of proteins is 
determined by comparing their mobility with that of a protein standard. 
 
The resolving gel solution was prepared, poured between two glass plates and overlaid with 
butanol. After polymerization, the top of the gel was washed with water. Freshly prepared 
stacking gel solution was filled and allowed to polymerize. Subsequently the gel was placed in a 
vertical electrophoresis apparatus filled with 1x running buffer. Protein samples were diluted 1:1 
with 2x SDS sample buffer if not already prepared with 1x SDS sample buffer. The SDS sample 
buffer was supplemented with (reducing conditions) or without (non-reducing conditions) 
dithiothreitol (DTT). The protein samples and a protein standard were denatured by boiling for 
5 min and loaded onto the gel. Electrophoresis was carried out at 200 V. The resolving gel was 
subsequently subjected to western blot analysis or silver staining. 
 
Materials 
acrylamide/bis-acrylamide 30 % (w/v) solution, mix ratio 29:1; Bio-Rad 
APS    Bio-Rad 
DTT    stock solution: 1 M in 10 mM NaOAc, stored at –20°C 
electrophoresis apparatus          
          and supplies Mini-PROTEAN II Cell; Bio-Rad 
protein standards  prestained SDS-PAGE standards:      
    low range (20-112 kDa), broad range (7-207 kDa); Bio-Rad 
 
68  Materials and methods 
resolving gel (10 %)  5 ml 1.5 M Tris, pH 8.8      
    8.2 ml water        
    6.7 ml acrylamide/bis-acrylamide solution    
    125 µl 10 % (w/v) APS      
    7.5 µl TEMED 
running buffer (10x)  30 g Tris-base        
    142 g glycine        
    50 ml 20 % SDS       
    ad 1 l 
SDS sample buffer (2x) 100 mM Tris·HCl (pH 6.8)      
    20 % (v/v) glycerol       
    4 % (w/v) SDS       
    0.01 % (w/v) bromphenol blue     
    50 mM DTT (where appropriate) 
stacking gel   1.25 ml 0.5 M Tris, pH 6.8      
    3.25 ml water        
    0.5 ml acrylamide/bis-acrylamide     
    30 µl 10 % APS       
    5 µl TEMED 
 
 
3.13.5. Western blot analysis 
Western blotting consists of the transfer of electrophoretically separated proteins from a SDS-
PAGE gel to a nitrocellulose membrane by electrophoresis. The membrane-immobilized target 
protein is immunologically identified by an appropriate primary antibody and a horseradish 
peroxidase (HRP)-conjugated secondary antibody directed against the primary antibody. 
Detection of the antigen-antibody-antibody complex occurs by HRP-mediated oxidation of the 
chemiluminescent substrate luminol, a cyclic diacylhydrazide. The reaction product exhibits an 
excited state which decays to ground state via a light emitting pathway, and is detectable by 
exposure of the membrane to an autoradiography film. 
 
A nitrocellulose membrane was placed onto the polyacrylamide gel and both were sandwiched 
between electrode papers, pads and a plastic support. The proteins were transferred to the 
membrane by electrophoresis towards the anode at 200 mA for 1 h at 4°C in ice-cold transfer 
buffer. Non-specific binding sites on the blotted membrane were blocked by shaking in 
TBS/milk for 1 h at room temperature. The membrane was successively incubated with the 
primary and secondary antibodies for 1 h at room temperature, with washing by rinsing in TBST 
three times for 10 min. Antibodies used were diluted in TBST/milk to appropriate 
concentrations. The freshly prepared chemiluminescent substrate working solution was added to 
the surface of the membrane (approx. 0.2 ml/cm2) and incubated for 4 min at room temperature. 
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The membrane was wrapped in plastic foil and exposed in the darkroom for 10 s - 30 min to an 
autoradiographic film that was subsequently developed in dark room conditions. 
 
Materials 
antibodies, primary  for source and concentrations see 3.14.1. 
antibodies, secondary  HRP-conjugated; for source and concentrations see 3.14.2. 
autoradiography film  Hyperfilm ECL high performance chemiluminescence film; 
    Amersham Pharmacia (Buckinghamshire, UK) 
blocking milk   non-fat dry milk, blotting grade blocker; Bio-Rad 
blotting apparatus            
  and supplies Mini Trans-Blot Cell; Bio-Rad 
chemiluminescent substrate SuperSignal West Pico Chemiluminescent Substrate (for normal 
    applications) and SuperSignal West Dura Extended Duration 
    Substrate (for applications requiring higher sensitivity);  
    comprises luminol/enhancer solution and stable peroxide  
    solution mixed 1:1 to prepare the working solution; light  
    emission wavelength: 425 nm; Pierce (Rockford, IL) 
electrode paper Novablot Filter Paper, Grade 1F, Amersham 
film developer   G150 developer; Agfa-Gevaert (Mortsel, Belgium) 
film fixing bath  G354 fixing bath; Agfa-Gevaert (Mortsel, Belgium) 
nitrocellulose membrane Hybond-C super; Amersham Life Science (Buckinghamshire, UK) 
TBS    10 ml 1M Tris        
    33 ml 5 M NaCl       
    ad 1 l 
TBS/milk   TBS supplemented with 5 % (w/v) blocking milk 
TBST    TBS supplemented with 0.05 % (v/v) tween 20 
TBST/milk   TBST supplemented with 5 % (w/v) blocking milk 
transfer buffer   3.03 g Tris        
    14.4 g glycin        
    200 ml methanol       
    ad 1 l 
tween 20   polyoxyethylenesorbitan monolaurate; Bio-Rad 
 
 
3.13.6. Silver staining of polyacrylamide gels 
Silver staining of polyacrylamide gels allows the detection of proteins separated by SDS-PAGE 
to a limit of 2-5 ng protein/band. The staining relies on differential reduction of silver ions 
close-to protein bands. 
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Fixation 2 x 30 min CH3OH/H2O/glacial acetic acid (4:3:1)    
  2 x 10 min H2O wash        
  1 x 15 min 2.4 g sodium tetraborate (Na2B4O7) decahydrate   
    ad 148 ml H2O       
    2 ml 25 % glutaraldehyde      
  3 x 30 min H2O wash 
 
Incubation 1 x 15 min merge in order as indicated:      
    24 ml H2O        
    2.3 ml 1 M NaOH       
    2,5 ml 25 % NH3 solution      
    5 ml 20 % (w/v) AgNO3      
    ad 125 ml H2O       
  2 x   5 min H2O wash 
 
Development   until desired staining level with:     
    13 ml ethanol        
    750 µl 1 % (w/v) citric acid      
    90 µl 37 % formaldehyde      
    ad 150 ml H2O 
 
Reduction termination          
  1 x 10 min 3.7 g Tris·HCl        
    2.5 g Na2S2O3        
    ad 100 ml H2O 
 
Backround destaining  exposure until desired background attenuation with   
    Farmer’s Reducer:       
    2.5 ml 20 % (w/v) Na2S2O3      
    2.5 ml 1 % (w/v) K3[Fe(CN)6]     
    ad 220 ml H2O       
  3 x 10 min H2O wash 
 
For storage purpose the stained polyacrylamide gel was incubated in 20 % glycerin for 2 h. The 
gel was then placed between a wet Whatman 3MM paper and a cellophane sheet on the top and 
dried under vacuum for 2 h at 85°C. 
 
Materials 
cellophane sheets  Amersham 
gel dryer   model 583; Bio-Rad 
Whatman 3MM paper 3MM-Chr chromatography paper, Whatman (Maidstone, UK) 
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3.13.7. Flow cytometry 
Flow cytometry analysis enables the determination of optical and immunofluorescence 
characteristics of a single cell. Inside a flow cytometer the cell suspension passes the 
measurement cell as a laminar flow of single cells in isotonic shear fluid, where they are 
intersected by monochromatic light (488-nm argon ion laser). Measurement of light diffraction 
allows determination of the physical properties of the cell, such as the size (represented by 
forward scatter, FSC) and internal complexity (represented by side scatter, SSC) that was used to 
determine the cell number within cell suspensions in chemotaxis assays. Measurement of 
fluorescence activation further allows the quantification of the fluorescent dye uptake of 
immunofluorescence-labeled cells that enables the analysis of cellular protein expression. The 
flow cytometry results were digitized, computer analyzed and subsequently displayed as 
histograms describing the logarithmic distribution of the measured fluorescence intensity over 
the cell population. 
 
Cells were harvested, resuspended in HHMC, placed into round-bottom 96-well microtiter plates 
with 0.5·106 cells/200 µl/well and centrifuged. Each centrifugation step comprised capping of the 
plate with a self-adhesive plate sealer, centrifugation at 1,200 rpm for 3 min at 25°C and 
supernatant removal by a precipitous flick. In the case of intracellular immunofluorescence 
staining, cells were permeabilized with 50 µl 0.2 % (v/v) Triton X-100 for 2 min on ice, the cell 
suspension was diluted with 150 µl HHMC, centrifuged, washed with 200 µl HHMC and 
recentrifuged. For staining, the cells were resuspended in 50 µl HHMC supplemented with either 
a primary antibody directed against the target gene, an IgG isotype control or preimmunization 
serum. The cell suspension was incubated for 30 min at room temperature, diluted with 150 µl 
HHMC, centrifuged, washed with 200 µl HHMC and then recentrifuged. The cells were 
immunofluorescence labeled by resuspension in 50 µl HHMC supplemented with a 
corresponding secondary antibody conjugated with the fluorochrome fluorescein-5(6)-
isothiocyanate (FITC). Subsequent incubation and washing was performed as before but in 
darkness. The stained cells were finally resuspended in 500 µl HHMC, transferred into FACS-
tubes and subjected to flow cytometry measurement. In general a constant number of 
10,000 cells was analyzed. Protein expression was indicated by a positive shift in the 
fluorescence intensity of the two histograms obtained for i) cell populations incubated with an 
IgG isotype control or preimmunization serum and ii) antigen-labeled cell populations. 
 
Materials 
antibodies, primary  for source and concentrations used see 3.14.1. 
antibodies, secondary  FITC-conjugated; for source and concentrations used see 3.14.2. 
FACS-tubes   5-ml Falcon polystyrene tubes; Becton Dickinson (Meylan, France) 
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flow cytometer  FACScan, fluorescence-activated cell analyzer;    
    software: CellQuest; Becton Dickinson Immunochemistry  
    Systems (San Jose, CA) 
IgG isotype controls  for source and concentrations used see 3.14.3. 
isotonic shear fluid  FACSFlow shear fluid; Becton Dickinson 
plate sealer    Linbro plate sealer with adhesive back;     
    ICN Biomedicals (Aurora, OH) 
Triton X-100, 0.2 %  t-octylphenoxypolyethoxyethanol; used at a concentration of  
    0.2 % (v/v) in PBS 
 
 
 
3.14. Antibodies and sera 
3.14.1. Primary antibodies 
αL (CD11a) pAb C-17 goat IgG, directed against the cytosolic domain of CD11a,  
    200 µg/ml; Santa Cruz Biotechnology    
    western blotting:  1:300 dilution, non-reducing conditions 
αL (CD11a) mAb MCA502 rat IgG2a, 2 mg/ml; Serotec (Oxford, UK)    
    western blotting:  1:1000 dilution, non-reducing conditions 
αM (CD11b) mAb            
          CBRM 1/29 mouse IgG1,1 mg/ml; from T.A. Springer (Center of Blood  
    Research, Boston, MA)       
    used:   10 µg/ml 
β2 (CD18) mAb MEM48 mouse IgG1, 100 µg/ml; R&D Systems (Wiesbaden, Germany)  
    Western blotting:  1:200 dilution, non-reducing conditions 
HA pAb Y-11   rabbit IgG, 200 µg/ml; Santa Cruz Biotechnology   
    flow cytometry: 10 µg/ml     
    western blotting:  1:300 dilution 
ICAM-1 Fab    Fab fragment of the ICAM-1 mAb RR1/1; from R. Rothlein 
    (Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT)  
    used:   10 µg/ml 
ICAM-1 mAb RR1/1  mouse IgG1, 1.7 µg/µl; from R. Rothlein (Boehringer Ingelheim 
    Pharmaceuticals, Ridgefield, CT)     
    used:   10 µg/ml 
JAM-1 pAb   (see 3.14.4. and 3.15.2.) 
TS1/18   hybridoma cell line secreting mouse IgG1 mAb directed against the
    LFA-1 β2 subunit (CD18); ATTC (Sánchez-Madrid et al., 1982) 
    used:   1:2 dilution of hybridoma supernatant or 
       10 µg/ml 
Materials and methods  73 
TS1/22   hybridoma cell line secreting mouse IgG1 mAb directed against the
    LFA-1 αL subunit (CD11a); ATTC (Sánchez-Madrid et al., 1982) 
    used:   1:2 dilution of hybridoma supernatant or 
       10 µg/ml 
VLA-4 mAb HP1/2  α4 (CD49d) mAb, mouse IgG1, 4.9 µg/µl; from M.E. Hemler 
    (Harvard Medical School, Boston, MA)    
    used:   10 µg/ml 
 
 
3.14.2. Secondary antibodies 
horseradish peroxidase (HRP)-conjugated (for western blotting) or        
fluorescein-5(6)-isothiocyanate (FITC)-conjugated (for flow cytometry) mAbs 
 
anti-goat IgG HRP-conjugated         
    from rabbit, 400 µg/ml; Santa Cruz Biotechnology   
    used:    1:3000 dilution 
anti-mouse IgG (Fc specific) FITC-conjugated,       
    F(ab')2 fragment, from goat, 2.2 µg/µl; Sigma   
    used:    1:200 dilution 
anti-mouse IgG HRP-conjugated         
    from sheep, 500 µg/ml; Amersham Life Science   
    used:    1:3000 dilution 
anti-rabbit IgG FITC-conjugated         
    from goat, 400 µg/ml; Santa Cruz Biotechnology   
    used:      1:50 dilution 
anti-rabbit IgG HRP-conjugated         
    from goat, 400 µg/ml; Santa Cruz Biotechnology   
    used:      1:2500 dilution 
 
 
3.14.3. IgG isotype controls 
mouse IgG1, κ (MOPC 21) 200 µg/ml; Sigma       
    used:   10 µg/ml     
    flow cytometry: 1:100 dilution 
rabbit IgG   500 µg/ml; Santa Cruz Biotechnology    
    used:   1:250 dilution 
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3.14.4. Sera 
human serum   Bio-Whittaker (Walkersville, MD); used in concentrations as 
    indicated 
JAM-1 pAb   polyclonal mouse serum; generated to order by Eurogentec 
    (Herstal, Belgium) as described (see 3.15.2.)   
    Antibody inhibition studies were performed with polyclonal 
    serum of mouse TS, western blot analysis with polyclonal  
    serum of mouse DS.       
    used:   1:50 dilution     
    flow cytometry: 1:100 dilution     
    western blotting: 1:1500 dilution 
preimmunization serum murine control serum for JAM-1 polyclonal Ab gathered from 
    mouse TS and mouse DS, respectively, prior to DNA-mediated 
    immunziation (Eurogentec); used in concentrations equivalent to 
    anti–JAM-1 
 
 
 
3.15. Antibody preparation 
3.15.1. Hybridoma cell lines: maintainance and antibody isolation 
3.15.1.1. Propagation 
B cell hybridomas are immortalized cell lines derived by cell fusion between a normal 
B lymphocyte from an immunized animal and a myeloma cell of an immortalized tumor line. 
B cell hybridomas secrete individual monoclonal antibodies of a single antigen-specificity 
derived from the normal B lymphocyte cell. 
 
The hybridoma cell lines TS1/22 and TS1/18 (Sánchez-Madrid et al., 1982) were cultured in a 
5 % CO2 atmosphere at 37°C in DMEM medium containing 4.5 g/l glucose, 1 mM sodium 
pyruvate and 4 mM L-glutamine and supplemented with 10 % heat-inactivated FCS and 50 mg/l 
gentamicin. The cultures were maintained between 105-106 cells/ml and then subcultured by 
centrifugation and subsequent seeding in fresh medium. The remaining medium supernatant was 
stored at 4°C for further experimental applications or antibody extraction. 
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3.15.1.2. Isolation of hybridoma-secreted monoclonal antibodies 
Protein G, a cell surface protein of group G streptococci, is a type III Fc receptor that binds to the 
Fc region of IgG. It was used for isolation of the secreted IgG1 mAbs TS1/22 (anti-CD11a) and 
TS1/18 (anti-CD18) from hybridoma medium supernatant by affinity chromatography. 
 
An agarose bead-coupled protein G-affinity column was equilibrated with 10 volumes of binding 
buffer. The hybridoma medium supernatant was applied to the column until saturation 
(determined by flow cytometry analysis of Jurkat cells stained with different fractions of the 
effluents). The column was washed with 10 volumes binding buffer and the antibodies were 
eluted with 4 volumes acidic elution buffer. Thereby the eluate was partitioned into collection 
tubes filled with 30 µl neutralization buffer to a final volume of 500 µl. Fractions with high 
antibody concentrations, estimated by measurement of OD280, were pooled and subjected to 
protein concentration determination by the BCA method. All solutions used were filter-sterilized. 
 
 
3.15.1.3. Materials 
affinity column  HiTrap Protein G Sepharose column, 1 ml volume; Amersham 
binding buffer   20 mM sodium phosphate, pH 7.0, prepared from 1 M Na2HPO4  
    and 1 M NaH2PO4 according to the Henderson-Hasselbalch 
    equation 
DMEM   Dulbecco’s modified Eagle’s medium; GibcoBRL 
elution buffer   0.1 M glycine, pH 2.7, titrated with HCl 
hybridoma cell lines  (see 3.14.1.) 
neutralization buffer  1 M Tris, pH 9.0, titrated with HCl 
 
 
 
3.15.2. DNA-mediated immunization of mice 
Mouse anti-JAM-1 polyclonal antisera were commercially produced to order by DNA-mediated 
immunization (Eurogentec, Herstal, Belgium). The immune response against a foreign protein is 
induced in mice by direct gene transfer of plasmid DNA and subsequent in vivo expression of the 
vector-encoded antigen (Davis et al., 1995). The DNA is injected into young myofibres of 
regenerating skeletal muscles that have been degenerated by injection of necrotizing snake-
venom cardiotoxin. 
 
For mice immunization, the JAM-1 antigen-encoding mammalian expression vector pJM1121 
was amplified and isolated by a endotoxin-free maxiprep. 100 µg pJM1121 in endotoxin-free 
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PBS was injected at a concentration of 1 µg/µl into regenerating mouse tibialis anterior (TA) 
muscle 5 days postdegeneration (Eurogentec). Final bleedings were taken after 102 days and 
antisera were tested under experimental conditions versus preimmunization sera withdrawn from 
each mouse prior to their immunization. The polyclonal serum of mouse DS was sufficient for 
western blot analysis, whereas flow cytometry, transmigration and adhesion assays were carried 
out using the anti-JAM-1 serum of mouse TS. 
 
Materials 
endotoxin-free maxiprep  EndoFree Plasmid Maxi Kit; Qiagen (Hilden, Germany) 
PBS (1x)   sterile and endotoxin-free; Sigma 
TE (100x)   sterile and endotoxin-free; Sigma 
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4. Results 
4.1. Determination of JAM-1 as CD11a-interacting protein 
A yeast two-hybrid screen (as described in detail in 3.8.) was used to investigate new specific 
interaction partners of the β2 integrin lymphocyte function-associated antigen-1 (LFA-1) αL 
subunit, CD11a. The cDNA sequence of the cytoplasmic domain of CD11a was subcloned into 
the yeast two-hybrid (YTH) vector pAS2-1 and used to transform S. cerevisiae CG-1945. After a 
second transformation of this bait-expressing yeast strain with a human leukocyte cDNA library, 
CD11a was screened in vivo with cDNA library-encoded leukocyte proteins (table 4). 
 
       
transformation efficiency 
(cfu/µg library DNA)  
      
 
1.7·103 
 
screened clones 
    
3.4·105 
His+ clones 
 
615 
β-Gal+ clones  3 
 
table 4: Results of the YTH screening experiment for CD11a against a 
human leukocyte cDNA library. 
Out of 3.4·105 clones screened, three candidate colonies (αLMC1 – αLMC3) appeared positive 
for β-galactosidase (β-Gal) expression indicating lacZ reporter gene activation (fig. 5A). Isolation 
of library plasmid DNA from these clones allowed the sequence analysis of the respective prey-
encoding cDNA inserts (fig. 5B). Subsequent database alignment revealed one relevant candidate 
(αLMC3) plus two false-positives that contained library plasmids with cDNA inserts generating 
an AluI repetitive sequence warning. The library plasmid of the bona fide candidate contained a 
cDNA insert of approximately 1.8 kb with an open reading frame (ORF) of 900 bp. The coding 
sequence encoded a prey protein that exhibited 75 % homology with the recently published 
junctional adhesion molecule (JAM)-1 of mice (Martìn-Padura et al., 1998) and was previously 
identified as the human homologue (Ozaki et al., 1999; Williams et al., 1999). Hereafter a cDNA 
sequence of ~800 bp 3' to the ORF was shown to be identical to the published 3'-UTR1 of human 
JAM-1 (Naik et al., 2001). Thus, human JAM-1 was identified by the YTH system as a 
candidate CD11a-interacting protein. 
 
                                                 
1 GenBank accession number AF172398 
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figure 5: (A) β-Gal filter assay for detection of lacZ reporter gene activated yeast cells. HIS3+ colonies that survived 
primary nutritional selection together with a yeast positive control were replicated on filter paper and subjected to an 
enzymatic β-Gal assay that results in blue coloration of candidate positive clones bearing interacting bait and prey proteins 
due to the activity of lacZ-encoded β-galactosidase. lacZ-negative yeast colonies (not marked) showed no coloration. PC: 
positive control yeast strain (see 3.8.5.3.); αLMC2: second candidate yeast colony; αLMC3: third candidate yeast colony 
(bona fide). The β-Gal filter with the candidate yeast colony αLMC1 is not shown. (B) Analysis of the cDNA inserts of 
library plasmids isolated from the candidate yeast colonies αLMC1 (500 bp; lane 3), αLMC2 (1 kb; lane 5) and the bona 
fide candidate αLMC3 (1.8 kb; lane 4) by analytical PCR. Primers flanking the MCS of the YTH library vector pGAD10 
allowed amplification of the prey-encoding cDNA inserts (see 3.11.5.). A complete reaction mix without template DNA 
served as a negative control for the PCR (lane 2). The PCR samples were subjected to analytical agarose gel 
electrophoresis. A representative 1 % agarose gel is shown stained with ethidium bromide and visualized under UV light. 
Molecular size markers are indicated in bp (lane 1). 
 
 
 
4.2. Expression of JAM-1 in CHO transfectants and various cell 
types 
To further elucidate the in vivo findings in yeast and to explore functional consequences of the 
supposed interaction between LFA-1 and JAM-1, both an eukaryotic cell model for JAM-1 
surface expression and a polyclonal antibody directed against human JAM-1 were established. 
Isolation of the YTH library plasmid from the bona fide candidate yeast colony αLMC3, 
encoding the full-length prey protein, enabled the direct subcloning of human JAM-1 cDNA into 
the mammalian expression vector pcDNA3 (pJM1121). Chinese hamster ovary (CHO) cells, 
adherent cells which grow to confluent monolayers but do not express endogenous JAM-1, were 
transfected with pJM1121 (CHO-JAM cells) or the pcDNA3 alone (CHO-vector cells). 
Polyclonal sera raised against human JAM-1 (anti–JAM-1) were generated by DNA-mediated 
immunization of mice with pJM1121 and enabled expression analysis of JAM-1 in CHO 
transfectants and various other cell types. 
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figure 6: Wild-type CHO cells (CHO-WT), CHO-vector and CHO-JAM transfectants were stained with an IgG1 isotype 
control (upper plots), murine preimmunization serum (mid plots) or anti–JAM-1 (lower plots) for JAM-1 surface 
expression analysis by flow cytometry. “FL1-H” represents the logarithmic fluorescence intensity. Representative 
histograms are shown. 
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figure 7: Cytosolic (lane 1, 3) and membrane fractions 
(lane 2, 4) of whole cell lysates from wild-type CHO cells 
(CHO-WT; lane 1, 2) and CHO-JAM transfectants (lane 3, 4) 
were separated by SDS-PAGE and subjected to western blot 
analysis using anti–JAM-1. The antigen was detected as a 
single band at ~40 kDa, as indicated. The size of protein 
molecular weight markers is expressed in kDa. A representative 
blot is shown. 
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Flow cytometry analysis with anti–JAM-1 revealed surface expression of heterogeneous JAM-1 
in CHO-JAM but not in CHO-vector transfectants (fig. 6). Specificity of the polyclonal antibody 
was demonstrated by the use of an isotype control and in particular murine preimmunization 
serum, both of which did not induce any shift in the distribution of fluorescence intensities for 
CHO transfectants or wild-type (CHO-WT) cells (fig. 6). Expression and localization of JAM-1 
was further confirmed by immunoblotting, where the protein was detected by anti–JAM-1 
exclusively in membrane but not in cytosolic fractions of whole cell lysates from CHO-JAM 
cells (fig. 7). Consistent with the lack of endogenous JAM-1 expression, wild-type CHO cells 
were not detected by anti–JAM-1 by either flow cytometry or immunoblotting analysis 
(fig. 6, 7). 
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figure 8: Flow cytometry analysis of endogenous JAM-1 expressed on the surface of endothelial, epithelial and 
leukocytic cells in culture or isolated from the human vasculature, as indicated. The charts shown display overlaid 
histograms of cells stained with murine preimmunization serum (grey plots with thin line) and mouse anti–JAM-1 
(white plots with thick line), respectively. JAM-1 was not detectable on the surface of myeloid HL-60 cells 
preincubated with 5 % human serum to block Fc receptors. “FL1-H” represents the logarithmic fluorescence intensity. 
Histograms shown are representative. 
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Native JAM-1 surface expression could be detected by anti–JAM-1 to a variable extent in 
different immortalized lines, i.e. epithelial-like HeLa cells, monocytic Mono Mac 6 and THP-1 
cells, Jurkat and J-β2.7 T lymphoid cells, and in several cells isolated from the human vascular 
system, i.e. CD4+CD45RO+ memory T cells and endothelial HUVECs, but was barely detectable 
on myeloid HL-60 cells (fig. 8). These results are consistent with published data (Ozaki et al., 
1999; Williams et al., 1999). 
 
 
 
4.3. Specific ability of CHO-JAM transfectants to support LFA-1–
mediated leukocyte adhesion 
Notably, the sequence of JAM-1 revealed structural homology with the LFA-1 ligands, IgSF 
proteins which are all members of the ICAM family. Given the importance of ICAMs in the 
formation of firm adhesive cell-cell interactions by integrins, a functional role for JAM-1 in 
leukocyte adhesion was assumed. To test this hypothesis and to verify the finding of a potential 
interaction between LFA-1 and JAM-1 identified in the YTH system, CHO transfectants were 
subjected to static leukocyte adhesion assays. 
 
Incubation of fluorescence-labeled Jurkat T cells in suspension with adherent CHO cell 
monolayers grown in 96-well microtiter plates allowed the measurement of their mutual 
adhesion under static conditions by fluorescence spectrometry. Jurkat T cells, which express 
LFA-1 on their cell surface (see fig. 12B), were transformed in an integrin-activated state by 
pretreatment with phorbol-12-myristate-13-acetate (PMA). Thus, stimulated Jurkat T cells 
showed significant binding to CHO-JAM but not to CHO-vector (fig. 9A, black column) or wild-
type CHO cells (data not shown), confirming JAM-1 may function as a heterophilic cell 
adhesion molecule (CAM). Shielding of JAM-1 surface ligands with anti–JAM-1 led to a 
significant decrease of the four-fold enhanced values for leukocyte adhesion on CHO-JAM cell 
monolayers to the background levels observed on cell monolayers lacking JAM-1 expression 
(fig. 9A, grey column). To validate the involvement of leukocyte LFA-1 in the observed 
attachment, static adhesion assays were performed using Jurkat T cells preincubated with the 
CD18-blocking mAb TS1/18. In this case, adhesion of Jurkat T cells to JAM-1–expressing CHO 
cells was reduced to background levels, indicating that the binding was specifically mediated by 
leukocytic β2 integrins (fig. 9A, white column). An isotype control for TS1/18 and 
preimmunization serum directed against Jurkat and CHO-JAM cells, respectively, had no effect 
on adhesion (data not shown). 
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figure 9: (A) Adhesion of PMA-stimulated Jurkat T cells to adherent monolayers of CHO-vector and CHO-JAM cells, as 
indicated, under static conditions. Experiments were performed without application of antibodies (control; black column) 
or involving pretreatment of Jurkat T cells with the CD18-blocking mAb TS1/18 (white column) and preincubation of 
CHO cell monolayers with anti–JAM-1 (grey column). (B) Adhesion of PMA-stimulated Jurkat T cells without (control) 
or with anti–JAM-1 pretreatment, as indicated, to adherent CHO-JAM cell monolayers under static conditions. (A-B) 
Background binding of unstimulated Jurkat cells was negligible and was subtracted from stimulated binding. Adhesion 
was measured as the percentage of input Jurkat cells. Data are expressed as the mean ± s.d. of four separate experiments 
performed in triplicate. 
Extracellular, homophilic interactions between JAM-1 proteins on opposite cells had previously 
been reported to occur (Martìn-Padura et al., 1998; Liu et al., 2000b). Since Jurkat T cells 
themselves express JAM-1 (see fig. 8) a homophilic interaction in trans between leukocytic 
JAM-1 and CHO cell-expressed JAM-1 in the observed cellular arrest was possible. Therefore, 
Jurkat T cells were pretreated with anti–JAM-1 and then subjected in a control experiment to 
adhesion on CHO-JAM cell monolayers (fig. 9B). The pretreatment had no significant effect on 
cellular adhesion, thus excluding a significant participation of homophilic JAM-1 interactions in 
the firm arrest of Jurkat cells. 
 
Static adhesion experiments therefore revealed that leukocyte arrest to CHO-JAM transfectants 
was specifically mediated by a heterophilic interaction between LFA-1 and JAM-1 and thus 
confirmed both the YTH findings and the presumed functional role of JAM-1 as a CAM. 
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4.4. Recognition of surface-expressed JAM-1 by purified LFA-1 
receptor molecules 
To further confirm a specific receptor-ligand interaction between LFA-1 and JAM-1 in cell 
adhesion, JAM-1–expressing CHO cells in suspension were exposed to purified and immobilized 
LFA-1 molecules instead to LFA-1 expressing Jurkat cells. Consistent with the previous 
findings, only JAM-1–transfected CHO cells but not CHO-vector transfectants developed 
adhesive binding to immobilized LFA-1 (fig. 10, black column). In turn, treatment of CHO cells 
with anti–JAM-1 (fig. 10, grey column) or neutralization of immobilized LFA-1 with TS1/18 
(fig. 10, white column) completely inhibited the specific adhesion of CHO-JAM cells to the 
integrin receptor. 
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figure 10: Adhesion of CHO-vector and CHO-JAM cells, as 
indicated, to purified and immobilized LFA-1 receptor molecules 
under static conditions. Experiments were performed without 
application of antibodies (control; black column) or by blocking 
LFA-1 molecules with anti–CD18 mAb TS1/18 (white column) and 
preincubation of CHO cells in suspension with anti–JAM-1 (grey 
column). Isotype control and preimmunization serum had no effect 
on adhesion (data not shown). Adhesion was measured as the 
percentage of input CHO cells. Data are the mean ± s.d. of four 
separate experiments performed in triplicate. 
Both the αL (CD11a; 180 kDa) and the β2 (CD18; 95 kDa) integrin chain could be detected in the 
LFA-1 preparation after SDS-PAGE by immunoblotting using appropriate antibodies (fig. 11). 
However, the polyclonal serum anti–JAM-1 failed to detect any JAM-1 impurity at the 
concentrations of LFA-1 used for the coating in static adhesion assays (fig. 11). Similarly, silver 
staining of the LFA-1 preparation after gel electrophoresis revealed distinct bands for the LFA-1 
subunits (fig. 11) but did not indicate any JAM-1 impurity. An appreciable co-purification of 
JAM-1 in the course of LFA-1 isolation from human organs could therefore be excluded, which 
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was in principle possible, given the evidence for a receptor-ligand interaction between LFA-1 
and JAM-1. 
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figure 11: Protein analysis of the molecular LFA-1 preparation. Purified LFA-1 
was subjected to SDS-PAGE at the same concentrations used in static adhesion 
assays. Immunoblot analysis with anti-αL C-17 (also verified with the mAb 
MCA 502; data not shown) and β2 mAb MEM48, respectively, under non-
reducing conditions (left panels) revealed a distinct band for αL at ~180 kDa and 
a double band for β2 between 100-120 kDa, presumably due to differential 
glycosylation. JAM-1 impurity that would be expected at ~40 kDa was not 
detectable by western blotting with anti–JAM-1 (third panel). Protein detection 
by silver staining (right panel) did not indicate any protein impurities and 
revealed distinct bands corresponding to the α and β chains of LFA-1 as 
observed in the corresponding immunoblots. Protein molecular weight markers 
are indicated in kDa. Representative blots and gels are shown. 
The results obtained using purified LFA-1 (in this way excluding the cellular background 
provided by the LFA-1–expressing Jurkat T cells used in the previous static adhesion 
experiments), strongly support a functional role for the cell-surface expressed JAM-1 as a 
specific ligand for the integrin receptor LFA-1 in cell-cell adhesion. The lack of leukocytic 
JAM-1 as a potential adhesion target for CHO-JAM transfectants in these experiments on 
immobilized LFA-1, confirmed the heterophilic nature of the cell adhesion-mediating molecular 
interaction and revealed that Jurkat T cell arrest on CHO-JAM cells (see fig. 9) was not 
supported by homophilic interactions with leukocytic JAM-1. These results are consistent with 
findings that recombinant solid-phase JAM-1 does not mediate adhesion of JAM-1–transfected 
COS cells (Williams et al., 1999). 
 
 
 
4.5. Receptor specificity of JAM-1 for the β2 integrin LFA-1 
The cell line J-β2.7 is a mutant Jurkat T cell line deficient in αL (CD11a) expression due to 
chemical mutagenesis (Weber et al., 1997b). Since subunit heterodimerization is required for 
integrin translocation to the plasma membrane, integrin α and β chains are interdependent for 
their cell surface expression (Anderson et al., 1987; Arnaout, 1990). The αL-deficient J-β2.7 cells 
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are therefore characterized as a lymphoid cell line lacking LFA-1 cell surface receptors despite 
normal expression of endogenous β2 (CD18) chains. They provided an ideal system to 
investigate the specific involvement of LFA-1 in cellular arrest of the primordial Jurkat T cells to 
JAM-1–expressing CHO cells. 
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figure 12: (A) Adhesion of (left panel) PMA-stimulated wild-type Jurkat cells and (right 
panel) PMA-stimulated αL-deficient Jurkat J-β2.7 cells to adherent monolayers of 
CHO-vector and CHO-JAM cells, as indicated, performed in parallel under static 
conditions. Experiments were performed without (control; black column) or with (white 
column) preincubation of Jurkat cells with the β2-blocking mAb TS1/18. Background 
binding of unstimulated wild-type and mutant Jurkat cells was negligible and was 
subtracted from stimulated binding. Adhesion was measured as percentage of input 
Jurkat cells. Data are mean ± s.d. of four separate experiments performed in triplicate. 
(B) Flow cytometry control analysis of LFA-1 surface expression in wild-type Jurkat 
cells (left plot) and mutant Jurkat J-β2.7 cells (right plot). The charts shown display 
overlaid histograms of cells stained with a mouse IgG1 isotype control (grey plots with 
thin line) and TS1/18 mAb (white plots with thick line). “FL1-H” represents the 
logarithmic fluorescence intensity. Representative histograms are shown. 
Static leukocyte adhesion assays on CHO cell monolayers were performed in parallel with PMA-
stimulated wild-type Jurkat cells (fig. 12A, left panel) and mutant Jurkat J-β2.7 cells (fig. 12A, 
right panel). Wild-type Jurkat cells adhered exclusively to CHO-JAM cell monolayers. This 
specific cell-cell interaction was suppressed by neutralization of leukocytic LFA-1 receptors with 
the blocking β2 mAb TS1/18 (fig. 12A, left panel) as has been shown in previous experiments 
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(see fig. 9A). In contrast to the wild-type cells, PMA-stimulated J-β2.7 mutants completely failed 
to adhere onto CHO-JAM transfectants (fig. 12A, right panel). This clearly confirms the reliance 
on LFA-1 for leukocyte binding to JAM-1–presenting cells. As expected for αL-deficient cells, 
incubation of J-β2.7 cells with TS1/18 had no effect on adhesion values (fig. 12A, right panel). As 
a control, LFA-1 expression profiles of Jurkat and J-β2.7 cells were verified by flow cytometry 
(fig. 12B). 
 
Transfection of J-β2.7 cells with αL-encoding cDNA (referred to hereafter as J-β2.7/αL cells) 
reconstituted LFA-1 surface expression formerly knocked out in J-β2.7 cells, as confirmed by 
flow cytometry analysis (fig. 14A). Compared to its parental cell line, transfected J-β2.7/αL cells 
showed restored adhesion to CHO-JAM cells under static conditions that was not observable on 
CHO-vector cell monolayers (fig. 13, left panel). This reconfirmed the requirement of intact 
LFA-1 surface expression for adhesion of Jurkat T cells to JAM-1–presenting cells. 
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figure 13: Adhesion of (left panel) PMA-stimulated J-β2.7/αL cells 
expressing reconstituted LFA-1 and (right panel) PMA-stimulated 
J-β2.7/αM cells expressing heterotopic Mac-1 to adherent monolayers of 
CHO-vector and CHO-JAM cells, as indicated, under static conditions. 
α chain-transfected J-β2.7 cells without PMA-stimulation showed 
negligible background binding that was subtracted from stimulated 
binding. Adhesion was measured as the percentage of input cells. Data 
are the mean ± s.d. of four separate experiments performed in triplicate. 
Although the YTH data implied an interaction between JAM-1 and CD11a and thus a specific 
interaction with the β2 integrin LFA-1 (αLβ2; CD11a/CD18), affinity of JAM-1 for other 
members of the β2 integrin family could not be excluded. This possibility was tested by static 
adhesion assays of J-β2.7/αM cells to CHO-JAM cell monolayers. Due to transfection of J-β2.7 
cells with αM–encoding cDNA, J-β2.7/αM cells expressed heterotopic αM. Heterodimerization of 
this α subunit with the endogenously translated β2 subunit led to the formation and subsequent 
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surface expression of the β2 integrin Mac-1 (αMβ2; CD11b/CD18) normally not expressed by 
lymphoid cells (Weber et al., 1999a). The J-β2.7/αM cells, still deficient in αL, thus carried 
Mac-1 (αMβ2) but not the homologous LFA-1 (αLβ2) receptors on their cell membrane. 
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figure 14: Control experiments. (A-B) Flow cytometry analysis for surface 
expression of (A) reconstituted LFA-1 on J-β2.7/αL cells and (B) heterotopic 
Mac-1 on J-β2.7/αM cells. Charts shown display overlaid histograms of cells 
stained with an IgG1 isotype control (grey plots) and αL mAb TS1/22 respective 
αM mAb CBRM1/29 (white plots). “FL1-H” represents the logarithmic 
fluorescence intensity. Histograms shown are representative. (C) Adhesion of 
J-β2.7/αM cells expressing heterotopic Mac-1 onto purified and immobilized 
ICAM-1 molecules under static conditions. Experiments were performed without 
(control; white column) or with PMA-stimulation (black column) of J-β2.7/αM 
cells and application of blocking αL mAb TS1/22 respective blocking αM mAb 
CBRM1/29, as indicated. An IgG1 isotype control had no effect on adhesion (data 
not shown). Adhesion was measured as the percentage of input J-β2.7/αM cells. 
Data are the mean ± s.d. of three separate experiments performed in triplicate. 
In contrast to J-β2.7/αL cells (fig. 13, left panel), J-β2.7/αM cells failed to develop adhesive cell-
cell interactions with monolayers of CHO-JAM transfectants (fig. 13, right panel) despite surface 
expression of Mac-1, as revealed by flow cytometry analysis (fig. 14B). Nevertheless, Mac-1 
expression on the plasma membrane was functional as determined by Mac-1–dependent 
adhesion of PMA-stimulated J-β2.7/αM cells onto purified ICAM-1 (fig. 14C) consistent with 
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previous data (Weber et al., 1999a). Thus, JAM-1 specifically interacts with LFA-1 and not with 
the homologous β2 integrin Mac-1. 
 
 
 
4.6. Inability of homophilic JAM-1 interactions to support leukocyte 
adhesion 
Murine as well as human JAM-1 functions as CAMs between endothelial and epithelial cells in a 
homophilic manner. However, as both LFA-1–bearing wild-type Jurkat cells and αL-deficient 
Jurkat J-β2.7 cells showed equivalent JAM-1 expression on their cell membranes (see fig. 8), the 
marked difference in their adhesion to JAM-1–presenting CHO cell monolayers (see fig. 12A) 
indicated that homophilic interactions of JAM-1 do not contribute to such a cell-cell interaction. 
The complete suppression of Jurkat cell adhesion to CHO-JAM cell monolayers to background 
levels by the use of a LFA-1 blocking mAb (see fig. 9A) led to the prediction that leukocytic 
JAM-1 does not bind to CHO cell–expressed JAM-1 in a homophilic manner that would be 
sufficient to mediate firm cell-cell adhesion. 
 
To further test for a possible involvement of homophilic JAM-1 interactions in cellular adhesion, 
CHO-JAM cells in suspension, that showed significant arrest on immobilized LFA-1 (see 
fig. 10), were subjected to static adhesion on CHO-JAM cell monolayers. The adhesion values 
did not differ from those of wild-type CHO cells in suspension (fig. 15). This indicated that 
CHO-JAM transfectants were not capable to perform mutual cellular arrest via homophilic 
JAM-1 binding in trans. 
 
Leukocyte adhesion due to homophilic JAM-1 interactions was also ruled out by experiments 
with HL-60 cells. Consistent with published data (Williams et al., 1999), this myeloid cell line 
lacked detectable JAM-1 surface expression as verified by flow cytometry (see fig. 8). However, 
HL-60 cells were able to form adhesive cell contact with CHO-JAM cells mediated by their 
LFA-1 receptor as shown in adhesion studies using the LFA-1 αL mAb TS1/22 (fig. 16). 
 
Together, these data showed that homophilic interactions of surface JAM-1 appear to be 
insufficient to mediate firm cellular arrest of leukocytes. 
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figure 15: Adhesion of wild-type CHO cells and CHO-JAM transfectants in suspension 
to adherent monolayers of wild-type CHO and CHO-JAM cells, as indicated, under 
static conditions. Adhesion was measured as the percentage of input of CHO 
suspension cells. Data are the mean ± s.d. of four separate experiments performed in 
triplicate. 
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figure 16: Adhesion of PMA-stimulated myeloid HL-60 cells on 
adherent CHO-vector or CHO-JAM cell monolayers, as indicated, 
under static conditions. HL-60 cells were preincubated with 5 % 
human serum to block Fc receptors. Experiments were performed 
without (control; black column) or with (white column) 
preincubation of HL-60 cells with the αL-blocking mAb TS1/22. 
Background binding of unstimulated HL-60 cells was negligible and 
was subtracted from stimulated binding. Adhesion was measured as 
the percentage of input HL-60 cells. Data are the mean ± s.d. of four 
separate experiments performed in triplicate. 
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4.7. Dependence on Ig-like domain 2 for LFA-1 receptor binding of 
JAM-1 
Given that the IgSF member JAM-1 might function as a counter-receptor for the integrin LFA-1, 
it was of special interest to investigate which regions within the extracellular part of JAM-1 
could be essential for mediating this protein interaction. Considering the molecular structure of 
JAM-1 (fig. 17), a requirement of either the N-terminal Ig-like domain 1 or the membrane-
proximal Ig-like domain 2 for heterophilic interaction was conceivable. Therefore mutant JAM-1 
cDNA constructs were generated by PCR overlap extension that were each deficient in one of 
the extracellular domains (referred to hereafter as JAM?D1 and JAM?D2, respectively; fig. 17). 
figure 17: Schematic representation of the full-length human JAM-1 protein (aa 1-299) and the mutant JAM-1 protein 
constructs JAM ?D1 and JAM ?D2 as expressed in CHO transfectants. The N-terminal signal peptide (aa 1-27) is shown in 
light grey, the predicted transmembrane region (aa 236-260) in black. The C-terminal PDZ domain-binding motif FLV 
(aa 297-299) is shown in grey. The N-terminal Ig-like domain 1 and the membrane-proximal Ig-like domain 2 are 
shown striated, as indicated. Their Ig-like loop-confining disulfide bonds are each marked with two black points. 
cDNAs encoding the mutant JAM-1 proteins were generated by PCR overlap extension as described. Deleted regions 
are marked by curly brackets: region D1 (aa 42-131) in JAM ?D1 and region D2 (aa 132-217) in JAM ?D2. Resulting 
restriction sites are marked by a double-slash (||). JAM (HA), JAM ?D1(HA) and JAM ?D2(HA) protein constructs (not shown) 
correspond to the illustrated proteins with an additional hemagglutinin (HA) epitope fused to the respective C-terminus. 
The mutant JAM-1 cDNA constructs were subcloned into the mammalian expression vector 
pcDNA3 and subsequently transfected into wild-type CHO cells (CHO-JAM?D1 and 
CHO-JAM?D2 cells, respectively). However, anti–JAM-1 failed to detect mutant JAM-1 proteins 
in transfected cells (data not shown). Expression of JAM?D1 and JAM?D2 was therefore analyzed 
at the transcriptional level by reverse transcriptase polymerase chain reaction (RT-PCR) using 
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JAM
DD1
JAM
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total RNA isolated from wild-type and transfected CHO cells (fig. 18A). Agarose gel 
electrophoresis of the PCR products obtained by amplification with specific primers for human 
JAM-1 cDNA revealed transcription of full-length JAM-1 mRNA (900 bp) in CHO-JAM 
transfectants but not in CHO-vector transfectants nor in wild-type CHO cells (fig. 18A). 
Likewise, expression of domain 1-deficient JAM-1 mRNA (660 bp) in CHO-JAM∆D1 cells and 
domain 2-deficient JAM-1 mRNA (672 bp) in CHO-JAM∆D2 cells was confirmed at the 
transcriptional level (fig. 18A). 
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figure 18: (A) Expression analysis of transcribed full-length human JAM-1 mRNA (900 bp) in wild-type CHO (lane 4), 
CHO-vector (lane 5) and CHO-JAM cells (lane 6), and of mutant JAM-1 mRNA deficient in either the N-terminal Ig-like 
domain 1 (JAM∆D1; 660 bp; lane 7) or the membrane-proximal Ig-like domain 2 (JAM∆D2; 672 bp; lane 8) expressed in 
CHO-JAM∆D1 and CHO-JAM∆D2 transfectants, respectively. PCR on pJM1121 plasmid DNA served as a positive control 
(900 bp; lane 1) for amplification of JAM-1–related cDNA. An unspecific band of ~580 bp appeared by amplification of 
the full-length JAM-1 cDNA due to the primer design (lanes 1 and 6). A complete reaction mix without template DNA 
served as negative control (lane 2) for the PCR. (B) Control expression analysis of β-actin mRNA transcripts (446 bp) in 
identical preparations of total RNA from CHO cells as used in (A). DNA contamination in the RNA samples was 
excluded by failure of a longer 652-bp fragment amplified from intron-containing genomic β-actin DNA. Thus, amplified 
cDNA fragments in (A) resulted exclusively from transcribed JAM-1 mRNA. A human foreskin fibroblast preparation 
served as positive control (446 bp; lane 1) for β-actin cDNA amplification. A complete reaction mix without template 
DNA served as negative control (lane 2). (A-B) Total RNA was isolated from CHO cells and mRNA was reverse 
transcribed by RT-PCR using random hexamer primers. For each investigated CHO cell line, target cDNAs were 
amplified in separate PCRs but from identical RNA preparations using primers specific for JAM-1–related and β-actin 
DNA, respectively. PCR samples were subjected to analytical agarose gel electrophoresis. Shown are representative 1 % 
agarose gels stained with ethidium bromide and visualized under UV light. Molecular size markers (lane 3) are indicated 
in bp. 
Possible DNA contamination of RNA extracts, leading to false-positive detection of genomic 
JAM-1 sequences instead of in vivo transcribed JAM-1 mRNA, was excluded by a control PCR 
using the respective RT-PCR samples and primers specific for the housekeeping gene β-actin 
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(fig. 18B). In the case of a DNA contamination this PCR would lead to additional amplification 
of a genomic β-actin fragment including intron sequences (652 bp; data not shown) in addition 
to the fragments derived from spliced β-actin mRNA transcripts (446 bp; fig. 18B). 
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figure 19: (A) Expression analysis of HA-tagged full-length and mutant JAM-1 proteins in permeabilized CHO-vector, 
CHO-JAM(HA), CHO-JAM∆D1(HA) and CHO-JAM∆D2(HA) transfectants, as indicated, by flow cytometry. Charts shown 
display overlaid histograms of cells stained with a rabbit IgG isotype control (grey plot with thin line) and anti-HA Y-11 
(white plot with thick line), respectively. “FL1-H” represents the logarithmic fluorescence intensity. Histograms shown are 
representative. (B) Western blot analysis of whole cell lysates from CHO-vector, CHO-JAM(HA) and CHO-JAM∆D2(HA) 
transfectants, as indicated. Protein samples were separated by SDS-PAGE and subjected to western blot analysis using 
anti-HA Y-11. Mutant JAM∆D2(HA) appeared in multiple bands at ~26 kDa. Molecular weight markers are expressed in 
kDa. A representative blot is shown. 
Despite confirmation of JAM∆D1 and JAM∆D2 mRNA transcription in the corresponding CHO 
transfectants, the presence of normal mRNA translation, absence of protein degradation and 
sufficient surface expression of the mutant JAM-1 molecules remained untested. For this reason, 
cDNA constructs were generated and transfected into wild-type CHO cells that allowed 
expression of full-length and mutant JAM-1 proteins fused to a C-terminal hemagglutinin (HA) 
epitope (CHO-JAM(HA), CHO-JAM∆D1(HA) and CHO-JAM∆D2(HA) cells, respectively). Expression 
of the HA-tagged constructs at the mRNA level was again verified by RT-PCR (data not shown). 
In addition, flow cytometry analysis of permeabilized CHO transfectants with anti-HA 
confirmed equivalent protein expression for all HA-tagged JAM-1 constructs (fig. 19A). Western 
blot analysis revealed the molecular size for mutant JAM∆D2(HA) to be approximately 26 kDa 
(fig. 19B). 
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Both types of CHO transfectants, expressing JAM-1 constructs with or without HA epitope, were 
grown to confluence and used as substrates for static adhesion assays with PMA-stimulated 
Jurkat T cells (fig. 20A+B). CHO-JAM∆D1 cells supported considerable adhesion of Jurkat T cells 
equivalent to that seen on CHO-JAM transfectants presenting full-length JAM-1 on their surface 
(fig. 20A). In contrast, adhesion of Jurkat T cells on CHO-JAM∆D2 cell monolayers did not show 
substantial differences from background binding on CHO-vector cell monolayers (fig. 20A). 
Equivalent results were obtained for leukocyte binding to CHO-JAM(HA), CHO-JAM∆D1(HA) and 
CHO-JAM∆D2(HA) cells, indicating that the cytoplasmic HA epitope did not altered the binding 
characteristics of the transfected cells (fig. 20B). 
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figure 20: (A) Adhesion of PMA-stimulated Jurkat T cells to CHO-vector cell monolayers and to CHO cell monolayers 
expressing wild-type JAM-1 (CHO-JAM) or mutant JAM-1 lacking the N-terminal Ig-like domain 1 (CHO-JAM∆D1) or 
the membrane-proximal Ig-like domain 2 (CHO-JAM∆D2), as indicated, under static conditions. JAM-1 and related 
proteins were expressed without HA epitope tag. (B) Adhesion of PMA-stimulated Jurkat cells as described for (A) but 
subjected to monolayers of CHO transfectants that expressed full-length and mutant JAM-1 with a C-terminal HA epitope 
tag, i.e. CHO-JAM(HA), CHO-JAM∆D1(HA) and CHO-JAM∆D2(HA) cells. (A-B) Background binding of unstimulated Jurkat 
cells was negligible and was subtracted from stimulated binding. Adhesion was measured as the percentage of input 
Jurkat cells. Data are the mean ± s.d. of four separate experiments performed in triplicate. 
Static adhesion assays with purified LFA-1 as adhesion target for CHO transfectants in 
suspension confirmed the importance of the membrane-proximal domain 2 of JAM-1 for 
receptor recognition. CHO-JAM∆D2 cells lacking this specific region failed to bind to 
immobilized LFA-1 and showed only nonspecific background binding similar to that of 
CHO-vector transfectants (fig. 21A). However, the absence of the N-terminal domain 1 in JAM-1 
did not interfere with normal receptor recognition and binding, leading to similar adhesion 
values for CHO-JAM∆D1 cells to those obtained with CHO-JAM cells on molecular LFA-1 
(fig. 21A). Again, performance of the binding assay with CHO transfectants expressing HA-
tagged JAM-1 proteins resulted in equivalent adhesion characteristics (fig. 21B). 
94  Results 
A  
A
dh
es
io
n 
to
 im
m
ob
ili
ze
d 
LF
A
-1
(%
 in
pu
t)
CH
O-v
ect
or  
CH
O-J
AM
  
CH
O-J
AM
∆D
1
CH
O-J
AM
∆D
2
15 -
10 -
5 -
0 -
A
dh
es
io
n 
to
 im
m
ob
ili
ze
d 
LF
A
-1
(%
 in
pu
t)
CH
O-J
AM
(HA
)
CH
O-v
ect
or  
CH
O-J
AM
∆D
1(H
A)
CH
O-J
AM
∆D
2(H
A)
B  
-
10 -
5 -
-
0 -
A
dh
es
io
n 
to
 im
m
ob
ili
ze
d 
LF
A
-1
(%
 in
pu
t)
A
dh
es
io
n 
to
 im
m
ob
ili
ze
d 
LF
A
-1
(%
 in
pu
t)
A
dh
es
io
n 
to
 im
m
ob
ili
ze
d 
LF
A
-1
(%
 in
pu
t)
A
dh
es
io
n 
to
 im
m
ob
ili
ze
d 
LF
A
-1
(%
 in
pu
t)
A
dh
es
io
n 
to
 im
m
ob
ili
ze
d 
LF
A
-1
(%
 in
pu
t)
A
dh
es
io
n 
to
 im
m
ob
ili
ze
d 
LF
A
-1
(%
 in
pu
t)
figure 21: Adhesion of CHO transfectants in suspension to purified and immobilized LFA-1 under static conditions. 
Wild-type and mutant JAM-1 proteins were expressed (A) without or (B) with C-terminal fused HA epitope tag (compare 
to fig. 20). Adhesion was measured as the percentage of input CHO cells. Data are the mean ± s.d. of four separate 
experiments performed in triplicate. 
Deletion analysis indicated that the membrane-proximal Ig-like domain 2 of JAM-1 is both 
crucial and sufficient to support direct interaction of JAM-1 with its receptor LFA-1. 
 
 
 
4.8. Contribution of JAM-1 in LFA-1–dependent adhesion of 
memory T cells to inflammatory stimulated endothelium 
The initial experiments designed to confirm a functional role for JAM-1 in LFA-1–mediated 
adhesion were performed using Jurkat T cells and CHO transfectants. Inevitably, the results of 
these experiments are based to some extent on the cellular background of these immortalized cell 
lines. To investigate the cooperation of LFA-1 and JAM-1 in a more physiological context, cells 
of the human vascular system were subjected to cell-cell adhesion assays under static conditions. 
Human umbilical vein endothelial cells (HUVECs) were isolated from the veins of umbilical 
cords freshly obtained after birth. CD4+CD45RO+ memory T lymphocytes were isolated from 
the blood of normal volunteers by magnetic cell separation and immediately subjected to 
HUVEC monolayer adhesion. HUVECs were left untreated or stimulated simultaneously with 
the inflammatory cytokines tumor necrosis factor (TNF)-α and interferon (IFN)-γ, the latter 
inducing a redistribution of junctional located JAM-1 to the endothelial cell surface (Ozaki et al., 
1999; Shaw et al., 2001c). TNF-α–activation of HUVECs induces expression of VCAM-1 that 
leads to stable arrest of CD4+ T cells under static and flow conditions (Luscinskas et al., 1995). 
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To exclude such an influence on CD4+CD45RO+ T cell adhesion exercised by VLA-4/VCAM-1 
interactions, all experiments on cytokine-stimulated HUVEC monolayers were performed with 
VLA-4–blocked memory T cells and in the presence of VLA-4 mAb. 
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figure 22: (A) Adhesion of PMA-stimulated CD4+CD45RO+ T cells to unstimulated HUVECs under static conditions. (B) 
Adhesion of PMA-stimulated CD4+CD45RO+ T cells to HUVECs costimulated with the inflammatory cytokines TNF-α 
and IFN-γ under static conditions. Experiments on cytokine-stimulated HUVECs were performed with VLA-4–blocked 
CD4+CD45RO+ T cells and in the presence of VLA-4 mAb to exclude VLA-4/VCAM-1–mediated cell adhesion. 
(A-B) Cell binding experiments with the exclusion of PMA stimulation were performed as controls (white columns). 
Antibody studies included the treatment of CD4+CD45RO+ T cells with LFA-1 mAb TS1/22 and preincubation of HUVEC 
monolayers with ICAM-1 mAb, anti–JAM-1 or ICAM-1 mAb/anti–JAM-1 in combination, as indicated. An IgG1 isotype 
control or preimmunization serum had no significant effects, whereas ICAM-1 Fab was as effective as ICAM-1 mAb (data 
not shown). Adhesion was measured as the percentage of input CD4+CD45RO+ T cells. Data are the mean ± s.d. of four 
separate experiments performed in triplicate. *P < 0.05, **P < 0.01. 
PMA-induced adhesion of CD4+CD45RO+ T cells on untreated HUVECs was largely decreased 
when the lymphocytes were preincubated with LFA-1 mAb TS1/22 (fig. 22A). This inhibition 
was more significant in experiments with inflammatory stimulated HUVECs, where adhesion 
was reduced to the background values observed with unstimulated memory T cells (fig. 22B). 
Stimulated CD4+CD45RO+ T cell arrest therefore appeared to be largely dependent on the 
presence of leukocytic LFA-1 receptors. In contrast, neutralization of the LFA-1 ligand ICAM-1 
on untreated or TNF-α/IFN-γ–costimulated HUVEC monolayers led to a far less pronounced 
inhibition of T cell arrest than achieved by receptor blockage (fig. 22A+B). Thus, LFA-1 ligand(s) 
in addition to ICAM-1 appeared to be involved in PMA-induced T cell arrest. This finding was 
also consistent with published results (Rothlein et al., 1986; Nortamo et al., 1991; de Fougerolles 
et al., 1992; Springer, 1994; Bleijs et al., 2000) and, together with the own previous results, 
allowed to postulate an interplay between ICAM-1 and JAM-1 as concerted LFA-1 ligands in 
cell-cell adhesion. Shielding JAM-1 on costimulated HUVECs by the use of anti–JAM-1 indeed 
significantly reduced LFA-1–mediated adhesion of activated CD4+CD45RO+ T cells (fig. 22B). 
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Moreover, combined treatment with ICAM-1 mAb and anti–JAM-1 completely impeded this 
adhesive cell interaction, resulting in the binding levels observed with unstimulated or LFA-1–
blocked stimulated CD4+CD45RO+ T cells (fig. 22B). In contrast, resting HUVECs underwent no 
significant changes in activated T lymphocyte binding when treated with anti–JAM-1 alone or 
together with ICAM-1 mAb and anti–JAM-1 (fig. 22A). Equivalent findings were obtained when 
T lymphocyte binding was induced by the more physiological stimulus of stromal cell-derived 
factor (SDF)-1α (CXCL12) instead of PMA (data not shown). 
 
The usage of CD4+CD45RO+ T lymphocytes and HUVECs isolated from the human vascular 
system confirmed the interaction between LFA-1 and JAM-1 in cell-cell adhesion in a more 
physiological context, but only under the specific conditions of inflammatory stimulation of 
endothelial monolayers with TNF-α and IFN-γ. The results additionally suggested that under 
these inflammatory conditions ICAM-1 works in tandem with JAM-1 to mediate LFA-1–
dependent adhesion of memory T cells. Thus JAM-1 could play an important role in the process 
of leukocyte recruitment in inflammation. 
 
 
 
4.9. Insistency of LFA-1/JAM-1–based cell adhesion under 
physiological conditions of flow 
Circulating leukocytes in vivo must resist the physical shear forces that act on them at the vessel 
wall and that oppose their adhesion to the endothelium or recruitment to sites of inflammation 
and during lymphocyte homing (see fig. 28). 
 
To further investigate the physiological relevance of the LFA-1/JAM-1 interplay, leukocyte 
adhesion assays were performed under laminar flow conditions to simulate in vitro the 
physiological fluid shear stress present in the human microvasculature. Memory T cells were 
perfused through a parallel plate flow chamber (see fig. 4) causing a laminar flow of cell 
suspension over embedded HUVEC monolayers that induced a regulated wall shear stress of 
1.5 dyn/cm2. Cell-cell interactions, i.e. leukocyte rolling, adhesion and transendothelial 
migration, was directly visualized by video microscopy. Inflamed HUVEC monolayers were 
immobilized with the chemokine SDF-1α to trigger integrin-mediated firm arrest of memory T 
cells under conditions of shear forces, as has been described for CD34+ progenitors (Peled et al., 
1999). Despite a redundancy of cell adhesion-mediating receptor-ligand pairs, flow experiments 
were performed under conditions blocking leukocytic VLA-4 integrins. This excluded 
intercellular VLA-4/VCAM-1 interactions enhanced by induction of endothelial VCAM-1 
expression through cytokine stimulation of HUVECs. 
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SDF-1α–triggered T lymphocyte adhesion to cytokine-stimulated HUVECs under flow appeared 
to be in large part mediated by LFA-1 as demonstrated with the mAb TS1/22 (fig. 23A+B). On 
TNF-α–stimulated HUVECs, ICAM-1 served exclusively as the LFA-1 ligand, whereas anti–
JAM-1 did not effect cellular interaction and thus had no additive effect when applied together 
with an ICAM-1 mAb (fig. 23A). In contrast, under conditions of costimulation with TNF-α and 
IFN-γ where JAM-1 is redistributed from cell-cell junctions to the cell surface, anti–JAM-1 
efficiently reduced adhesion of CD4+CD45RO+ T cells (fig. 23B). The cell binding inhibition 
was additively increased by simultaneous blocking of ICAM-1 and JAM-1 on the endothelial 
surface, attaining the levels observed for neutralization of the LFA-1 receptor (fig. 23B). The 
results from flow chamber experiments correlated with those obtained in the corresponding 
assays under static conditions (see fig. 22). 
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figure 23: Flow chamber experiments to study memory T cell adhesion to (A) TNF-α–stimulated HUVEC monolayers and 
to (B) TNF-α/IFN-γ–costimulated HUVEC monolayers under flow conditions. CD4+CD45RO+ T cells tempered to 37°C 
were perfused through the flow chamber at controlled flow rates of 0.1 ml/s effecting a wall shear stress of 1.5 dyn/cm2. 
T cell arrest was triggered by SDF-1α immobilized on HUVEC monolayers (black columns). Control experiments were 
performed without SDF-1α stimulation (white columns). Experiments were each performed with VLA-4–blocked 
CD4+CD45RO+ T cells and in the presence of VLA-4 mAb. Antibody studies included the treatment of CD4+CD45RO+ 
T cells with LFA-1 mAb TS1/22 and preincubation of HUVEC monolayers with ICAM-1 mAb, anti–JAM-1 or 
ICAM-1 mAb/anti–JAM-1 in combination, as indicated. An IgG1 isotype control and preimmunization serum had no 
significant effects, whereas ICAM-1 Fab was as effective as ICAM-1 mAb (data not shown). Firmly adherent T cells were 
counted after a 5-min equilibration of flow conditions and expressed as cells/mm2. Data are the mean ± s.d. and are 
representative of at least three experiments performed in duplicate. *P < 0.05, **P < 0.01. 
Even under the effect of physical shear stress forces, JAM-1 appeared able to engage in adhesive 
molecular interactions with the integrin receptor LFA-1 and thus to participate in the firm arrest 
of memory T cells on inflamed endothelium. The additive effect of ICAM-1 mAb and anti–
JAM-1 on LFA-1–mediated cell adhesion suggested that both IgSF proteins might function as 
alternative ligands for LFA-1 under certain inflammatory conditions. Experiments on HUVECs 
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solely stimulated with TNF-α revealed the requirement of JAM-1 redistribution from junctional 
structures to the apical surface to enable its participation in T cell binding. These findings 
strengthened the hypothesis of a crucial role for JAM-1 in leukocyte binding during 
inflammation in a more physiological context. 
 
 
 
4.10. Involvement of JAM-1 in memory T cell transmigration 
Dissociation of endothelial JAM-1 from TJs caused by combined cytokine treatment with TNF-α 
and IFN-γ interfere with the intercellular junctional integrity and the endothelial permeability 
(Ozaki et al., 1999; Shaw et al., 2001c). Such a process could enable leukocyte transmigration 
during inflammation. Given the ability of JAM-1 to participate under inflammatory conditions in 
firm leukocyte adhesion, an additional functional role for JAM-1 in leukocyte recruitment, i.e. 
diapedesis across the endothelial barrier, could be envisioned. To address this hypothesis, 
transendothelial migration of memory T cells was investigated under static and flow conditions. 
 
In static chemotaxis experiments, CD4+CD45RO+ T cells were allowed to transmigrate across 
resting HUVEC monolayers grown to confluence on 5.0-µm filter membranes towards a SDF-1α 
chemokine gradient (see fig. 3). Lymphocyte transmigration appeared dependent on SDF-1α 
stimulation and was mainly mediated by LFA-1 and its ligand ICAM-1 (fig. 24). In static 
adhesion assays, anti–JAM-1 did not effect PMA or SDF-1α–triggered lymphocyte adhesion on 
unstimulated HUVECs, either alone or in combination with an ICAM-1 mAb (see fig. 22A). In 
contrast, transendothelial chemotaxis under the same conditions was significantly impaired by 
anti–JAM-1 and completely inhibited to a level observed for LFA-1–independent background 
transmigration by the combined action with the ICAM-1 mAb (fig. 24). 
 
Similar results were obtained for transendothelial migration induced by SDF-1α under shear 
forces in flow chamber experiments, a phenomenon that has also been termed chemorheotaxis 
(Cinamon et al., 2001b; Luscinskas et al., 2001). In these assays, migration of firmly adherent 
memory T cells through the endothelial monolayer (indicated by leukocyte shape change and 
subsequent spreading), was directly visualized by video microscopy. The number of cells 
undergoing shape changes on inflamed endothelium was significantly reduced by each anti–
JAM-1 and ICAM-1 mAb alone (fig. 25). Notably, blocking JAM-1 attenuated also lymphocyte 
spreading on resting endothelium (data not shown). A combined treatment of inflamed ECs with 
both antibodies showed an additive effect and impaired lymphocyte shape change to a similar 
extent to that observed for LFA-1–blocked lymphocytes (fig. 25). 
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figure 24: Transendothelial chemotaxis of CD4+CD45RO+ T cells across unstimulated HUVEC monolayers triggered by 
SDF-1α. Experiments were performed in 5.0-µm transwell-filters with (black columns) or without (white column) chemokine 
stimulation. Antibody applications included the treatment of CD4+CD45RO+ T cells with LFA-1 mAb TS1/22 and preincubation 
of resting HUVEC monolayers with ICAM-1 mAb, anti–JAM-1 or ICAM-1 mAb/anti–JAM-1 in combination, as indicated. An 
IgG1 isotype control and preimmunization serum had no significant effects, whereas ICAM-1 Fab was as effective as ICAM-1 
mAb (data not shown). Transmigrated cells were counted by flow cytometry and expressed as the percentage of input 
lymphocytes. Data are the mean ± s.d. of four separate experiments performed in duplicate. *P < 0.05, **P < 0.01. 
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figure 25: Spreading and transmigration of CD4+CD45RO+ T cells induced by SDF-1α immobilized on HUVEC monolayers 
costimulated with TNF-α and IFN-γ under flow conditions. CD4+CD45RO+ T cells tempered to 37°C were perfused through the 
flow chamber at controlled flow rates of 0.1 ml/s effecting a wall shear stress of 1.5 dyn/cm2. Control experiments were 
performed without SDF-1α immobilization (white column). Experiments were each performed with VLA-4–blocked 
CD4+CD45RO+ T cells and in the presence of VLA-4 mAb. Antibody applications included the treatment of CD4+CD45RO+ T 
cells with LFA-1 mAb TS1/22 and preincubation of HUVEC monolayers with ICAM-1 mAb, anti–JAM-1 or 
ICAM-1 mAb/anti–JAM-1 in combination, as indicated. An IgG1 isotype control and preimmunization serum had no significant 
effects, whereas ICAM-1 Fab was as effective as ICAM-1 mAb (data not shown). Firm adherent cells undergoing shape change 
indicative of spreading and subsequent transmigration were analyzed by video microscopy and expressed as the percentage of 
adherent cells. Data are the mean ± s.d. and are representative of at least three experiments performed in duplicate. *P < 0.05, 
**P < 0.01. 
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Chemotaxis and flow experiments suggested that JAM-1 participates not only in leukocyte 
adhesion but also in transendothelial leukocyte migration. Inhibition of cell spreading appeared 
thereby to be largely independent from inflammatory stimulation of the endothelium. The 
influence of specific antibodies on T cell transmigration gave further confirmation for JAM-1 
acting as an interaction partner and alternative ligand of LFA-1. 
 
 
 
4.11. Involvement of JAM-1 in transmigration but not adhesion of                 
neutrophils 
The studies concerning an involvement of JAM-1 in leukocyte-EC interactions were further 
extended to myeloid cells. At first, neutrophil adhesion on HUVEC monolayers inflamed by 
combined treatment with TNF-α plus IFN-γ was investigated under laminar flow conditions 
exerting shear stress forces of 1.5 dyn/cm2. This CXCR2-triggered adhesion was not affected by 
the αL mAb TS1/22 but markedly decreased after neutrophil treatment with the β2 mAb TS1/18 
directed against both β2 integrins LFA-1 and Mac-1 (fig. 26A). Given the negligible effect of 
TS1/22, the failure of anti–JAM-1 to block neutrophil adhesion under the experimental 
conditions was expected (fig. 26A). Even the combined application of ICAM-1 mAb and anti–
JAM-1 did not reduce neutrophil adhesion more than ICAM-1 mAb alone. The latter itself 
showed a much more significant effect to that observed with LFA-1 mAb. This was most likely 
due to the capability of ICAM-1 to function not only as ligand for LFA-1 but also for Mac-1 
expressed on neutrophils (fig. 26A). In contrast to ICAM-1 mAb, the negligible effect of anti–
JAM-1 on neutrophil adhesion suggested that it did not interfere with the β2 integrin Mac-1. This 
further strengthened the notion of receptor-specificity of JAM-1. 
 
Transendothelial chemotaxis of neutrophils across resting HUVECs towards an interleukin 
(IL)-8 (CXCL8) gradient (fig. 26B) led to results similar to those obtained for SDF-1α–triggered 
chemotaxis of memory T cells (see fig. 24). LFA-1–dependent neutrophil transmigration under 
static conditions was reduced by ICAM-1 mAb or anti–JAM-1 alone, and simultaneous 
treatment of neutrophils with both antibodies appeared to have an additional inhibitory effect 
(fig. 26B). 
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figure 26: (A) Flow chamber experiments to study neutrophil adhesion on HUVEC monolayers costimulated 
with TNF-α and IFN-γ under flow conditions. Neutrophils were pretreated with 5 % human serum to block 
Fc receptors, tempered to 37°C and perfused through the flow chamber at controlled flow rates of 0.1 ml/s 
effecting a wall shear stress of 1.5 dyn/cm2. Antibody studies included neutrophils treatment with an IgG1 
isotype control, LFA-1 αL mAb TS1/22 or β2 integrin mAb TS1/18 and preincubation of inflammatory 
stimulated HUVEC monolayers with ICAM-1 mAb, anti–JAM-1 or ICAM-1 mAb/anti–JAM-1 in 
combination, as indicated. Preimmunization serum had no significant effects, whereas ICAM-1 Fab was as 
effective as ICAM-1 mAb (data not shown). Firmly adherent neutrophils were counted after a 5-min 
equilibration of flow conditions and expressed as cells/mm2. Data are the mean ± s.d. and are representative 
of at least three experiments performed in triplicate. *P < 0.05, **P < 0.01. (B) Transendothelial chemotaxis 
of neutrophils across unstimulated HUVEC monolayers triggered by IL-8 (CXCL8). Experiments were 
performed in 5.0-µm transwell-filters with (black column) or without (white column) IL-8–stimulation. 
Antibody applications included neutrophils treatment with an IgG1 isotype control, LFA-1 αL mAb TS1/22 or 
β2 integrin mAb TS1/18 and preincubation of resting HUVEC monolayers with ICAM-1 mAb, anti–JAM-1 
or ICAM-1 mAb/anti–JAM-1 in combination, as indicated. Preimmunization serum had no significant 
effects, whereas ICAM-1 Fab was as effective as ICAM-1 mAb (data not shown). Transmigrated cells were 
counted by flow cytometry and expressed as the percentage of input neutrophils. Data are the mean ± s.d. and 
representative of at least four experiments performed in duplicate. *P < 0.05, **P < 0.01. 
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A significant participation of JAM-1 in neutrophil adhesion under flow, as opposed to its 
prominent role in LFA-1–dependent memory T cell arrest, seemed not detectable due to the 
involvement of Mac-1. However, chemotactic transmigration assays revealed a crucial 
involvement of JAM-1 in transendothelial migration of myeloid cells as demonstrated above for 
T lymphocytes diapedesis. 
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5. Discussion 
5.1. Interaction of JAM-1 with the integrin subunit CD11a 
The adhesion receptor lymphocyte function-associated antigen (LFA)-1 is one of the most 
important integrins on leukocytes. It is involved in B cell, T cell and NK cell functions and 
mediates firm cellular arrest on endothelial and epithelial cells within the scope of lymphocyte 
homing and leukocyte recruitment (Dustin et al., 1989; Arnaout, 1990). 
 
Intercellular adhesion molecules (ICAMs) and in particular ICAM-1 are the extracellular ligands 
of LFA-1 and mediate cellular adhesion of leukocytes (Gahmberg et al., 1997). Cytoplasmic 
interaction partners of this integrin, on the contrary, play an important role in LFA-1–related 
signal transduction. For instance, the guanine nucleotide exchange factor (GEF) cytohesin-1 
induces LFA-1 activation via inside-out signaling (Kolanus et al., 1996), and outside-in signaling 
of LFA-1 can engage the transcriptional co-activator JAB1, inducing its nuclear localization and 
thus affecting c-Jun–driven gene transcription (Bianchi et al., 2000). Both cytohesin-1 and JAB1 
specifically interact with the β2 tail of LFA-1 (CD18) and both interactions were identified by 
the yeast two-hybrid (YTH) system. 
 
Specific integrin α subunits show high conservation among different species, and they mediate 
differential regulation of integrin function in between specific β subgroups of integrins (Hynes, 
1992; Sastry et al., 1993). For instance the dynamic mode of LFA-1 regulation by chemokines is 
specifically confered by the αL cytoplasmic domain (Weber et al., 1999a). It is conceivable that 
the α chain exerts regulatory function by modulating the signaling or binding properties of the 
associated β tail. Nevertheless, despite several indications for the importance of the α subunits in 
integrin function and in contrast to integrin β subunits, only few direct interactions of integrin α 
tails with cytoplasmic proteins have been reported to date (Hemler, 1998). One example is the 
αIIb-binding protein CIP (Naik et al., 1997) that has been identified, similarly to cytohesin-1 and 
JAB1, by employing the YTH system. However, none of the α subunit interaction partners were 
specific for the LFA-1 subunit CD11a, raising the question of the presence of further CD11a-
interacting proteins. Therefore this yeast genetic-based in vivo assay represents a promising tool 
to search for novel αL-specific binding partners of the integrin subunit CD11a. 
 
Using the cytoplasmic part of CD11a as bait construct, one prey protein was identified as a 
candidate interacting protein in a YTH screen of a human leukocyte cDNA library. Isolation of 
the library plasmid from the candidate yeast colony and subsequent sequencing of the prey-
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encoding cDNA insert revealed the full-length sequence of a gene that exhibited 75 % homology 
at the protein level with the previously published murine surface protein junctional adhesion 
molecule (JAM)-1 predominantly expressed at intercellular junctions (Martìn-Padura et al., 
1998). The striking high degree of homology and the utilization of a human cDNA library for the 
screening application predicted that the candidate prey was the human homologue of murine 
JAM-1. Thus, the putative human JAM-1 protein seemed a bona fide interaction partner for the 
CD11a subunit of LFA-1. 
 
Interestingly, murine JAM-1 revealed striking structural and functional similarity with the ICAM 
subfamily, the counter-receptors of LFA-1, with respect to its immunoglobulin superfamily 
(IgSF) affiliation and its CAM function. Furthermore, it has been implicated in the 
transendothelial migration of monocytes and neutrophils in vitro and in vivo (Martìn-Padura et 
al., 1998; Del Maschio et al., 1999). Given the fact that JAM-1 is not expressed on murine 
leukocytes and thus is not available for heterotypic JAM-1/JAM-1 interactions (i.e. between cells 
of different type) this implicated a potential functional role for JAM-1 as a heterotypic binding 
partner of LFA-1. Moreover, the junctional location of JAM-1 was highly suggestive for an 
interaction with LFA-1 which plays a crucial role in transendothelial diapedesis. 
 
To test this prediction, epithelial Chinese hamster ovary (CHO) cells were transfected with the 
full length JAM-1–encoding cDNA isolated from the library plasmid of the positive yeast 
colony. This eukaryotic cell model was particularly suited since CHO cells exhibit no 
preorganized tight junctions and do not express endogenous JAM-1 (Martìn-Padura et al., 1998). 
Moreover, this adherent cell type allowed generation of confluent cell monolayers for adhesion 
and transmigration experiments with leukocytic cells. Specificity of a polyclonal anti–JAM-1 
antibody raised by DNA-mediated immunization of mice was verified by flow cytometry and 
western blot analysis, where anti–JAM-1 revealed antigen binding only for CHO-JAM 
transfectants but not for CHO-vector transfectants or wild-type CHO cells. Gene expression of 
JAM-1 in CHO-JAM cells was also confirmed at the transcriptional level by RT-PCR. 
Generation of the JAM-1–expressing CHO cell line and anti–JAM-1 polyclonal antibody 
allowed subsequent verification of the YTH results in independent experiments. 
 
 
 
5.2. JAM-1 is expressed in human hematopoietic cells 
Remarkably, JAM-1 was reported not to be expressed in hematopoietic cells of mice, with the 
exception of megakaryocytes (Martìn-Padura et al., 1998). However, the isolation of a JAM-1–
encoding nucleotide sequence from the human leukocyte cDNA library being screened was itself 
a strong indication that JAM-1 is indeed expressed in human leukocytes. Flow cytometry using 
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anti–JAM-1 established human JAM-1 expression on endothelial HUVECs and epithelial-like 
HeLa cells. Most interestingly, and in contrast to data published for murine JAM-1, surface 
expression of human JAM-1 was clearly detectable on monocytic Mono Mac 6 and THP-1 cells 
as well as on lymphoid Jurkat cells. Even CD4+CD45RO+ memory T cells, freshly isolated from 
the blood of healthy donors, revealed JAM-1 surface expression. However, consistent with 
previous reports, JAM-1 was barely detectable on myeloid HL-60 cells (Williams et al., 1999). 
Together, these results confirmed that human JAM-1, as opposed to murine JAM-1, is expressed 
on hematopoietic cells. 
 
These expression studies were consistent with the previous identification of human JAM-1 
(Ozaki et al., 1999; Williams et al., 1999). The corresponding reports demonstrated a 
constitutive expression of human JAM-1 in circulating neutrophils, monocytes, platelets and 
lymphocytes. Additionally the platelet receptor F11 antigen (F11R) was shown to be identical to 
human JAM-1 (Sobocka et al., 2000; Gupta et al., 2000). With its expression on hematopoietic 
cells human JAM-1 seems to be strikingly different from JAM-1 in mice that exhibits a more 
restricted expression, detectable only in megakaryocytes, platelets and in MHC class II + antigen 
presenting cells (APCs) in lymphoid organs, but not in other hematopoietic cell types (Martìn-
Padura et al., 1998; Malergue et al., 1998). The significance of this different expression pattern 
remains unclear and requires the determination of the functional role of JAM-1 in circulating 
blood cells. 
 
 
 
5.3. Adhesive interaction between LFA-1 and its counter-receptor 
JAM-1 
Functional studies using static cell adhesion assays lent support to the hypothesis which was 
based upon structural and functional properties, namely that the β2 integrin LFA-1 and the IgSF 
member JAM-1 exert their mutual interaction by extracellular binding and thus display a 
receptor-ligand pair mediating cellular adhesion. 
 
Confluent monolayers of CHO-JAM transfectants were able to firmly bind integrin-activated 
Jurkat T cells. Several lines of evidence revealed that this cellular interaction was specifically 
mediated by leukocytic LFA-1 and JAM-1 expressed on the CHO cells. i), Jurkat cell adhesion 
was not observed with CHO-vector transfectants or wild-type CHO cells but only with 
CHO-JAM cells. ii), firm arrest of Jurkat cells to CHO-JAM cell monolayers depended to a 
considerable extent on their pretreatment with PMA. Most integrins are normally in an inactive 
state when expressed on the cell surface, and they require activation to gain high affinity and 
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avidity. Phorbol esters like PMA are regularly used in in vitro cell adhesion studies (Dustin et 
al., 1989). They are structural analogues of 1,2-diacylglycerol (DG) that is generated, besides 
inositol-1,4,5-triphosphate (IP3), from phosphatidylinositol-4,5-biphosphate (PIP2) by the 
activity of phospholipase C (PLC). Both second messengers have been demonstrated to lead to 
activation of LFA-1, e.g. DG by activation of protein kinase C (PKC) (Kolanus et al., 1997; Lub 
et al., 1995). Thus, the requirement for PMA-stimulation of Jurkat cells to induce their firm 
arrest to CHO-JAM cells suggested the involvement of PKC-activated integrin receptors. iii), 
blocking leukocytic LFA-1 with TS1/18 mAb reduced the heterotypic cell adhesion to 
background levels. This effect was not observed for Jurkat cells pretreated with an IgG1 isotype 
control. Finally, likewise incubation of CHO-JAM cell monolayers with anti–JAM-1 reduced 
Jurkat cell adhesion to levels observed on CHO cell monolayers lacking JAM-1 expression. In 
contrast, preimmune serum did not effect cellular binding. 
 
 
 
5.4. JAM-1 binds LFA-1 irrespective of cellular integrin surface 
expression 
The finding that LFA-1 functions as a leukocytic adhesion receptor for JAM-1 expressed in 
CHO cells was further substantiated in static adhesion assays where LFA-1 protein, immobilized 
as an adhesion target, specifically captured CHO-JAM transfectants but not CHO-vector or wild-
type CHO cells in suspension. Molecular specificity was confirmed by application of CD18 mAb 
and anti–JAM-1. With regards to the former adhesion assays using Jurkat cells as an LFA-1–
expressing cell model, these experiments excluded the possibility that leukocyte adhesion 
receptors other than LFA-1 have mediated the firm arrest on JAM-1–expressing CHO cells. 
 
The purified and immobilized LFA-1 remains in a constitutively active form as has been 
demonstrated elsewhere (Klickstein et al., 1996). It could thus be used as a substrate for cell 
adhesion experiments. The composition of this LFA-1 preparation was analyzed prior to use by 
SDS-PAGE with subsequent western blotting using antibodies directed against CD11a and CD18 
or with subsequent silver staining. Since the LFA-1 preparation was obtained from human tonsil 
and human spleen lysates by immunoaffinity chromatography (Klickstein et al., 1996; Dustin et 
al., 1989), the identification of JAM-1 as counter-receptor for LFA-1 raised the possibility that 
JAM-1 has been co-purified with LFA-1. In such a case it could not have been excluded that the 
arrest of CHO-JAM cells to immobilized LFA-1 could have been based, at least in part, on such 
a JAM-1 impurity that would be capable of homophilic interaction in trans (Bazzoni et al., 
2000a; Kostrewa et al., 2001). However, the silver staining experiments and JAM-1 immunoblot 
analysis of the LFA-1 preparation did not reveal detectable levels of coprecipitated JAM-1, at 
least at concentrations used in the cell adhesion assays. The absence of LFA-1/JAM-1 
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copurification from organ tissue might be due to a complex cellular regulation of this 
heterophilic interaction that may be transient and not retained under the conditions used in 
purification protocols. 
 
Static adhesion assays revealed that cell-surface expressed JAM-1 is a heterophilic ligand for 
LFA-1 and thus confirmed their interaction initially identified in the YTH system. The 
cell-protein adhesion data demonstrated here, however, were in contrast to a report where a 
recombinant human JAM-1–Fc chimera, ectopically expressed and secreted by insect cells, did 
not appear to support adhesion of lymphoid cells (Cunningham et al., 2000). This may have been 
due to a requirement of cell surface expression for correct orientation and function of JAM-1. 
Differences in the post-translational modification with regards to the expression in insect cells 
are conceivable. In particular glycosylation can affect the adhesive properties of IgSF members 
as demonstrated for ICAMs. The level of ICAM-1 glycosylation affects e.g. its binding to Mac-1 
that is enhanced for ICAM-1 molecules with smaller N-linked oligosaccharide side chains and 
for ICAM-1 mutants where N-glycosylation sites within the Mac-1 binding domain have been 
substituted (Diamond et al., 1991). Moreover, the interaction of ICAM-2 with LFA-1 depends on 
a tripod-like arrangement of N-linked glycans in the membrane-proximal region of the Ig-like 
domain 2 (Casasnovas et al., 1997). However, the different result is most likely due to the fact 
that the lymphoid cells used in their adhesion assay were unstimulated and therefore did not 
express activated LFA-1 integrin receptors. 
 
 
 
5.5. Absence of redundancy for JAM-1 binding between the β2 
integrins LFA-1 and Mac-1 
The IgSF member ICAM-1 is not only the principal ligand for LFA-1 (Rothlein et al., 1986; 
Marlin et al., 1987) but also a functional counter-receptor for Mac-1 (Smith et al., 1989). A 
cooperative involvement of both β2 integrins in adhesion of stimulated neutrophils to purified 
ICAM-1 has been demonstrated by the additive inhibitory effect of combinations of anti-CD11a 
and CD11b mAbs (Smith et al., 1989). Given the structural homology between ICAM-1 and 
JAM-1, J-β2.7 cells were used to investigate a potential role for Mac-1 as a JAM-1 binding 
receptor in addition to LFA-1. 
 
The Jurkat T cell-derived J-β2.7 cell line is deficient in surface expression of β2 integrins, due to 
chemical mutagenesis of the gene encoding the LFA-1 αL subunit (Weber et al., 1997b) and 
since Mac-1 is normally not expressed in lymphoid cells (Anderson et al., 1987). However, 
translation of the β2 subunit-encoding mRNA in J-β2.7 cells is unaffected (Weber et al., 1997b). 
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This provided the possibility to reconstitute LFA-1 (αLβ2) expression or to generate heterotopic 
integrin expression of Mac-1 (αMβ2) in J-β2.7 cells by transfection with integrin αL or αM 
subunit-encoding cDNA, respectively. Subsequent heterodimerization of the respective 
heterogenous α chain with the unaffected endogenous β2 chain is a presupposition for integrin 
surface expression (Anderson et al., 1987; Arnaout, 1990). The ability of a naturally expressed 
integrin subunit to dimerize with a recombinant counterpart subunit expressed in genetically 
deficient cells was shown with β2-deficient human lymphocytes derived from LAD-I patients 
(see 1.5.5.5.). Hybrids generated from these cells with LFA-1–expressing murine lymphocytes 
showed surface expression of interspecies αLhβ2m (h = human; m = murine) hybrid complexes 
(Marlin et al., 1986). Moreover, transfection of lymphocytes from LAD-1 patients with wild-
type β2 cDNA restored the surface expression and function of LFA-1 (Hibbs et al., 1990). 
 
Surface expression of reconstituted LFA-1 and heterotopic Mac-1 on αL-transfected J-β2.7/αL 
and αM-transfected J-β2.7/αM cells was detected by flow cytometry analysis. The J-β2.7/αM cells 
thus provided a LFA-1–deficient lymphocytic cell line expressing Mac-1 on their cell surface. 
Static adhesion assays on CHO cells expressing or not JAM-1 revealed that J-β2.7/αM cells did 
not bind to this IgSF protein, even though functional surface expression of Mac-1 on these cells 
has been demonstrated (Weber et al., 1999a) and was confirmed by static adhesion assays on 
purified, immobilized ICAM-1. This suggested a lack of redundancy between LFA-1 and Mac-1 
for JAM-1 binding that may hold true for the two other β2 integrins p150,95 and αDβ2 as well. 
Furthermore, the failure of J-β2.7 cells to adhere to CHO-JAM transfectants and the rescue of 
this ability by expression of LFA-1 via transfection with an αL-encoding cDNA (J-β2.7/αL cells) 
provided additional evidence that Jurkat T cell binding to JAM-1 expressing CHO cells was 
specifically mediated by LFA-1. 
 
 
 
5.6. Heterophilic nature of the molecular interaction mediating 
leukocyte arrest on JAM-1–expressing CHO cells 
Despite indirect evidence suggesting the existence of a extracellular heterophilic binding partner 
(Martìn-Padura et al., 1998), JAM-1 has only been described to interact in a homophilic manner 
both in cis (dimerization) and in trans. Such JAM-1/JAM-1 interactions appear to participate 
specifically in the formation and/or maintenance of intercellular junctions of endothelia and 
epithelia. The finding of JAM-1 expression in human hematopoietic cells, and in particular in 
Jurkat, J-β2.7 and CD4+CD45RO+ T cells used within this study, raised the important issue to 
test whether homophilic binding between leukocytic JAM-1 and CHO cell-expressed JAM-1 was 
involved in the observed cell-cell adhesion phenomena. 
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Several lines of evidence corroborated the conclusion that such homophilic interactions in trans 
were not crucial for the firm arrest of leukocytes. i), the surface expression of JAM-1 in wild-
type Jurkat cells and J-β2.7 cells did not correlate with the marked differences in their adhesion 
behaviour to CHO-JAM transfectants on the one hand and CHO-vector transfectants or wild-
type CHO cells on the other hand. The failure of αL-deficient but JAM-1 expressing J-β2.7 cells 
to bind to JAM-1–transfected CHO cells revealed a crucial role for heterophilic but not for 
homophilic JAM-1 interactions in Jurkat/CHO-JAM cell binding. Moreover, reconstitution of 
JAM-1 binding-properties of J-β2.7 cells by their transfection with an αL-encoding cDNA 
demonstrated the dependence on this integrin receptor. ii), leukocyte binding to CHO-JAM cells 
appeared to depend completely on stimulation by the phorbol ester PMA, suggesting that this 
cell adhesion required activated LFA-1 but not on the presence of leukocytic JAM-1 molecules. 
iii), preincubation of leukocytes with specific LFA-1 mAbs decreased their arrest on CHO-JAM 
cells to such an extent that a contribution of trans-homophilic JAM-1 binding to the observed 
cell adhesion could be convincingly excluded. iv), blocking leukocyte JAM-1 with anti–JAM-1 
did not affect binding of Jurkat T cells to CHO-JAM cells nor binding of CD4+CD45RO+ 
memory T cells to unstimulated or cytokine-treated HUVECs, as described below. v), CHO cells 
with or without expression of JAM-1 showed equivalent binding to purified, immobilized LFA-1 
receptor and to LFA-1–expressing Jurkat cells, respectively, and thus provided evidence against 
an involvement of homophilic JAM-1 interactions in the adhesive binding reported here. 
Notably, JAM-1 contamination of the LFA-1 preparation due to copurification was not 
detectable by protein analysis. vi), myeloid HL-60 cells, that did not show detectable JAM-1 
surface expression in flow cytometry analysis in accordance with published data (Williams et al., 
1999), showed a similar LFA-1–mediated binding pattern to CHO-vector or CHO-JAM cells 
than JAM-1–expressing Jurkat cells. This was in contrast to a report where HL-60 cells failed to 
bind recombinant human JAM-1 Fc chimera (Cunningham et al., 2000). However, this was most 
likely due to the fact that the monocytic cells were not stimulated and therefore did not express 
activated LFA-1. Finally, CHO-JAM transfectants in suspension failed to exert significant 
adhesive properties to confluent CHO-JAM cell monolayers under static conditions. 
 
The latter finding was supported by a report demonstrating that CHO cells expressing murine 
JAM-1 do not aggregate in suspension (Martìn-Padura et al., 1998). Possible explanations for 
this observation could be changes in intracellular complexes involving JAM-1 and regulatory 
cytoplasmic proteins, and/or alteration in the extracellular JAM-1 conformation due to the cell 
detachment. A similar phenomenon has been demonstrated for the adherens junction (AJ) protein 
VE-cadherin, which is unable to promote aggregation of detached CHO cells (Breviario et al., 
1995). However, this may not be relevant in this case since CHO cells in suspension expressing 
the homologous family member JAM-2 have been demonstrated to bind specifically to 
immobilized JAM-2–Fc chimera, thus identifying homophilic interactions in trans exerted by 
human JAM-2 (Cunningham et al., 2000). The results demonstrated here were also in 
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accordance with findings that recombinant mouse as well as human JAM-1 Fc chimeras did not 
mediate homophilic adhesion to JAM-1 expressed by transfected COS or CHO cells in solid 
phase adhesion assays (Williams et al., 1999; Cunningham et al., 2000). Furthermore, they were 
consistent with the idea that a homophilic interaction of JAM-1 molecules may arise 
preferentially in regions of cell-cell contacts that exhibit a sufficiently high JAM-1 density, e.g. 
at intercellular junctions. However, the homophilic JAM-1 binding investigated under the 
experimental conditions of adhesion assays could be of relatively low affinity. Although there 
was no clear evidence for the involvement of such a type of molecular interaction in the cellular 
arrest of lymphoid Jurkat cells on CHO-JAM transfectants or of CD4+CD45RO+ T cells on 
HUVECs (as described below), it cannot be ruled out that during leukocyte recruitment 
JAM-1/JAM-1 interactions in trans may occur that are only of low stringency and therefore 
difficult to detect. Indeed, JAM-1–transfected CHO cell monolayers were shown to facilitate 
adhesion of freshly isolated human platelets (Naik et al., 2001), presumably via homophilic 
interactions, although other heterophilic receptors on the surface of platelets have not been 
excluded, e.g. by blocking antibodies. Alternatively, anti–JAM-1 may not have an inhibitory 
effect on homophilic interactions. With regards to the blocking properties of anti–JAM-1 in 
LFA-1–mediated leukocyte adhesion and transmigration, the epitope targeted by this antibody is 
likely to be located in the LFA-1–binding membrane-proximal Ig-like domain 2 rather than in 
the N-terminal region that is implicated in homophilic JAM-1 interactions (Bazzoni et al., 2000a; 
Kostrewa et al., 2001). 
 
 
 
5.7. Structural duality of JAM-1 
Deletion mutagenesis revealed that the membrane-proximal Ig-like domain 2 of human JAM-1 is 
necessary and sufficient for LFA-1 binding, strongly suggesting that this domain bears the 
LFA-1 binding site. Thus, CHO cells expressing domain 2-deficient JAM-1 (CHO-JAM∆D2 
cells) failed to mediate adhesiveness to PMA-stimulated Jurkat T cells or to molecular LFA-1. In 
contrast, adhesion mediated by JAM-1 comprising only the Ig-like domain 2 (CHO-JAM∆D1 
cells) was equivalent to that seen with CHO-JAM transfectants. Expression of the mutated 
JAM-1 constructs was confirmed by RT-PCR though not verifiable at the protein level. An 
efficient recognition by polyclonal anti–JAM-1 appeared to require the presence of full-length 
JAM-1 and failed to detect the mutant proteins JAM∆D1 and JAM∆D2, probably due to recognition 
of an epitope encompassing or intervening both Ig-like domains 1 and 2. However, using 
CHO-JAM(HA), CHO-JAM∆D1(HA) and CHO-JAM∆D2(HA) cells presenting C-terminal HA-tagged 
JAM-1 constructs on their surface resulted in equivalent adhesion results. Flow cytometry 
analysis of the permeabilized CHO transfectants using anti-HA revealed that the failure of 
CHO-JAM∆D2(HA) cells to bind to cellular or molecular LFA-1 was not the consequence of a lack 
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of cell surface expression or to protein degradation of JAM∆D2(HA). It could be predicted that this 
was also the case for the non-tagged JAM∆D2 protein expressed by CHO-JAM∆D2 cells. 
Consistent with this prediction, with regards to the regulation of JAM-1 function by its 
C-terminal PDZ domain-binding motif, adhesion experiments with CHO cells expressing 
HA-tagged JAM-1 indicated that this C-terminal fused epitope tag did not impair the 
adhesiveness of these cells as compared to CHO cells expressing non-tagged JAM-1. 
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figure 27: Schematic diagram depicting the main known interactions of 
the β2 integrins LFA-1 and Mac-1 with IgSF members. Notably, the 
interaction of LFA-1 with ICAM-1, -2, and -3 requires the N-terminal 
domain 1 of these IgSF members as the primary binding site, whereas the 
membrane-proximal domain 2 of JAM-1 appears to be sufficient to 
mediate the binding of LFA-1. Similarly, ICAM-1 binds Mac-1 with its 
Ig-like domain 3. 
The ICAM proteins, vascular cell adhesion molecule (VCAM)-1 and mucosal addressin cell 
adhesion molecule (MAdCAM)-1 represent a subclass of the IgSF family that is able to bind 
integrins. They exhibit a greater amino acid sequence homology to one another than to other 
IgSF members (Tan et al., 1998). The functionally important integrin-binding regions seem to be 
located mainly in their N-terminal Ig-like domain 1 (fig. 27) with some contribution by the 
second domain, as demonstrated for ICAM-1/LFA-1 (Staunton et al., 1990; Stanley et al., 2000), 
ICAM-2/LFA-1 (Springer, 1994), ICAM-3/LFA-1 (Holness et al., 1995; Klickstein et al., 1996), 
VCAM-1/VLA-4 with an additional contribution of domain 4 (Vonderheide et al., 1994; 
Newham et al., 1997) and MAdCAM/α4β7 (Briskin et al., 1996; Tan et al., 1998). In this regard, 
the new IgSF-integrin interaction represented by JAM-1 and LFA-1 differs from the previous 
binding pairs in that it engages the second but not the first Ig-like domain of JAM-1 for the 
mutual interaction (fig. 27). Remarkably, ICAM-1 that binds LFA-1 with its N-terminal domain, 
engages its third (although not its membrane-proximal fifth) Ig-like domain to interact with 
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Mac-1 (fig. 27) (Diamond et al., 1991). Similarly to ICAM-1, JAM-1 thus displays structural 
duality in that the membrane-distal Ig-like domain 1 appears to exert homophilic JAM-1 binding 
in cis and in trans (see fig. 29) (Bazzoni et al., 2000a; Kostrewa et al., 2001), whereas the 
membrane-proximal Ig-like domain 2 mediates heterophilic receptor binding to LFA-1. This 
aspect raises the possibility that lateral dimerization of endothelial JAM-1 enhances binding to 
leukocyte LFA-1 in trans, as has been demonstrated for ICAM-1 dimers (Miller et al., 1995; 
Reilly et al., 1995). Such a scenario would be reasonable given the JAM-1 redistribution from 
intercellular junctions to the apical cell surface of ECs under certain inflammatory conditions 
(Ozaki et al., 1999; Shaw et al., 2001c). 
 
 
 
5.8. Validation of cellular adhesion with natural cells 
The finding that the molecular interaction of JAM-1 with LFA-1 was sufficient to mediate firm 
cellular arrest, as determined with transfected CHO cells and leukemic Jurkat T cells, was 
validated in a more physiological context. i), adherent HUVECs isolated from umbilical cord 
veins were used as a confluent cell monolayer expressing JAM-1. Cytokine-activated HUVECs 
provided an model of inflamed endothelium, since they express or upregulate expression of the 
major adhesive ligands found on many inflamed venules, i.e. mainly E-selectin, P-selectin, 
ICAM-1 and VCAM-1 (Luscinskas et al., 1995). A combined treatment with the 
proinflammatory cytokines TNF-α and IFN-γ was used to induce a redistribution of JAM-1 from 
the interendothelial junctions to the apical surface of the ECs. ii), LFA-1–bearing T lymphocytes 
were isolated from human venous blood. Whereas naive cells circulate predominantly through 
lymphoid tissues, trafficking to sites of inflammation is a characteristic property of memory 
CD4+ T lymphocytes. Therefore only memory T cells (CD4+CD45RO+) were used and separated 
from naive T cell phenotypes (CD4+CD45RA+) on the basis of their differential expression of 
CD45R isoforms (Springer, 1994). iii), in addition to the use of phorbol ester, T lymphocytes 
were stimulated in a more physiological way using stromal cell-derived factor (SDF)-1α 
(CXCL12) immobilized and displayed on the endothelial cells (ECs). This chemokine potently 
attracts lymphocytes and exerts chemoattractive and activating functions upon binding to its 
G protein-coupled receptor CXCR4 (Campbell et al., 1998; Peled et al., 1999). CD4+CD45RO+ 
memory T cells were suitable for SDF-1α stimulation since they express CXCR4 which is 
crucial for their inflammatory recruitment (Nanki et al., 2000). Exogenous application of 
SDF-1α was a prerequisite due to the fact that cultured ECs do not express lymphocyte-
stimulatory chemokines normally apically presented on lymphoid or inflamed endothelia in vivo 
(Cinamon et al., 2001b). VCAM-1/VLA-4 interactions have been implicated in the stable arrest 
of CD4+ T lymphocytes on TNF-α–activated HUVECs under static and flow conditions 
(Luscinskas et al., 1995). Blocking leukocytic VLA-4 therefore enabled the analysis of 
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JAM-1/LFA-1–mediated cellular arrest in the context of an induction of VCAM-1 surface 
expression on cytokine–stimulated HUVECs. 
 
Antibody studies revealed that adhesion of CD4+CD45RO+ T cells on untreated or costimulated 
HUVECs was largely dependent on LFA-1. On resting HUVECs this interaction was only in part 
mediated by the main LFA-1 ligand ICAM-1, and was not affected by anti–JAM-1. However, 
JAM-1 significantly participated in the lymphocyte arrest on proinflammatory costimulated 
HUVECs. Under these specific conditions it appeared to function in conjunction with ICAM-1 
as a second LFA-1 counter-receptor, since anti–JAM-1 or ICAM-1 mAb alone failed to 
completely inhibit LFA-1–mediated lymphocyte adhesion that was in contrast achieved by the 
use of both these antibodies in combination. Interestingly, blocking LFA-1 has often reported to 
be more effective in the inhibition of leukocyte extravasation than blocking any of its known 
endothelial ligands, e.g. ICAM-1 (Smith et al., 1989; Weber et al., 1997a). This has prompted 
speculation concerning the importance of additional LFA-1 ligands in transmigration. Hence, the 
interaction of LFA-1 with JAM-1 documented in this thesis has substantiated the hypothesis that 
LFA-1 may use, or even require, multiple junctional ligands during diapedesis. 
 
The differences observed in cell adhesion on resting and costimulated HUVECs, were most 
likely due to the fact that ICAM-1 expression is upregulated in activated cells or inflamed tissue 
whereas normally it is expressed only at low levels (Nortamo et al., 1991), and that an increased 
surface density of JAM-1 is induced under the specific conditions of a combined TNF-α/IFN-γ 
cytokine treatment (Ozaki et al., 1999; Shaw et al., 2001c). In contrast to the data described here, 
adhesion of monocytes to JAM-1–expressing endothelial cells was not affected by treatment 
with the murine JAM-1 mAb BV11 (Martìn-Padura et al., 1998). This could be explained by a 
redundancy in adhesive receptor-ligand pairs, e.g. Mac-1/ICAM-1 and VLA-4/VCAM-1, or 
more likely by insufficient surface expression when JAM-1 is not redistributed from the 
interendothelial junctions. 
 
In conclusion JAM-1 was confirmed as a novel counter-receptor of LFA-1 in a more 
physiological context. Furthermore, the results implicated a functional role for this molecular 
interaction in the inflammatory recruitment of memory T lymphocytes. Interestingly, endothelial 
expressed human JAM-2 is also able to bind T lymphocytes (Cunningham et al., 2000). The 
receptor recognizing endothelial JAM-2 is lymphocytic JAM-3 (Arrate et al., 2001; Liang et al., 
2002). Thus these JAM isoforms constitute mutual heterophilic interaction partners in trans. 
Notably, human JAM-2 expression is increased in tissues with chronic inflammatory disease 
(Liang et al., 2002) and human JAM-3 expression is highly up-regulated in activated 
lymphocytes (Arrate et al., 2001), indicating a functional role of the heterophilic JAM-2/JAM-3 
interaction in inflammatory processes. 
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5.9. Validation under conditions of laminar flow 
The process of leukocyte diapedesis through the endothelium in vivo occurs in the context of 
blood flow. To reach a site of inflammation, the cells must first marginate to the blood vessel 
wall and form stable adhesions before migrating into the extravascular space. Their rolling, 
adhesion and transmigration are thereby subjected to physiological shear (fig. 28). 
figure 28: Flow profile in a parallel plate flow chamber. Both 
cylindrical blood vessel and parallel-plate flow chamber (see fig. 4) 
geometries exhibit the demonstrated flow profile with parabolic 
increase of the flow velocity (V) from the wall toward the centerline. 
The shear rate describes the change in velocity (dV) per change in 
radial displacement (dr) and is highest at the wall. The physical 
forces acting on a cell under flow correlates with the shear stress, 
defined as product of shear rate and viscosity, that is directly 
proportional to the flow rate. Adapted from Lawrence et al., 1991. 
In vivo these external mechanical forces not only counteract initial adhesive processes by their 
disruptive property (Lawrence et al., 1991) but they are also crucial for establishing them, e.g. by 
triggering mechanoresponsive elements, such as focal adhesion kinases or stretch-activated ion 
channels, on both migrating leukocytes and endothelial cells (Cinamon et al., 2001b). Moreover, 
it has been demonstrated that threshold levels of fluid shear promote leukocyte adhesion through 
selectins (Lawrence et al., 1997). Torque forces generated by shear stress may increase 
leukocyte contact with the EC barrier by deformation and thereby facilitate its exposure to EC-
displayed CAMs (Moazzam et al., 1997). Fluid shear stress also affects the endothelial lining 
that functions as a transducer of this biomechanical stimuli into biological responses within the 
vessel wall. This includes induction of nitric oxide synthase (NOS), production of prostacyclin, 
cytokines, growth factors, extracellular matrix components and vasoactive mediators as well as 
transcriptional activation of genes containing the shear stress response element (SSRE) in their 
promoter regions (Gimbrone, 1999). 
 
By incorporating shear flow conditions into the adhesion assay set-up (see fig. 4), some of the 
physical constrains of force and contact time were simulated that affect leukocyte margination 
and cell wall attachment in vivo. This allowed the testing of the LFA-1/JAM-1 interaction for its 
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ability to form stable shear-resistant bonds and thus to verify its physiological relevance in cell 
adhesion and leukocyte recruitment. Flow chamber experiments were performed under a wall 
shear stress of 1.5 dyn/cm2. This value is in the range estimated to exist in post-capillary and 
high-endothelial venules, i.e. approx. 1 – 4 dyn/cm2 (Lawrence et al., 1991; Jones et al., 1996a). 
Stimulation of CD4+CD45RO+ T cells with the chemokine SDF-1α was appropriate for flow 
chamber experiments, primarily due to its ability to induce integrin–mediated arrest of rolling 
T lymphocytes within subseconds even under conditions of flow (Grabovsky et al., 2000; 
Campbell et al., 1998; Constantin et al., 2000). The useful characteristics of SDF-1α in this 
context has been previously demonstrated for CD34+ progenitor cells (Peled et al., 1999). 
 
The parallel-plate flow chamber data further strengthened the results obtained in static adhesion 
assays. Anti–JAM-1 did not affect the LFA-1–dependent adhesion of CD4+CD45RO+ memory T 
cells when the endothelium was not costimulated with TNF-α/IFN-γ and JAM-1 was located in 
the junctions. The redistribution of JAM-1 to the surface induced by this combined cytokine 
treatment led to firm cellular arrest that was resistant to mechanical shear stress of 1.5 dyn/cm2. 
Again, leukocyte-EC binding was reduced by anti–JAM-1 and ICAM-1 mAb alone and was 
diminished to background binding levels when these antibodies were combined. Their additive 
effect suggested that JAM-1 cooperates with ICAM-1 as an alternative IgSF ligand for the β2 
integrin LFA-1. Importantly, the shear-resistance of JAM-1/LFA-1–mediated cell arrest revealed 
the functional consequence of this heterophilic interaction under conditions simulating the blood 
circulation in post-capillary venules. 
 
 
 
5.10. LFA-1 and JAM-1 in transendothelial extravasation of 
leukocytes 
In contrast to tethering, rolling and firm adhesion, less is known about the molecular basis of the 
late steps in leukocyte recruitment controlling the cellular extravasation through tightly apposed 
endothelial cells (Bianchi et al., 1997). It was proposed that transendothelial migration of 
neutrophils may involve a bypass of junctional barriers and occur at preexisting discontinuities in 
both their tight junctions (TJs) and adherens junctions (AJs) at tricellular corners (Burns et al., 
1997). This process would not require disruption or loss of junctional components. The same 
applies for the mechanism of transcellular extravasation observed for chemoattractant-stimulated 
neutrophils that traversed ECs predominantly through their cell body (Feng et al., 1998). 
However, it appears that transmigration occurs primarily along the paracellular route, requiring a 
highly coordinated and reversible opening and closing of intercellular junctions in order to 
preserve vascular integrity (Springer, 1994; Balda et al., 2000). Leukocyte diapedesis has 
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therefore been associated with a reversible remodeling of endothelial AJs between neighboring 
cells (Del Maschio et al., 1996; Allport et al., 2000). However, the exposure of ECs to histamine, 
which increases permeability and clearly induces disorganization of AJs, does not augment or 
substitute for chemokine-triggered leukocyte transendothelial migration (Andriopoulou et al., 
1999). Thus, changes in endothelial permeability per se do not appear to be rate-limiting for 
diapedesis. Nevertheless, migrating leukocytes have been found to induce a delocalization of 
VE-cadherin from AJs by as yet unidentified mechanisms allowing leukocytes to traverse the 
opened gap (Shaw et al., 2001b). While gap junctions have thus far not been implicated in the 
process of diapedesis, the strictly occluded apical barrier of endothelial TJs must to be physically 
separated by extravasating leukocytes. 
 
Localized at intercellular junctions nearby TJs and apparently involved in sealing the endothelial 
barrier via homophilic interactions in trans (Martìn-Padura et al., 1998; Liu et al., 2000b; Liang 
et al., 2000), JAM-1 appeared to be ideally situated to play a functional role in leukocyte 
transmigration. Indeed, murine JAM-1 mAb BV11 inhibited leukocyte transmigration across 
endothelial cells in tissue culture assays as well as in an in vivo model of skin inflammation 
(Martìn-Padura et al., 1998). Moreover, BV11 interfered with the accumulation of leukocytes in 
the cerebrospinal fluid in cytokine-induced meningitis (Del Maschio et al., 1999). The mode of 
BV11 action remains unknown but could be based upon a stabilization of homophilic JAM-1 
interactions between neighbouring ECs, thus inhibiting the dissociation of the junctional barrier. 
In this regard, the BV11 mAb was reported to specifically bind dimers but not monomers of 
murine rsJAM-1 in vitro, and not to induce dissociation of these dimers (Bazzoni et al., 2000a). 
Alternatively, BV11 could inhibit transmigration by blocking the interaction of JAM-1 with an 
unidentified heterophilic receptor on leukocytes that was subsequently postulated (Martìn-Padura 
et al., 1998). 
 
Given the functional involvement of JAM-1/LFA-1 binding in leukocyte adhesion on ECs under 
inflammatory conditions, this raised the possibility that the JAM-1/LFA-1 interaction might also 
be involved in leukocyte diapedesis. Transmigration assays both under static and flow conditions 
were therefore applied to question this potential role. Extravasation of leukocytes in stasis was 
investigated in transwell chambers (see fig. 3) where chemotaxis was induced by gradients of 
soluble chemoattractants generated beneath endothelial monolayers. Transmigration assays were 
also performed in a flow system (see fig. 4). This was appropriate since transwell chamber 
assays reflect only poorly the physiological situation prevailing during diapedesis, due to the 
lack of a physiological mechanical context and the prolonged time scales for extravasation. 
Moreover, it is unclear whether leukocytes under shear flow can sense and respond to 
sublumenal tissue chemokines within the short time frame of their contact with the endothelium 
(Cinamon et al., 2001a). Therefore it has been hypothesized that diapedesis across the 
paracellular cleft is mediated by a haptotactic gradient, i.e. a gradient of solid-phase–bound 
adhesion molecules like platelet endothelial cell adhesion molecule (PECAM)-1 and cadherins, 
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rather then by chemotactic migration, i.e. along a gradient of soluble chemokines that may 
predominate in subendothelial migration through extravascular tissues (Bianchi et al., 1997). In 
this regard, it was demonstrated that CD3+ T lymphocyte migration across vascular endothelium 
in vitro can be triggered solely by continuously applied physiological shear stress and apical 
immobilized chemokines (chemorheotaxis2) without the need for a chemotactic gradient 
(Cinamon et al., 2001b; Luscinskas et al., 2001). However, these data contrast markedly with 
previous results where neutrophils and monocytes efficiently migrated across cytokine-
stimulated EC monolayers under either static or flow conditions without exogenously applied 
chemokines (Shaw et al., 2001b). 
 
Chemotaxis experiments under static conditions revealed that SDF-1α–triggered migration of 
CD4+CD45RO+ T cells across resting HUVEC monolayers was mainly LFA-1–dependent. Anti–
JAM-1 significantly reduced this chemotactic emigration, which was consistent given the 
transmigration-blocking properties of this antibody. This finding suggested a functional role for 
JAM-1 in transendothelial extravasation of T lymphocytes. Experiments performed in the flow 
system confirmed and further strengthened these results. Blocking anti–JAM-1 reduced the 
LFA-1–mediated spreading or transendothelial migration of memory T cells under flow 
conditions. A combined blockade of JAM-1 and ICAM-1 inhibited migration additively, 
suggesting that both molecules display alternative ligands for LFA-1 and are required to achieve 
optimal diapedesis. In contrast to the failure of JAM-1 to participate under flow conditions in 
firm leukocyte arrest on unstimulated ECs, a dependence of JAM-1–mediated transendothelial 
migration under flow on TNF-α/IFN-γ–costimulation, and thus on the redistribution of JAM-1 
from intercellular junctions to the apical surface, was not evident. 
 
Besides such a redistribution, a combined treatment with these proinflammatory cytokines 
induces an increased paracellular permeability of endothelial monolayers (Shaw et al., 2001c), 
indicating a decrease in paracellular barrier function. An increased junctional permeability may 
participate in leukocyte diapedesis by promoting accessibility to basolaterally localized JAM-1 
that might guide attached T cells along the intercellular cleft in a haptotactic manner. The 
findings concerning the consequences of TNF-α/IFN-γ–induced endothelial permeability for 
leukocyte extravasation are however contradictory. Neutrophil emigration in vitro across 
costimulated endothelium was reported to be reduced in stasis (Rival et al., 1996) while 
unaltered in flow (Shaw et al., 2001c) and increased in vivo (Munro et al., 1989), when 
compared to a stimulation with only TNF-α that alone does not significantly influence EC 
permeability (Shaw et al., 2001c). These findings indirectly suggest a mutual independence in 
the control of endothelial permeability on one hand and transendothelial migration on the other 
hand. However, members of the JAM family may be directly involved in the permeability 
control of endothelial barriers. Thus, the expression of murine JAM-3 is restricted mainly to ECs 
                                                 
2 in regard to the term “chemotaxis”; chemo: abbreviation for chemoattractant; rheo: flow; taxis: movement 
118  Discussion 
of high endothelial venules (HEVs) and lymphatic vessels, two highly permeable compartments 
specialized in lymphocyte homing, whereas murine JAM-1 is only expressed in low amounts. At 
the same time murine JAM-1 is highly expressed in the vasculature of adult brain, which forms 
one of the tightest blood tissue barriers of the body, whereas murine JAM-3 is not expressed 
therein. In accordance with these findings, stable expression of JAM-1 in Madin-Darby canine 
kidney (MDCK) cell monolayers did not affect the paracellular permeability, whereas JAM-3 
expression caused a 5-fold increase (Aurrand-Lions et al., 2001b). In CHO cell monolayers 
murine JAM-1 even reduced the paracellular permeability (Martìn-Padura et al., 1998). Murine 
JAM-1 and JAM-3 therefore appear to exert opposite functions at intercellular junctions. 
Whether their effect on permeability directly influences leukocyte transmigration remains to be 
tested. 
 
 
 
5.11. JAM-1 in the extravasation of myeloid cells 
As JAM-1 has been implicated in the transmigration of myeloid cells (Martìn-Padura et al., 
1998), the analysis of leukocyte adhesion and transmigration was extended from previously 
investigated T lymphocytes to isolated human neutrophils. Whereas the recruitment of memory 
T cells to sites of inflammation is considerably dependent on the chemokine receptor CXCR4 
(Nanki et al., 2000), neutrophil arrest is mainly mediated by CXCR2. Exogenous application of 
neutrophil stimuli was not required since TNF-α–treatment of HUVECs induces endogenous 
expression of the CXCR2 ligands IL-8 (CXCL8) and growth-related oncogene (GRO)-α 
(CXCL1) on ECs (Miller et al., 1992). 
 
In contrast to the data obtained with memory T cells, JAM-1 exerted no significant participation 
in CXCR2-mediated arrest of neutrophils on inflamed HUVECs under shear flow. Similar 
observations concerning neutrophil arrest were reported in parallel by others (Shaw et al., 
2001c). This result was in accordance with blocking data revealing that the JAM-1–receptor 
LFA-1 alone was not sufficient to meditate firm arrest of rolling neutrophils, whereas the 
combined blockade of both LFA-1 and Mac-1 by a β2 mAb resulted in marked inhibition of 
neutrophil adhesion. These findings confirmed a report showing that both LFA-1 and Mac-1 are 
redundantly involved in neutrophil arrest under flow (Gopalan et al., 2000), even though the 
relative contribution of these two β2 integrins in neutrophil adhesion and transendothelial 
migration in vivo is still a matter of debate (Lu et al., 1997; Ding et al., 1999; Henderson et al., 
2001). The absence of an marked influence in neutrophil adhesion by JAM-1, as opposed to its 
prominent role in T lymphocyte arrest, thus appears to depend on the corresponding lower 
contribution of its receptor LFA-1 to neutrophil adhesion due to the redundant involvement of 
other receptor-ligand pairs, e.g. Mac-1/ICAM-1 (Gopalan et al., 2000) and VLA-4/VCAM 
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(Henderson et al., 2001). Remarkably, neutrophil adhesion was inhibited by blocking ICAM-1, 
which serves as a ligand for both LFA-1 and Mac-1 (Diamond et al., 1991), but not by anti–
JAM-1. This observation suggested that JAM-1 is a specific counter-receptor for LFA-1 but not 
Mac-1 and confirmed equivalent results obtained with cell adhesion assays using J-β2.7/αM 
lymphocytes and JAM-1–expressing CHO cells. Furthermore, cellular arrest was also 
investigated for myeloid HL-60 cells. These cells revealed LFA-1–mediated adhesion to 
CHO-JAM cells in a JAM-1–dependent manner. 
 
In contrast, transendothelial chemotaxis of neutrophils, triggered by a chemotactic gradient of 
IL-8 (CXCL8) depended considerably on the involvement of both LFA-1 counter-receptors 
JAM-1 and ICAM-1. This result was in accordance with blocking data revealing that the 
chemotactic migration of the neutrophils, in contrast to their adhesion, was mainly LFA-1–
mediated. The notion by others that human JAM-1 mAbs did not block transendothelial 
migration of neutrophils or monocytes in flow (Shaw et al., 2001c), as opposed to murine JAM-1 
mAb BV11 (Del Maschio et al., 1999), is likely due to their epitope specificity. This is supported 
by the finding that these antibodies influence JAM-1–dependent homotypic cell-cell adhesion 
(Liu et al., 2000b; Sobocka et al., 2000), which is mediated by the membrane-distal Ig-like 
domain 1 (Kostrewa et al., 2001; Bazzoni et al., 2000a) but not the LFA-1–binding domain 2 of 
JAM-1. This further substantiates the functional dichotomy between both JAM-1 domains. By 
identifying the involvement of both LFA-1 ligands JAM-1 and ICAM-1 in myeloid cell 
transmigration, this adds to results that implied JAM-1 participation in chemokine-induced 
transmigration of monocytes and neutrophils in vitro and in vivo (Martìn-Padura et al., 1998; Del 
Maschio et al., 1999). The findings described here therefore reveal that JAM-1, although it may 
facilitate firm arrest of T cells but not neutrophils, may play a more prominent role in 
transendothelial diapedesis of myeloid cells. 
 
 
 
5.12. The molecular zipper model 
The involvement of human JAM-1 in two key aspects of leukocyte recruitment, i.e. adhesion and 
diapedesis, suggests that this IgSF protein may be particularly well suited to guide leukocyte 
extravasation from the apical surface across the lateral intercellular junctions. The findings 
described within the presented study raise the possibility that beyond a primary adhesive 
interaction with endothelial JAM-1, leukocytic LFA-1 may serve to intercept interendothelial 
JAM-1/JAM-1 interactions at cellular junctions during diapedesis of leukocytes across the 
endothelial barrier (see fig. 30). 
 
120  Discussion 
The participation of JAM-1 in the initial arrest of leukocytes on inflamed endothelia may be 
enabled by partial redistribution of JAM-1 localized at intercellular junctions to the apical 
surface under specific inflammatory conditions (Ozaki et al., 1999; Shaw et al., 2001c). 
Subsequent LFA-1–mediated leukocyte adhesion possibly depends on or is supported by a cis-
dimeric state of endothelial JAM-1 (Bazzoni et al., 2000a), similar to what has been 
demonstrated for the interaction of ICAM-1 with LFA-1 (Miller et al., 1995; Reilly et al., 1995). 
Crystallographic data of recombinant soluble JAM-1 revealed that such lateral homophilic 
association is mediated by the N-terminal Ig-like domain 1 of both molecules, leading to a 
U-shaped cis-configuration of JAM-1 dimers on the cell surface (fig. 29).  
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figure 29: Molecular structure of recombinant soluble murine JAM-1 (rsJAM) and its homophilic complexes in cis and in 
trans based on crystallographic data. (A) Complex of two JAM-1 molecules interacting in cis (lateral homophilic 
interaction). One molecule is coloured in blue. Its N-terminal Ig-like domain 1 is labeled N1 and its C-terminal membrane-
proximal Ig-like domain 2 is labeled C1. Both domains are connected at an angle of about 125° by a short linker (Val127-
Leu128-Val129). The second molecule is coloured in orange and its Ig-like domains are labeled N2 and C2, respectively. 
Dimerized JAM-1 molecules contact each other with their N-terminal domains (N1 and N2), leading to an U-shaped 
conformation. The monomers are thereby related by a crystallographic twofold rotation axis, indicated by an arrow and a 
dyad symbol. (B) Complex of two U-shaped JAM-1 dimers from opposite cell membranes interacting homophilically in 
trans. One dimer is coloured in blue and orange in the same orientation as shown in (A), the other dimer in violet (with its 
Ig-like domains N3 and C3) and green (with its Ig-like domains N4 and C4), respectively. The pair of cis-dimers contact 
each other at their N-terminal domains (N2 and N3) such that their C-terminal domains point pair-wise in opposite 
directions, representing a trans-interaction. The membrane-proximal Ig-like domains stick out almost perpendicular from the 
lipid bilayer. The predicted distance between the opposing cell surfaces is about 105-110 Å, which is comparable with the 
estimated distance of about 100 Å at TJs. The interacting N-terminal domains of the U-shaped cis-dimers lie almost parallel 
to the cell surfaces and contact each other in a common central plane. Repeating this structural motif over several 
neighbouring cells would lead to a model of a two-dimensional network of trans-homophilic interacting JAM-1 dimers that 
might participate in this way to the integrity of the junctional barrier. Adapted from Kostrewa et al., 2001. 
A model based on this analysis proposed a two-dimensional network of N-terminal associated 
JAM-1 molecules interacting in trans with JAM-1 dimers from the opposite cell surfaces in a 
common central plane (Kostrewa et al., 2001). The structure analysis suggested that also this 
trans-homophilic interaction is mediated by domain 1 of JAM-1. These data support the finding 
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described herein, that LFA-1 binds its ligand JAM-1 at the membrane-proximal Ig-like 
domain 2. According to the X-ray structure this domain protrudes almost perpendicular from the 
cell surface (fig. 29). The accessibility of domain 2 for a heterophilic trans-interaction with 
opposing LFA-1 appears ensured by a steric inclination of the N-terminal domain 1 by about 
~55° (Kostrewa et al., 2001). 
 
Residual junctional JAM-1 not redistributed under inflammatory conditions may guide 
extravasating leukocytes along the cellular cleft in a haptotactic manner. It can be speculated that 
leukocytic LFA-1 may sterically intercept domain 1-mediated homophilic trans-interactions of 
junctional JAM-1 by binding to domain 2, thus disrupting or intercalating their intercellular 
interaction and thereby unlocking cell-cell junctions in a zipper-like manner. On the other hand, 
it may be feasible that homotypic JAM-1 interactions on opposing ECs are replaced by an 
interaction of endothelial JAM-1 with JAM-1 of intruding leukocytes via the domain 1 (fig. 30). 
It is conceivable that LFA-1 may bind laterally (in cis) to the cytoplasmic and/or other domains 
of leukocytic JAM-1. For LFA-1, such an initial cis-binding would facilitate the recruitment of 
its final interaction partner, i.e. endothelial JAM-1, by helping to bring LFA-1 into closer 
proximity with domain 2 of this molecule following homotypic interactions of leukocyte and 
endothelial JAM-1 (fig. 30). 
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figure 30: A molecular zipper model for leukocyte diapedesis mediated by heterophilic LFA-1/JAM-1 interactions as 
described. (1) Homotypic endothelial JAM-1 interactions in trans intercepted by leukocytic JAM-1 result in heterotypic 
JAM-1 binding. (2) Lateral binding between LFA-1 and leukocytic JAM-1 results in close proximity to endothelial 
JAM-1. (3) LFA-1 interacts in trans with endothelial JAM-1 via its membrane-proximal Ig-like domain 2. (3→1) Further 
homotypic endothelial JAM-1 pairs are intercepted by leukocytic JAM-1 as described in (1) thus guiding the leukocyte 
across the interendothelial cleft in a zipper-like manner. 
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This scenario is intriguing in light of the initial findings in the YTH assay, that the interaction of 
LFA-1 and JAM-1 occurs via their cytoplasmic domains. This may suggest the possibility of a 
LFA-1/JAM-1 interaction in cis on leukocytes and would parallel a report showing that the IgSF 
member PECAM-1, which also engages in homophilic associations with other PECAM-1 
molecules, functions as a cis-interacting ligand for the integrin αvβ3 (Wong et al., 2000). Such an 
interaction would be indicative of a close proximity of LFA-1 and JAM-1 on leukocytes and may 
be highly regulated by cellular activation, so that it may not be consistently detectable in 
purification methods. 
 
Altogether, the leukocytes may employ a complex interplay of homophilic JAM-1/JAM-1 and 
heterophilic JAM-1/LFA-1 interactions to open junctions, to migrate in a haptotactic manner 
along the intercellular cleft and to subsequently restore – again in a zipper-like manner – the 
junctional integrity (see fig. 31). Given its junctional localization and the redistribution under 
specific inflammatory conditions, JAM-1 appears ideally suited to provide such a molecular 
zipper for leukocyte diapedesis. 
 
 
 
5.13. Sequential steps of leukocyte diapedesis 
Emerging data provide support for the concept that junction-localized IgSF proteins, which can 
interact intercellularly via homophilic binding, may be particularly well suited to support 
transendothelial migration of leukocytes. One important example is PECAM-1 (fig. 31). The 
expression pattern and molecular structure of PECAM-1 shows a remarkable similarity to that of 
JAM-1, with expression at intercellular junctions (although more basolaterally localized and not 
associated with either TJs or AJs), as well as on circulating blood cells (Ayalon et al., 1994; 
Johnson-Léger et al., 2000). Like JAM-1, PECAM-1 can also be redistributed from cell-cell 
contacts by costimulation with the cytokines TNF-α and IFN-γ (Romer et al., 1995). It has been 
implicated in two distinct steps during emigration of monocytes, neutrophils and NK cells. First, 
homophilic interactions of leukocytic PECAM-1 with their endothelial counterparts, mediated by 
the Ig-like domains 1 and 2 (Newton et al., 1997), appear to contribute to diapedesis per se, since 
blockade of this step by antibodies arrests leukocytes on the apical surface of the endothelium 
(Muller et al., 1993). Second, the domain 6 of leukocyte PECAM-1 undergoes heterophilic 
interactions with yet unidentified binding partners in the basement membrane, since blocking 
this step retains leukocytes between the basal surface of the EC and the basal lamina (Liao et al., 
1995). However, PECAM-1–deficient mice do not reveal a major defect in inflammatory disease 
models (Duncan et al., 1999), indicating that the requirement for this IgSF molecule is not 
obligatory for leukocyte extravasation. By analogy with the redundancy displayed in the cascade 
of leukocyte recruitment, this suggests a crucial involvement of other junction molecules in the 
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process of diapedesis, e.g. JAM-1 which might collaborate with PECAM-1 in guiding the cell 
along the intercellular cleft. 
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figure 31: Novel molecular mechanisms in leukocyte extravasation. (left part) Intercellular homophilic interactions 
by PECAM-1 and JAM-1 mediate, in addition to other molecules (not shown) the integrity of the junctional barrier in 
resting endothelium. (right part) Inflammatory stimulation leads to expression of ICAM-1 on the apical surface and 
redistribution of JAM-1 and in part PECAM-1 from the intercellular junctions to the luminal surface. After tethering 
and rolling, leukocytes are activated by chemokines which leads to LFA-1 engagement with vascular ICAM-1 and 
JAM-1 and to firm arrest of the leukocyte on the inflamed endothelium. During diapedesis, homophilic interactions 
of JAM-1, PECAM-1 and CD99 between opposing endothelial cells (homotypic interactions) might guide the 
leukocyte across the intercellular cleft, thereby being disrupted by the leukocyte and replaced by homophilic 
interactions of PECAM-1 and CD99 between the leukocyte and endothelial cells and by heterophilic interactions of 
endothelial JAM-1 with leukocytic LFA-1 (in each case heterotypic interactions) in a haptotactic and zipper-like 
manner. Adapted from Johnson-Léger et al., 2000, and Aurrand-Lions et al., 2002. 
CD99, a heavily O-glycosylated 32-kDa type I transmembrane protein expressed on most 
hematopoietic cells and likewise concentrated at interendothelial junctions (fig. 31), has been 
recently shown to play an important role in the last stage of monocyte diapedesis (Schenkel et 
al., 2002). Whereas blocking PECAM-1 arrests leukocytes on the apical surface of the 
endothelium, with pseudopods attempting to protrude into the junctions, blocking CD99 arrests 
monocytes distal to the PECAM-1–dependent step at a point where they are partially through the 
junction (fig. 31). The late arrest may be explained by a blockade of the uropod, the trailing end 
of the migrating cell and a membrane region that concentrates high numbers of CAMs such as 
ICAM-1, although it is not known whether CD99 is enriched in this region (Aurrand-Lions et al., 
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2002). Diapedesis involves the homophilic interaction between monocytic and endothelial 
CD99. However, since CD99 regulates expression and affinity of the integrin LFA-1 via an 
unknown signal transduction pathway (Hahn et al., 1997), CD99 interactions may indirectly 
influence leukocyte transendothelial migration, possibly by regulating the function of integrins in 
the uropod. 
 
It appears that emigrating leukocytes first use heterophilic LFA-1/JAM-1 and homophilic 
PECAM-1 interactions to penetrate the apical entry of the junction and to initiate emigration. 
Homophilic CD99 interactions then allow the invading leukocyte to transmigrate through clefts 
in the endothelial wall and to complete emigration. Thus, diapedesis is regulated sequentially in 
a multi-step process by these three distinct molecules (fig. 31). Taken together, the recent 
insights into mechanisms of transendothelial migration suggest that a multi-layered molecular 
zipper set up by JAM-1, PECAM-1 and CD99 enables effective diapedesis of leukocytes across 
the endothelial barrier without a detremental leakage of the vascular endothelium. 
 
 
 
5.14. Perspectives 
This study has identified a heterophilic interaction between the β2 integrin LFA-1 and the IgSF 
molecule JAM-1 and demonstrated its role in adhesion and transendothelial migration of 
leukocytes in the context of inflammation. 
 
A molecular zipper model might explain the involvement of JAM-1 in leukocyte emigration. 
Given the redundancy of PECAM-1 illustrated in deficient mice, it remains to be determined 
whether the LFA-1/JAM-1 interaction cooperates with PECAM-1 and CD99 in leukocyte 
transendothelial migration or constitutes an alternative pathway. 
 
Although JAM-1 is expressed in human circulating cells, its functional role in these cells remains 
unclear. Interestingly, initial findings within this study indicated a lateral interaction of JAM-1 
and LFA-1 on the surface membrane of leukocytes. An understanding of the significance of 
JAM-1 expression in blood cells would be of particular interest given the highly distinctive 
expression pattern with abundant expression in human and lack of expression in most murine 
hematopoietic cells. Similarly, the striking differences which exist between the two species 
concerning JAM-1 expression in the brain is not understood. Whereas JAM-1 is abundantly 
expressed in murine brain tissues (Martìn-Padura et al., 1998) it is barely detectable in human 
brain (Williams et al., 1999; Naik et al., 2001; Gupta et al., 2000). This finding is tantalizing 
given the involvement of JAM-1 in the constitution of the blood-brain barrier (BBB) 
impermeability. 
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Although the membrane-proximal Ig-like domain 2 of JAM-1 has been characterized as the 
LFA-1 binding domain, it would be of special interest to further define the region or even 
identify critical amino acids in both LFA-1 and JAM-1 essential for their heterophilic 
interaction. It remains to be determined whether the I domain of the LFA-1 α chain is not only 
implicated in ICAM-1 but also in JAM-1 binding. Furthermore, it is remarkable that both 
N-glycosylation sites of human JAM-1 are localized within the LFA-1 binding domain 2 of 
JAM-1. Given the influence of glycosylation in regulation of the ICAM-1/Mac-1 and the 
ICAM-2/LFA-1 interactions (Diamond et al., 1991; Casasnovas et al., 1997) and different levels 
of JAM-1 glycosylation within some cell types (Liu et al., 2000b; Liang et al., 2000; Sobocka et 
al., 2000), it will be important to determine whether the carbohydrate side chains of JAM-1 have 
any functional role in the binding of LFA-1. Moreover, it will be interest to confirm whether the 
lateral dimerization of JAM-1 molecules is crucial or supportive for the interaction with LFA-1, 
e.g. by providing a specific and functionally necessary orientation of these molecules on the cell 
surface. The precise stereochemical complementarity of the homophilic binding-mediating 
interface (see fig. 29) and the high affinity of rsJAM homophilic interactions in vitro (Bazzoni et 
al., 2000a) suggests that JAM-1 dimers might be permanent and obligatory complexes (Jones et 
al., 1996b) and that cis-dimers might occur prior to any adhesive homophilic or heterophilic 
trans-interactions of JAM-1. 
 
An important aspect not investigated in this study is the functional role that the cytoplasmic tail 
of JAM-1 might play during emigration of leukocytes but also in the binding of its receptor 
LFA-1. Thus it should be examined whether the engagement of leukocytic LFA-1 during 
diapedesis induces any signal transduction by endothelial JAM-1 that may be involved in further 
regulation of leukocyte extravasation through the vascular wall. It would be intriguing if 
regulatory elements could be discovered within the cytoplasmic domain of JAM-1 that are able 
to participate in signal transduction. Thus JAM-1 has been shown to be phosphorylated by PKC 
upon platelet activation (Ozaki et al., 2000). Moreover, it remains to be clarified whether the 
intracellular tail of leukocytic JAM-1 interacts laterally with the α tail of LFA-1. 
 
Beside the important role of leukocyte recruitment for immune homeostasis and surveillance 
under physiological conditions, particular acute inflammation states such as meningitis (Del 
Maschio et al., 1999) can lead to severe alterations in physiology and cause severe tissue damage 
due to excessive release of microbicidal oxygen radicals, proteases and inflammatory stimuli by 
emigrating leukocytes. Moreover, inflammatory processes have been implicated in human 
diseases such as allergic airway inflammation, rheumatic arthritis (Strieter et al., 1996) and 
atherosclerosis (Ross, 1999; Lusis, 2000) and are implicated in allograft rejection after organ 
transplantation (Gerard et al., 2001). The incidence of such pathological inflammation 
underscores the need for a more detailed understanding of the complex molecular and cellular 
regulation of inflammatory processes. In this regard, one principal goal is the assessment of 
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JAM-1 as a potential therapeutic target. At present, this is a subject of controversy. Intravenous 
injection of the mAb BV11 directed against murine JAM-1 into mice with bacterial meningitis 
caused severe complement-dependent damage in blood vessel endothelia of the brain and led 
consequently to central nervous system (CNS) bleeding. This could be prevented by removal of 
the complement-activating Fc part of the antibody but application of BV11 Fab did not show any 
beneficial effect to mice (Lechner et al., 2000). However, in a murine model for cytokine-
induced experimental meningitis, BV11 administration blocked the recruitment of neutrophils 
into the CNS, decreasing the permeability of the BBB and attenuating meningitis (Del Maschio 
et al., 1999). The different mechanisms underlying leukocyte trafficking in these models should 
first be clarified in order to properly assess the potential of JAM-1 as a therapeutic target, in 
particular with respect to an improvement in the survival rate in severe pathological cases of 
meningitis. Moreover, the significance of JAM-1 (F11R) auto-antibodies in the circulation of 
patients with thrombocytopenia (Sobocka et al., 2000) remains to be determined. 
 
The functional implication of heterophilic LFA-1/JAM-1 interactions in diapedesis across 
inflamed endothelium was confirmed in in vitro assays performed under physiological 
conditions. Thus, the experiments were performed with cells isolated from the human vascular 
system, with physiological stimuli and under conditions of laminar flow simulating the 
microcirculation. Nevertheless, a confirmation of the results presented within this study in 
relevant in vivo models will be of compelling interest, e.g. employing intravital microscopy. 
Furthermore, it would be of particular interest to investigate the phenotype of JAM-1–deficient 
mice in terms of diapedesis during lymphocyte homing and inflammatory reactions. 
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6. Note added in proof 
The recent identification of the interaction between the β2 integrin LFA-1 (αLβ2) and the human 
IgSF protein JAM-1 constitutes a model for additional integrin-JAM binding pairs published just 
prior to completion of this manuscript. 
 
Thus, the second major leukocyte β2 integrin Mac-1 (αMβ2) is reported to bind specifically to the 
third member of the JAM family (JAM-3) expressed on human platelets (Santoso et al., 2002). 
This specific interaction appears to be mediated by the I domain of Mac-1. There were also 
indications that JAM-3 binds to a lesser extent to p150.95 (αXβ2). An interaction with LFA-1, 
however, was specifically excluded. JAM-3 together with the glycoprotein (GP) Ibα (Simon et 
al., 2000) thus serves as the major ligand on the surface of platelets for leukocyte Mac-1. 
Cellular interactions mediated by this binding pair may occur in the context of leukocyte 
attachment to and transmigration across surface-adherent platelets at sites of vascular injury 
under certain pathological conditions (Diacovo et al., 1996). 
 
In contrast to the other JAM proteins, human JAM-2 engages leukocyte VLA-4, a β1 integrin 
(α4β1), in cellular interactions with T lymphocytes (Cunningham et al., 2002). The primary 
binding site for VLA-4 is the N-terminal Ig-like domain 1 of JAM-2, in contrast to the 
requirement for the membrane-proximal domain 2 of JAM-1 to bind to its integrin receptor 
LFA-1. Interestingly, an involvement of the only acidic residue in the C-D loop of this domain, 
namely Asp82, in binding to VLA-4 was excluded, thus JAM-2 deviates from the mechanism 
used by other IgSF proteins to engage integrins. Whether JAM-2 can also function as a ligand for 
the second α4 integrin α4β7, similarly to VCAM-1, remains unknown. The Mn2+-dependent 
molecular interaction between JAM-2 and leukocytic VLA-4 , however, was reported to require 
prior adhesion of JAM-2 with leukocytic JAM-3 in trans and was not detectable in cells lacking 
JAM-3 expression. Such an interaction in trans of JAM-2 and JAM-3 between opposing cell 
surfaces might facilitate the subsequent JAM-2/VLA-4 binding by providing more frequent and 
closer contacts. This scenario resembles the hypothesis that LFA-1 might engage leukocytic 
JAM-1 in cis despite its homophilic binding to endothelial JAM-1 in trans, and that this lateral 
association may facilitate the interaction of LFA-1 with its opposite endothelial ligand JAM-1. 
 
Whether the recently reported integrin-JAM interactions are directly involved in the diapedesis 
of leukocytes remains to be investigated but appears most likely. The observation that human 
JAM-1, JAM-2 and JAM-3 can independently function as ligands for the integrins LFA-1, 
VLA-4 and Mac-1, respectively, provides a completely new perspective in understanding the 
processes involved in inflammatory cell recruitment. 
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7. Summary 
The recruitment of circulating leukocytes to sites of inflammation is a multi-step processes 
leading to their transmigration (diapedesis) through the blood vessel wall into the subvascular 
tissue. This process requires highly regulated cellular interactions at the molecular level to 
withdraw leukocytes from the blood stream and to finally enable their effective passage across 
the tightly connected endothelial barrier without a detremental leakage of the vessel wall. 
Whereas the initial steps of this process are well understood, i.e. leukocyte tethering, rolling on 
and firm adhesion to the endothelium, the molecular basis of the last step, i.e. the extravasation 
itself, remains largely unknown. 
 
The leukocyte-specific β2 integrin LFA-1 plays an important role in this process since it 
mediates firm adhesion of rolling leukocytes to the vessel wall. The cellular arrest depends 
thereby mainly on the molecular interaction of LFA-1 with its endothelial ligands ICAM-1 and 
ICAM-2, both of which are members of the IgSF family. 
 
JAM-1, which is also an IgSF protein, is predominantly expressed at intercellular cell-cell 
contacts of endothelia and epithelia. Here it associates at the apical region with proteins of tight 
junctions (TJs) and exerts homophilic interactions in trans with JAM-1 molecules of opposite 
cells, thus participating in the arrangement of the endothelial barrier and presumably in the 
regulation of its paracellular permeability. JAM-1 may therefore be ideally situated to serve as a 
junctional gatekeeper promoting the transmigration of leukocytes. 
 
In this study a novel candidate interaction partner of LFA-1 was identified by a yeast two-hybrid 
(YTH) screening of a human leukocyte cDNA library that revealed 75 % sequence homology to 
murine JAM-1. The identity of the candidate clone was clarified with the subsequent 
identification of human JAM-1 by other groups. Since LFA-1 is known to be crucial for 
leukocyte transmigration and given the striking structural and functional homology of JAM-1 
with the main LFA-1 ligand ICAM-1 or the IgSF protein PECAM-1, it was hypothesized that 
JAM-1 may act as a functional ligand for LFA-1 in terms of cell adhesion and may thereby also 
be involved in leukocyte diapedesis. 
 
Isolation of the full-length JAM-1 cDNA from a YTH assay clone allowed for the generation of a 
JAM-1 polyclonal antibody by DNA-mediated mouse immunization and the establishment of a 
CHO cell line expressing heterogeneous JAM-1 (CHO-JAM cells). Specificity of anti–JAM-1 
and correct surface expression of JAM-1 in CHO-JAM cells was verified by flow cytometry and 
immunoblot analysis. Expression studies using anti–JAM-1 revealed abundant surface 
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expression of JAM-1 on human hematopoietic cells which is in contrast to published expression 
patterns of murine JAM-1 absent on leukocytes. The significance of this finding still remains to 
be determined. 
 
Static adhesion assays revealed that JAM-1 acts as a cell adhesion molecule (CAM) able to 
mediate LFA-1–dependent firm arrest of Jurkat T lymphocytes on JAM-1–expressing CHO cell 
monolayers and of CHO-JAM cells on purified, immobilized LFA-1. The specificity of this cell 
attachment was confirmed by the application of blocking antibodies directed against JAM-1, and 
by control experiments using CHO cells that lacked JAM-1 expression. Furthermore, Jurkat T 
cells deficient in LFA-1 expression due to chemical mutagenesis failed to bind to CHO-JAM 
cells but regained this ability after reconstitution of LFA-1 surface expression by cell 
transfection with an appropriate cDNA construct. 
 
ICAM-1 serves as counter-receptor for both β2 integrins LFA-1 and Mac-1. However, the failure 
of Mac-1–transfected but LFA-1–deficient Jurkat T cells to adhere to JAM-1 expressing CHO 
cells suggested a lack of redundancy for JAM-1 binding between this integrin receptors. Deletion 
mutagenesis revealed that the membrane-proximal Ig-like domain 2 of human JAM-1 is 
necessary and sufficient for LFA-1 binding. Thus CHO-JAM∆D2 cells lacking this specific 
domain (∆132-217) were unable to capture T lymphocytes. However, appropriate expression of 
mutant JAM∆D2 was confirmed by RT-PCR, flow cytometry and western blot analysis. This 
finding suggested structural duality of JAM-1 that employs its N-terminal Ig-like domain 1 for 
homophilic interaction in cis (dimerization) and in trans and domain 2 as a heterophilic LFA-1 
receptor binding site. 
 
Several lines of evidence supported the conclusion that homophilic JAM-1 interactions in trans, 
implicated to occur at intercellular junctions, were not involved in the observed cellular 
attachment. These studies included the use of the anti–JAM-1 antibody and the JAM-1–deficient 
myeloid cell line HL-60. Moreover, a hypothetical contamination of the LFA-1 preparation, 
isolated from human organs and used in static adhesion assays, with co-purified JAM-1 was 
excluded by silver staining and western blot analysis. 
 
The findings obtained with static adhesion assays were further confirmed by using memory T 
cells isolated from human blood and HUVECs isolated from umbilical cord veins. Firm cellular 
arrest of T lymphocytes to HUVEC monolayers required costimulation of the endothelial cells 
with the proinflammatory cytokines TNF-α and IFN-γ that induces redistribution of junctional 
localized JAM-1 to the apical surface. Equivalent results were obtained in experiments 
performed in a flow chamber system simulating the blood stream. This implicated a functional 
role of the LFA-1/JAM-1 interaction under inflammatory conditions. The finding that cell 
adhesion mediated by this receptor-ligand pair was able to resist shear stress forces induced by 
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laminar flow emphasized the physiological relevance of this molecular interaction. Furthermore, 
the use of antibodies directed against ICAM-1 and JAM-1, alone or in combination, suggested 
that both IgSF molecules display alternative ligands for leukocytic LFA-1. 
 
Functional chemotaxis and flow chamber assays with physiologically relevant cell types showed 
that JAM-1 also plays an important role in LFA-1–dependent transendothelial migration of 
memory T cells under static and flow conditions. Again, a combined blockade of JAM-1 and 
ICAM-1 inhibited migration additively, suggesting that both molecules are required for optimal 
diapedesis. In contrast to lymphocyte adhesion, transmigration did not seem to be dependent on 
inflammatory conditions. The analysis of leukocyte adhesion and transmigration was further 
extended to include isolated human neutrophils. The absence of a marked influence of JAM-1 
upon neutrophil adhesion, as opposed to its prominent role in T lymphocyte arrest, appeared to 
depend on the redundant involvement of other receptor-ligand pairs. However, diapedesis of 
neutrophils depended considerably on the involvement of both LFA-1 ligands JAM-1 and 
ICAM-1. 
 
A molecular zipper model is proposed for the mechanisms of action of JAM-1 in leukocyte 
emigration at sites of inflammation. Redistribution of junctional JAM-1 under inflammatory 
conditions enables LFA-1–mediated leukocyte binding at the apical surface of the endothelium. 
Upon transmigration across the endothelial barrier, LFA-1 might repetitively intercept or 
intercalate junctional JAM-1 engaged in homophilic interactions in trans. Such sequential 
interactions may unlock intercellular junctions and guide the leukocyte along the basolateral site 
of the intercellular cleft in a zipper-like manner. These findings may explain the documented 
involvement of LFA-1 in leukocyte extravasation that could not be explained until now due to 
the absence of basolateral ICAM-1 expression which is encountered instead exclusively at the 
luminal surface of inflammatory endothelium. 
 
In summary, human JAM-1 was identified as the first counter-receptor of LFA-1 that does not 
belong to the ICAM subgroup. The membrane-proximal Ig-like domain 2 of JAM-1 was shown 
to bear the LFA-1 binding site. It could be verified that the JAM-1/LFA-1 interaction is 
functionally implicated in lymphocyte adhesion and leukocyte transmigration under 
inflammatory conditions. The presented data establishes a fourth type of interaction between 
IgSF and integrin adhesion molecules besides the interaction of PECAM-1 with αvβ3, of 
VCAM-1 respective MAdCAM-1 with α4 integrins and of ICAMs with β2 integrins. Moreover, 
they constitute a general model for JAM-integrin binding pairs recently extended by the 
identification of the interaction partners JAM-2/VLA-4 and JAM-3/Mac-1. 
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